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Abstract 
The importance of biotherapeutic proteins for the treatment of various diseases has grown 
exponentially over the last few decades, and this growth is predicted to continue in the 
coming years. Among these, monoclonal antibodies (mAbs) represent the largest class for 
both revenues and new approvals. Chinese hamster ovary cells (CHO) are the leading 
platform in industry for the production of these complex molecules requiring human-like 
post-translational modifications, in particular mAbs. Although CHO cells are capable of 
producing and secreting mAbs at acceptable yields, numerous attempts to increase the 
maximum viable cell concentration and productivity have been described in literature 
exploiting modification of culture conditions, changing the genetic makeup of the vector(s) 
used to drive expression of the gene(s) of interest, and by engineering host cells. The 
application of non-coding RNAs, such as miRNAs and siRNAs, to reprogram CHO cells has 
been explored and allows specific targeting of detrimental genes without loading an 
additional translational burden on the cell. However, Long non-coding RNAs (LncRNAs), non-
coding transcripts >200 nucleotides in length have only recently emerged as key regulators 
of epigenetics, splicing, microRNAs and translation. Despite the potential for applications in 
cell engineering, these molecules remain largely unexplored in mammalian expression 
systems. Further, whilst mRNA translation of coding transcripts is a central regulatory step 
for cell growth, and thus the yield and quality of recombinant proteins, non-coding tRNAs 
are an important regulatory molecule in the decoding process. Although recombinant gene 
sequences are often codon optimized, we do not currently have all the information required 
around tRNA abundance, modifications and tRNA charging to fully harness codon usage in 
recombinant sequences. The work reported here presents the first lncRNA and tRNA 
expression landscape in CHO cells under a variety of conditions and discusses the 
implications of these on recombinant protein production. To investigate lncRNA and tRNAs 
in CHO cells, a CHO-S cell line grown under batch and fed-batch culture was sampled at day 
4 and 7 of culture while six IgG1-producing CHO cell lines cultivated in an ambr®15 system 
with different fed strategies were sampled before inoculation and at day 4, 7 and 12 of 
culture. The whole transcriptomes were investigated using a mouse microarray providing the 
surveillance of 24,881 mRNAs and 35,923 lncRNAs for CHO-S samples and RNA-Seq for the 
IgG-producing cell lines. tRNA abundances were quantified using a previously optimized 
ARM-Seq protocol. Thousands of differentially expressed lncRNAs were filtered by counting 
the occurrences of each transcript, assessing sequence conservation, secondary structure 
and RT-qPCR validation. The behaviour of a group of lncRNAs is described for the first time 
in CHO cells and the applications for cell engineering discussed. In particular, the CHO cell 
long non-coding RNA (lncRNA) transcriptome from cells grown in controlled miniature 
bioreactors is defined under fed-batch conditions using RNA-Seq to identify lncRNAs and 
how the expression of these changes throughout growth and between IgG producers. 
lncRNAs associated with productivity and growth characteristics are identified, in particular 
finding that Adapt15, linked to ER stress, GAS5, linked to mTOR signalling/growth arrest, and 
PVT1, linked to Myc expression, are differentially regulated during fed-batch culture and 
whose expression relates to productivity (Adapt15) or growth (GAS5, PVT1). Changes in 
(non)-coding RNA expression between the seed train and the equivalent day of fed-batch 
culture are also reported, showing large differences in gene expression between these. The 
ARM-Seq protocol allowed the identification of 4-5 fold more tRNAs compared to standard 
sequencing, and was applied to yeast and HEK293 cells to allow comparisons with CHO. 
Ultimately, tRNA quantifications were used in a translation elongation model to calculate the 
decoding speed of model recombinant proteins and to generate codon optimized versions 
based on tRNA abundances.   
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Chapter 1 Introduction 
1.1 The emergence and growth of recombinant biotherapeutic proteins for the 
treatment of disease 
Since the approval by the FDA in 1982 of the first biopharmaceutical Humulin, a recombinant 
human insulin produced in E. coli, the importance of biotherapeutic proteins for the 
treatment of disease has grown exponentially (Walsh, 2014). Indeed, 47% of the new drug 
approvals in the US between 2014 and 2018 were biopharmaceuticals, as opposed to just 
21% in 2006-2010 and 26% in 2010-2014 (Walsh, 2018). Based on current late-stage clinical 
trials, where protein-based therapeutics represent the majority of products, this trend is 
predicted to continue in the coming years (Walsh, 2018). Among these, monoclonal 
antibodies (mAbs) currently dominate the scene, representing 53% of new approvals 
between 2015 and 2018 and reaching $123 billion in global sales in 2017, and the sales are 
still predicted to grow in the next few years due to the flux of recent new approvals and 
current pipelines (Walsh, 2018). The mAb Humira (adalimumab) alone had global sales just 
short of $19 billion in 2017. As a comparison, insulins are collectively the second most 
lucrative product class at $22 billion in 2017 (Walsh, 2018).  
 
1.1.1 Comparison of different recombinant protein expression systems 
After human tissue plasminogen activator became the first therapeutic protein to be 
produced in cultured mammalian cells in 1986 by Genentech, this expression system has now 
become the most common for recombinant protein production of biopharmaceuticals (F. M. 
Wurm, 2004). Nonetheless, a variety of alternative organisms are used in industry and 
academic research for the expression of recombinant proteins. Each one of these platforms 
present intrinsic advantages and disadvantages which are summarised in Table 1.1 and 
discussed in the following paragraphs of this chapter. 
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Table 1.1 - Comparison of different recombinant protein expression systems 
Host Advantages Disadvantages Examples on the market References 
 
E. coli 
Fast doubling time 
High cell density 
Inexpensive media 
Extensive biology knowledge 
Disulphide bonds formation in the periplasm 
Limited PTMs  
Limited glycosylation 
Presence of endotoxins 
Admelog, rapid-acting human insulin 
analogue 
Increlex, rh IGF-1 
Pegasys, PEGylated IFN-α-2b 
(Daegelen, Studier, Lenski, 
Cure, & Kim, 2009; Marisch 




Fast doubling time 
High cell density 
Inexpensive media 
Extensive biology knowledge 
Cellular machinery to undertake complex PTMs 
Hyper-mannosylation 
N-linked and O-linked fungal 
glycans 
Ryzodeg, combination of two 
engineered insulins 
Victoza, GLP-1 analogue with attached 
fatty acid 
Fasturtec, urate oxidase 
(Baghban et al., 2019; 
Fernández, López-Estepa, 




Fast doubling time 
High cell density 
Inexpensive media 
Cellular machinery to undertake complex PTMs 
Reduced hyper-glycosylation 
Presence of N-linked and O-
linked fungal glycans 
Kalbitor, plasma kallikrein inhibitor 
Jetrea, truncated form of human 
plasmin 
(Baghban et al., 2019; 
Macauley-Patrick, Fazenda, 
McNeil, & Harvey, 2005) 
 
Insect cells 
Growth in suspension at 28 °C in serum-free 
media in the absence of CO2 
Cellular machinery to undertake complex PTMs 
More complex glycan structures 
Costly downstream purification 
steps 
Compatibility of the 
glycosylation patterns with 
human 
Low yields 
Cervarix, VLP vaccine for the 
prevention of human papilloma virus 
infection  
Provenge, prostatic acid phosphatase 




Molina-Grima, & Chisti, 
2014; Jarvis, 2009; van Oers, 
Pijlman, & Vlak, 2015) 
 
CHO cells 
Growth in suspension in chemically defined 
serum-free media 
Human-like PTMs 
Effective folding and secretion of large and 
complex molecules 
Yields in excess of 5 g/L 
Expensive media and reagents 
Slower doubling times  
Examples of immunogenic N-
glycosylation patterns 
Luveris, rh luteinizing hormone 
Biopoin, rh EPO 
Avastin, humanized mAb against VEGF 
Humira, anti-TNF human mAb 
Vimizim, rh N-acetlygalactosamine-6-
sulfatase 
(Fischer, Handrick, & Otte, 
2015; J. Y. Kim, Kim, & Lee, 
2012) 
Summary of the advantages and disadvantages of different cell factories utilised for biopharmaceuticals production with examples of products on the market produced in 
the respective host and references to relevant literature on the expression system. 
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1.1.1.1 Bacteria  
Bacterial systems are one of the most common expression systems used for recombinant 
proteins, both at laboratory and manufacturing scale, especially Escherichia coli BL21(DE3) 
strains and derivatives of the K-12 lineage (Daegelen et al., 2009; Marisch et al., 2013; Rosano 
& Ceccarelli, 2014). After the first human polypeptide was expressed in E. coli more than 40 
years ago (Itakura et al., 1977), this host gained popularity for recombinant protein 
production due to various advantages, including extremely fast growth kinetics with high cell 
densities (Sezonov, Joseleau-Petit, & D’Ari, 2007), significantly lower culture media and 
reagents costs compared to mammalian systems (Fernández & Vega, 2016) and relatively 
straightforward genetic manipulation (Pope & Kent, 1996). Different forms of insulin, human 
hormones, human IgG fragments, fusion proteins and recombinant enzymes are all examples 
of biopharmaceuticals on the market produced in E. coli (Walsh, 2018). Nonetheless, 
microbial cell factories have intrinsic limitations which can prevent the expression of more 
complex proteins with acceptable quality attributes.  
Human-compatible glycosylation patterns, correct folding and the formation of disulphide 
bonds can be difficult to obtain in E. coli, leading to protein aggregation with the formation 
of inclusion bodies that require supplementary downstream processing and loss of functional 
product (Carrió & Villaverde, 2002; Derman, Prinz, Belin, & Beckwith, 1993; Hartley & Kane, 
1988). While the reducing environment of the cytoplasm in E. coli prevents the formation of 
disulphide bonds, a common strategy is to direct proteins to the periplasm where these can 
be formed, although specific steps are then required for downstream purification 
(Mergulhão, Summers, & Monteiro, 2005; Messens & Collet, 2006). Bacterial endotoxins like 
lipopolysaccharides (LPSs) are required components in the outer membrane of most Gram-
negative bacteria, including E. coli, and their presence can affect safety of a 
biopharmaceutical for use in humans (Raetz & Whitfield, 2002). The recombinant protein 
itself can be toxic to the host causing detrimental functions in the cell and ultimately slow 
growth rate, low cell density and insufficient protein yield (Doherty, Connolly, & Worrall, 
1993; Dong, Nilsson, & Kurland, 1995). Targeting the protein to the periplasm can solve the 
problem of protein toxicity as well as promoting disulphide bond formation (de Marco, 2009; 
Mergulhão et al., 2005).  
 15 
1.1.1.2 Yeast expression systems 
Unicellular yeast organisms retain many of the advantages offered by bacterial hosts, notably 
fast doubling times, high cell densities and inexpensive media, coupled with an ability to 
undertake a wider range of post-translational modifications and folding capacity and 
extracellular secretion into the medium (Fernández et al., 2016). The two main hosts among 
yeast cell expression systems are the non-methylotrophic Saccharomyces cerevisiae and the 
methylotrophic Pichia pastoris (Fernández et al., 2016). While this phenotypical distinction 
is based on the capacity to utilize methanol as a carbon and energy source, requiring distinct 
cell culture protocols, these two hosts present specific advantages and disadvantages. The 
deep knowledge on the microbiology (Barnett & Barnett, 2011), genetics (Duina, Miller, & 
Keeney, 2014), molecular and cellular biology (Resnick & Cox, 2000) and stress response 
during cell culture (Bawa et al., 2011) available for S. cerevisiae allows extensive genetic 
engineering and targeted process optimization to increase yield and quality of the product 
(Bonander & Bill, 2012), making this yeast one of the most common hosts for recombinant 
protein production. S. cerevisiae is currently used for the production of several commercially 
available biotherapeutics, including rh factor XIII A-subunit, various forms of insulin, 
glucagon, Hepatitis B antigens, and HPV capsid proteins (Walsh, 2018).  
The main limitation for complex heterologous protein expression is frequently the glycan 
structure of the final product, as S. cerevisiae tends to form hyper-mannosylated highly 
immunogenic structures (Baghban et al., 2019). Genetic engineering approaches have been 
shown to successfully alleviate this problem through the removal of key enzymes involved in 
glycosylation pathways (Tang et al., 2016) but the use of P. pastoris is often preferred when 
hyper-glycosylation is a concern (Macauley-Patrick et al., 2005). While maintaining most of 
the advantages outlined for S. cerevisiae, P. pastoris adds shorter glycan chains due to the 
lack of the α-1,3-mannosyltransferase enzyme (Wildt & Gerngross, 2005). Examples of 
commercially available biopharmaceuticals produced in P. pastoris are Kalbitor® 
(ecallantide), a plasma kallikrein inhibitor introduced onto the market in 2009, and Jetrea®, 
a truncated form of human plasmin approved for use in 2012 (Walsh, 2018). However, 
although engineering strategies have been tried to closely mimic mammalian-like glycan 
structures (Bobrowicz et al., 2004), the presence of N-linked and O-linked fungal glycans can 
still reduce efficacy or even elicit an immunogenic response in humans (Nett et al., 2013).  
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1.1.1.3 Baculovirus and insect cells 
Back in 1983, Max Summers and co-workers reported the production of a functional human 
IFN-β in insect cells infected by a recombinant baculovirus for the first time using the polh 
promoter (G. E. Smith, Summers, & Fraser, 1983). One year later, Lois Miller and colleagues 
expressed high levels of Escherichia coli beta-galactosidase under the p10 promoter 
(Pennock, Shoemaker, & Miller, 1984). More than three decades since these fundamental 
contributions, the baculovirus expression vector systems (BEVS) has become a widespread 
technology in academic research as well as industrial manufacturing of a wide range of 
proteins (van Oers et al., 2015). Insect cell cultures provide some advantages over other 
systems, including the ability to grow in suspension in serum free medium at 28°C in the 
absence of CO2 with scale-up potential using bioreactors, shake flasks, stirred tanks and 
single use wavebag systems (Contreras-Gómez et al., 2014; Jarvis, 2009; van Oers et al., 
2015). Moreover, being a higher eukaryote, insect cells express protein with more complex 
glycan structures than yeast or bacteria and can be effectively engineered to partly resemble 
human-like glycosylation profiles (Mabashi-Asazuma et al., 2013). A particularly successful 
application for BEVS is the production of virus-like particles (VLPs) (Fernandes, Teixeira, 
Carinhas, Carrondo, & Alves, 2013; Yamaji, 2014). An example of BEVS produced VLP is the 
commercially available vaccine for the prevention of human papilloma virus infection, 
Cervarix (Deschuyteneer et al., 2010). Protein therapeutics expressed in insect cells now 
account for approximately 1% of all approved biotherapeutics for human use (Yee, Zak, Hill, 
& Wen, 2018), including the prostatic acid phosphatase Provenge (Burch et al., 2000; 
Cheever & Higano, 2011; Finer-Moore, Czudnochowski, O’Connell, Wang, & Stroud, 2015), 
and a subunit for the influenza vaccine Flublok (Cox & Hollister, 2009). Major limitations to 
a more widespread use of BEVS in manufacturing of biotherapeutics are the presence of 
baculovirus progeny contamination in the culture along with cellular proteins and debris 
from lysed cells, requiring costly downstream purification steps (Fernandes et al., 2013), 
altered less-complex glycosylation patterns than the human equivalents (Harrison & Jarvis, 
2006; Hollister, Grabenhorst, Nimtz, Conradt, & Jarvis, 2002) with much lower yields 
compared to cultured mammalian cells. 
 
1.2 Chinese hamster ovary cells are the leading system for the expression of 
complex recombinant proteins  
The majority of approved recombinant biopharmaceuticals, including monoclonal antibodies 
(mAbs), are produced in mammalian cell expression systems, predominantly in Chinese 
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hamster ovary (CHO) cells under fed-batch culture conditions (Butler & Spearman, 2014; 
Dumont, Euwart, Mei, Estes, & Kshirsagar, 2016; Mauro, 2018). CHO cells are the current 
leading expression system for the production of biopharmaceuticals due to their 
demonstrated ability to produce complex and correctly folded proteins with ‘human like’ 
post-translational modification (PTMs) coupled with an effective secretion of the mature 
produced protein (J. Y. Kim et al., 2012). In addition, CHO cells can grow in suspension in 
chemically defined serum-free media, on a large scale and produce secretory yields of 
monoclonal antibody in fed-batch culture in excess of 5 g/L (Povey et al., 2014). The secretory 
yield from such an expression system results from the combination of the number of viable 
cells across culture (the integral of viable cell concentration or IVC) and the average amount 
of material expressed by each cell (cell specific productivity, Qp) (Kunert & Reinhart, 2016). 
These attributes can be positively influenced by selecting improved CHO cell hosts, 
modification of the culture conditions, changing the genetic makeup of the vector(s) used to 
drive expression of the gene(s) of interest, and by engineering host cells to enhance their 
growth and/or recombinant protein capacity. The work described in this thesis is focussed 
upon providing a better understanding of the non-coding transcriptome in CHO cells, the 
impact of this on cell growth and recombinant protein production and the potential for 
engineering the non-coding transcriptome to enhance CHO cell growth recombinant protein 
production and quality from CHO cells. 
A short review of relevant engineering approaches taken to improve CHO cell phenotype 
under industrially relevant conditions has previously been described (Fischer et al., 2015; J. 
Y. Kim et al., 2012; J. S. Lee, Grav, Lewis, & Faustrup Kildegaard, 2015). Briefly, approaches 
such as process and media optimisation have been used extensively to accelerate growth 
and increase maximum viable cell density (VCD) (F. Li, Vijayasankaran, Shen, Kiss, & 
Amanullah, 2010). Genetic engineering can further improve cell lines characteristics by 
introducing external genes, overexpressing transcripts beneficial to the cell or preventing the 
expression of transcripts with a detrimental effect. Although most PTMs performed in CHO 
are human-compatible, stably introducing enzymes to decrease immunogenic reaction to 
certain N-glycosylation patterns has been successfully reported (Davies et al., 2001; Ferrara 
et al., 2006; Jeong et al., 2008). An example is the introduction of the alpha-2,6-
sialyltransferase (ST6GAL) enzyme, allowing the expression of proteins with α2,6-sialylated 
glycans (E. U. Lee, Roth, & Paulson, 1989). In addition, cell lines with a complete absence of 
FUT8 activity and subsequent lack of fucosylation in mAbs have been reported (Yamane-
Ohnuki et al., 2004).  
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Altering the metabolism of a CHO cell can reduce nutrient consumption and accumulation of 
toxic by-products, increasing at the same time growth rate and final yield (Chong et al., 2010; 
Fogolıń, Wagner, Etcheverrigaray, & Kratje, 2004; Tabuchi & Sugiyama, 2013). Further, 
metabolic manipulations have generated dihydrofolate reductase (DHFR) and glutamine 
synthetase (GS) defective cell lines, two of the most commonly used CHO cell lines among 
biopharmaceutical manufacturers (Fan et al., 2012; Urlaub & Chasin, 1980; Urlaub, Käs, 
Carothers, & Chasin, 1983). Transfecting these cell lines with vectors containing both a 
transgene and a functional DHFR or GS gene sequence allows metabolic selection of stable 
transfectants through media containing the dihydrofolate analogue methotrexate (MTX) or 
methionine sulfoximine (MSX) (F. M. Wurm, 2004).  
A substantial increase in specific productivity is often a target of cell engineering. Cells 
overexpressing the transcription factors ZFP-TF, ATF4 or GADD34 expressed up to 10-fold 
more recombinant proteins compared to parental cells (Kwon et al., 2006; Ohya et al., 2008; 
Omasa et al., 2008). The elimination of BCL2-associated X protein (BAX) and BCL2-
antagonist/killer (BAK) expression using zinc-finger nucleases causes resistance to apoptosis, 
leading to a final mAb yield up to 5-fold higher (Cost et al., 2010). Integrating these cell 
engineering approaches using the precise gene editing capabilities offered by CRISPR/Cas9 
can be extremely beneficial for cell line development (Fischer et al., 2015).  The disruption 
of COSMC and FUT8 represented the first example of generating multiplexed knockout 
(Ronda et al., 2014), followed by simultaneous disruption of FUT8, BAX and BAK and 
knockout of 10 genes combined with the insertion of the human ST6GAL1 enzyme to 
generate fully humanized N-glycosylation profiles (Amann et al., 2019).  
For the purpose of the work in this thesis, mRNA translation has previously been identified 
as a potential limitation on recombinant protein production from cultured CHO cells, 
particularly the production of monoclonal antibodies (mAbs). mRNA translation is a key 
control point in gene expression and hence in determining CHO cell growth and recombinant 
protein production capacity. Indeed, mRNA translation is a key biological process 
determining global and protein specific synthesis, and hence controlling many cellular 
activities, impacting on IVC, Qp and protein quality (Mead et al., 2015). We recently reviewed 
the key steps regulating translation, how this can be tuned by small non-coding mRNAs such 
as microRNAs and siRNAs, and the expanding knowledge around Long Non-Coding RNAs 
(lncRNAs) and their control of cell phenotype with relevant examples selected from 
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literature. This review was published in the Journal Current Opinion in Chemical Engineering 
as follows; 
Vito D and Smales CM (2018), Engineering of the cellular translational machinery and non-
coding RNAs to enhance CHO cell growth, recombinant product yields and quality, Current 
Opinion in Chemical Engineering 22:199–208, doi: 10.1016/j.coche.2018.11.002. 
This review is reported here and expanded to reflect the full background behind the entire 
PhD project.  
1.3 Engineering of the Cellular Translational Machinery and Non-Coding RNAs to 
Enhance CHO Cell Growth, Recombinant Product Yields and Quality 
1.3.1 Introduction 
As described above, for the production of biopharmaceuticals, Chinese hamster ovary 
(CHO) cells are the most widely used mammalian cell expression system, able to produce 
secretory yields of monoclonal antibody in fed-batch culture in excess of 5 g/L (Povey et 
al., 2014). The secretory yield from such an expression system is governed by the number 
of cells in the bioreactor across the culture (the integral of viable cell concentration or 
IVC) and the average amount of material expressed by each cell, usually referred to as the 
cell specific productivity (Qp) and expressed as pg of protein/per cell/per day (Kunert & 
Reinhart, 2016). mRNA translation is a key cellular process that is involve in determining 
global and protein specific synthesis, and hence control of the abundance of proteins that 
constitute the cellular machinery, cell growth, division and the IVC of culture. Likewise, 
mRNA translation plays a key role in determining the Qp of a given cell line and hence is 
a key regulatory process impacting on the yields and quality of recombinant protein from 
CHO cells (Mead et al., 2015).  
mRNA translation is the process by which the ribosome and associated cellular machinery 
decodes a target mRNA to yield a polypeptide. Translation is a key step in the gene 
expression pathway and is the predominant process by which protein cellular abundance 
is controlled (Schwanhäusser et al., 2011). Over the last few decades it has been 
established that the control in mammalian cells of mRNA translation, and hence protein 
synthesis, is not only determined by the translational machinery, modulation of the 
activity of various translation factors by phosphorylation, and the abundance, availability 
and makeup of a given mRNA, but also by availability, abundance and activity of non-
coding RNAs (H. Janakiraman et al., 2018). Non-coding RNAs are generally described as 
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either long non-coding RNAs of >200 nucleotides in length or small non-coding RNAs <200 
nucleotides and include microRNAs (also referred to as miRs) and tRNAs. A summary of 
the main classes of non-coding RNAs is reported in Table 1.2. 
The discovery of the mechanism(s) by which non-coding RNAs exert an influence on gene 
expression has opened up new opportunities for the engineering of cells to manipulate 
cell processes that underpin cell growth and recombinant protein production and quality. 
Further, manipulation of such non-coding RNAs offers the advantage of not placing an 
additional translational burden on the cell that over-expression of coding mRNAs does. 
Here we briefly review our understanding of the control of mRNA translation in CHO cells, 
describe approaches and outcomes to engineer the translational machinery and non-
coding RNAs in CHO cells, and discuss current and future cell engineering opportunities 
and challenges such approaches present (Summarised in Table 1.3).  
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Table 1.2 - Main classes of non-coding RNAs 
Type Length Transcription Function(s) Characteristics References 
Long non-coding 
RNAs 
>200 nt Pol II Epigenetic modifications 
Assembly of protein complexes 
miRNA decoy 
Translation regulation 
With or without polyA 
Cytoplasmic or nuclear localisation 
Low sequence conservation between 
species 
(Mattick, 2018) 
Transfer RNAs 76-90 nt Pol III Translation of mRNAs 
Generation of short RNAs 
Highly modified 
Compact secondary structure 
(Marín, Fernández-
Calero, & Ehrlich, 2017) 
Ribosomal RNAs 5S - 121 nt  
5.8S - 156 nt  
28S - 5070 nt 
Pol I - 18S, 28S 
and 5.8S 
Pol III - 5S 
 
Translation of mRNAs 
 
Form 60S and 40S ribosomal subunits 




150 nt Pol II and Pol III Processing of pre-mRNA in the nucleus 
Regulation of transcription factors (7SK 
RNA) or RNA polymerase II (B2 RNA) 
Maintaining the telomeres 
Found within the splicing speckles 




- Pol II or Pol III Post-transcriptional modifications to 
rRNAs, tRNAs and snRNAs 
Two large families termed box C/D 
and H/ACA  
(Bachellerie, Cavaillé, & 
Hüttenhofer, 2002) 
microRNAs 21-24 nt Pol II Translation attenuation of target mRNAs  Complete or partial sequence 
complementarity with target (Ambros, 2004) 
short interfering 
RNAs 
20-25 nt Pol III Degradation of target mRNAs  Full sequence complementarity with 
target (Dana et al., 2017) 
Piwi-interacting 
RNAs 
24-32 nt Pol II Epigenetic and post-transcriptional 
silencing of transposons 
Regulation of other genetic elements in 
germ line cells 
 Lack of sequence conservation 
 (Siomi, Sato, Pezic, & 
Aravin, 2011) 
Summary of all known types of mammalian non-coding RNAs with the respective lengths, functions, specific characteristics and references. 
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Table 1.3 - Cell engineering approaches in CHO cells for recombinant protein production 
Method Effect Reference 
Cold Shock Level of luciferase activity increased 6.5-fold at 32 C relative to 37 C due to higher fidelity and accuracy of post-translational events 
(Masterton, Roobol, Al-Fageeh, Carden, & 
Smales, 2010) 
 Protein aggregation of TNFR-Fc was partly reduced in a PERK-dependent way at 31°C (K. Wang et al., 2018) 
 Cooling-induced reprogramming of the translatome increases synthesis of RTN3 (Bastide et al., 2017) 
mTOR 
Signalling 
Adenosine induced growth arrest improved IFN-γ titer 1.4-fold alongside a 2.5-
fold increase in average specific productivity (Chong, Sim, Wong, & Yap, 2009) 
 Expression and phosphorylation profiles of the mTORC1 substrate 4E-binding 
protein 1 (4E-BP1) fluctuate throughout the course of cell culture, with a positive 
correlation between the eIF4E/4E-BP1 stoichiometry and cell productivity in an 
IgG4 producing CHO cell line 
(Jossé, Xie, Proud, & Smales, 2016) 
 Cultivation of mTOR-transgenic CHO-derived cell lines engineered for secretion of 
a therapeutic IgG resulted in antibody titers of up to 50 pg/cell/day, which 
represents a four-fold increase compared to the parental production cell line 
(Dreesen & Fussenegger, 2011) 
siRNA LDH-A activities were decreased by 75-89%, while the specific glucose 
consumption rates were reduced to 54-87% and the specific lactate production 
rates were reduced to 45-79% of the control cell line level, without impairing 
either cell proliferation or productivity 
(S. H. Kim & Lee, 2006) 
 
 siRNA mediated inhibition of PDHKs and LDH-A in CHO cells expressing a 
therapeutic monoclonal antibody reduced lactate production, increased specific 
productivity and volumetric antibody production by 90%, 75% and 68%, 
respectively, without appreciable impact on cell growth 
(Zhou et al., 2011) 
 Ribosome profiling identified NeoR as a highly transcribed and translated gene an 
IgG-producing CHO cell line. Viable cell density was increased by 35% upon siRNA 
knock-down of NeoR, which was accompanied by an 18% increase in product titer 
(Kallehauge et al., 2017) 
 Combined transient siRNA-mediated knockdown of the endoplasmic reticulum 
localized proteins CerS2 and Tbc1D20 resulted in a 50-66% increase in specific 
productivity of CHO-IgG cells 
(Pieper et al., 2017) 
miRNA Co-expression of miR-557 and difficult-to-express antibody resulted in a two-fold 
increase in product titer (Fischer et al., 2017) 
 miR-143 overexpression resulted in a 20% ﬁnal increase in mAb productivity (Schoellhorn, Fischer, Wagner, Handrick, & Otte, 2017) 
 Addition of a synthetic 3'UTR to destabilize DHFR expression allowed the 
generation of stable DG44-derived cell pools expressing a model monoclonal 
antibody (mAb) with low MTX concentrations 
 
(Jossé, Zhang, & Smales, 2018) 
 Inhibition of miR-124-3p and miR-19b-3p in CHO increased X-linked inhibitor of 
apoptosis protein levels, enhancing CHO cell growth and prolonging culture 
longevity while additionally boosting productivity 
 
(Griffith et al., 2018) 
lncRNA Engineering of CHO cells with SINEUP long non-coding RNAs resulted in 150% 
increase in periostin levels in cell supernatant at 72 h post-transfection (Patrucco et al., 2015) 
 The development of a 'universal' protein expression enhancer tool based upon 
long non-coding RNAs allowed expression enhancement in various mammalian 
cells of recombinant proteins in the order of 50-1000%, with more than 200% 
enhancement achieved in most cases 
(Yao et al., 2015) 
Codon 
optimization 
Modification of human interleukin-2 (IL-2) through codons with high gene copy 
number and high codon usage bias significantly increased protein productivity in 
CHO-K1 cells 
(Ou et al., 2014) 
 The majority of gene sequence optimization studies report an increase in protein 
expression level but with huge variability, ranging from none to >1000-fold (Gustafsson et al., 2012) 
 Codon de-optimization of a bispecific antibody sequence through the 
introduction of less frequently occurring codons in CHO showed a doubled final 
yield 
(Magistrelli et al., 2017) 
 In vivo expression of various codon context (CC) optimized IFN-γ in CHO cells 
exhibited at least 13-fold increase in expression level compared to the wild-type 
IFN-γ while a maximum of 10-fold increase was observed for the individual codon 
usage (ICU) optimized genes.  
(B. K. S. Chung, Yusufi, Mariati, Yang, & Lee, 
2013) 
Summary of cell engineering studies discussed in this review grouped by type of approach, with the reported 
experimental effect and the relative reference. 
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1.3.2 The translation machinery, mRNA analysis and manipulation 
As mRNA translation is a key process in defining cell growth, biomass accumulation and 
recombinant protein yields and quality from cultured CHO cells (McLeod et al., 2011; 
Mead et al., 2015), the translational machinery and the abundance and availability of 
global and recombinant mRNAs between cell lines and process conditions has been 
investigated using a variety of approaches. For example, the phosphorylation of the 
translation initiation factor eIF2a and attenuation of global protein synthesis during 
recombinant protein production in CHO cells is known to occur (Figure 1.1A, Steps 1-5) 
(Underhill, Birch, Smales, & Naylor, 2005). Culture temperature has been shown to impact 
mRNA translation and the quality of recombinant product produced (Masterton et al., 
2010) and the PERK-eIF2a pathway (Figure 1.1A, Steps 1-5) was reported to impact upon 
the aggregation of a recombinant TNFR-Fc fusion protein (K. Wang et al., 2018). PERK is a 
type I transmembrane kinase located in the endoplasmic reticulum (ER), that under ER 
stress conditions oligomerizes and trans-autophosphorylates, inhibiting general protein 
translation through the phosphorylation of eukaryotic translation initiator factor-2 
(eIF2α) at serine 51. This event alleviates the overload of proteins entering the ER but at 
the same time allows the selective translation of the transcription factor ATF4, thus 
promoting an antioxidant response, the enhancement of the folding capacity of the ER, 
and the upregulation of macroautophagy. (Hetz & Papa, 2018). Indeed the activity and 
availability of translation factors has been shown to change during culture and under 
different culture conditions, where for example under reduced temperature translation 
elongation factor 2 (eEF2) becomes phosphorylated (Figure 1.1B) and a reprogramming of 
translation occurs that means transcripts with particular codon usage can escape the 
general global attenuation of translation under such conditions and the translation of 
these transcripts is actually enhanced (Bastide et al., 2017). Further, high producing 
antibody cell lines have been shown to maintain translation initiation factors at levels that 
allow such cells to maintain enhanced recombinant protein synthesis above that of lower 
producing cells (Mead et al., 2015). 
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Figure 1.1 - Eukaryotic mRNA translation initiation and elongation  
A | Schematic of eukaryotic translation initiation divided into 9 stages. Following translation termination and recycling of the post-
termination complex (post-TC)(1), the 40S subunit, eIF1, eIF1A and eIF3 bind to the eIF2 ternary complex composed of eIF2, GTP, Met-
tRNAiMet (2) to form the 43S preinitiation complex with eIF5 (3). The phosphorylation of eIF2⍺, one of the subunits of eIF2, causes 
global translation attenuation in response to cellular stress. Subsequently to ATP-dependent mRNA activation (4) by eIF4F and eIF4B, 
the 43S complex attaches on the mRNA (5) and starts scanning of the 5ʹ UTR in a 5ʹ-3ʹ direction (6). Once the initiation codon is 
recognised, the 48S initiation complex is formed, switching the scanning complex to a ‘closed’ conformation (7). The 60S subunit 
together with eIF5B-GTP joins the 48S complex while eIF1, eIF3, eIF4B, eIF4F and eIF5 and eIF2–GDP are displaced (8). Finally, the 80S 
initiation complex ready to start the elongation phase is formed as a result of GTP hydrolysis by eIF5B and release of eIF1A and GDP-
bound eIF5B (9). This figure was modified from “The mechanism of eukaryotic translation initiation and principles of its regulation, 
Jackson RJ, Hellen CU, Pestova TV, Nat Rev Mol Cell Biol. 2010 Feb;11(2):113-27. doi: 10.1038/nrm2838”, to show eIF2⍺ 
phosphorylation control. B | Schematic of eukaryotic translation elongation. Starting with a complex formed by the aminoacyl-tRNAs, 
eIF5A, eEF1A and GTP (not shown) in the ribosome, when the peptide-bond is formed the tRNAs are positioned in a ‘hybrid’ state with 
respect to the ribosome subunits. eEF2 drives translocation, causing tRNA repositioning to a ‘classical’ state, and creating an open A 
site for the incoming aminoacyl-tRNA. Phosphorylation of eEF2 as a result of reduced temperature reprograms translation promoting 
the expression of transcripts with a particular codon usage. This figure was modified from “Roadblocks and resolutions in eukaryotic 














With regard to monoclonal antibody synthesis in CHO and other cells, investigations have 
shown that recombinant antibody production is limited by translational efficiency (Mead 
et al., 2012, 2015; O’Callaghan et al., 2010). Manipulation of the cellular translational 
machinery is however, not straightforward. One global regulator of ribosome biogenesis 
and translation is mTORC1, which coordinates cellular responses to signalling pathways 
involved in sensing growth factors, nutrient availability, intracellular energy status and 
other perceived cell stresses and modulates translation and ribosome biogenesis in 
response (Foster & Fingar, 2010). In particular, mTORC1 can influence translation 
initiation via phosphorylation of eukaryotic initiation factor 4E binding protein (4E-BP1), 
which when phosphorylated at multiple sites promotes dissociation of 4E-BP1 from the 
initiation factor eIF4E (Figure 1.2). Increased phosphorylation of 4E-BP1 has been 
correlated with increased interferon-g production (Chong et al., 2009) whilst the 
stoichiometry of 4E-BP1 to eIF4E is reported to relate to recombinant antibody 
productivity (Jossé et al., 2016) (Figure 1.2). Exogenous mTOR expression has also been 
shown to enhance recombinant protein expression in CHO cells by improving culture 
viability, cell growth, proliferation and cell specific productivity (Dreesen & Fussenegger, 
2011) (Figure 1.2).  
One approach applied to investigate mRNA amounts, and hence determine gene 
expression profiles of high producing or fast-growing recombinant cell lines is 
transcriptomics. A general assumption of most such studies is that the amount of mRNA 
present at a given timepoint reflects the ‘state’ or ‘need’ of a cell with regard to the 
proteins that these mRNAs encode for. As such, transcriptomic profiling has been applied 
to identify mRNAs whose abundance correlates with cell growth and recombinant protein 
productivity and quality with a view to using the identification of such targets to engineer 
the cell for improved performance. Many of these initial studies were hampered by the 
lack of the CHO genome and appropriate arrays, however the elucidation of the genome 
(Lewis et al., 2013; Xun Xu et al., 2011) and advent of RNA-Seq has made it possible to 
undertake such studies with a higher degree of precision. Despite this, there has been 
little consensus across transcriptomic studies to date with regard to those mRNAs that 
correlate with cell growth and recombinant protein productivity (Tamošaitis & Smales, 
2018). Further, previous correlation analysis has shown that transcript amounts and 
translation efficiency are uncoupled for around 95% of investigated genes (Courtes et al., 
2013), providing strong evidence that global and mRNA specific translational control 
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needs to be understood and determined to evaluate the impact of mRNAs on phenotype 
rather than simple mRNA abundance itself.  
In order to address this issue, investigators have begun to apply ribosome footprint 
profiling or RiboSeq analysis to unravel the fine detail of translational control in CHO cells 
(Tzani et al., 2018). This powerful approach allows genome wide, but also transcript 
specific, detail on initiation and elongation stages of mRNA translation to be studied and 
identification of those mRNAs that are being translated at any given time (as opposed to 
just their abundance), the efficiency of mRNA translation and how this changes during a 
process or between cell lines to identify targets for cell line engineering (Tzani et al., 
2018). Indeed, any given mRNA in the cell may be translated by one or multiple ribosomes 
(so called polysomes) at any one time (Godfrey et al., 2017). In some cases the number of 
ribosomes per transcript has been used to estimate translational efficiency of a transcript 
assuming that more ribosomes on a transcript indicates greater translational efficiency 
(Botao Liu & Qian, 2016), but this does not account for elongation speed that RiboSeq 
analysis can. RNA-Seq approaches can also potentially be used to investigate translational 
activity at the single cell level. The application of such approaches is certain to provide a 
more detailed understanding of mRNA translation and its control in recombinant protein 
producing CHO cells, at the population and single cell level and at a global and transcript 
specific level, revealing new engineering approaches by which translation can be 
modulated to enhance protein production.  
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Figure 1.2 - mTOR regulated signalling pathway to control translation initiation 
In response to mitogenic and growth-promoting external signals, receptor tyrosine kinases stimulate Ras and 
PI3K. PI3K causes activation of AKT, which as a result reduces TSC1–TSC2 GAP activity, allowing activation of 
mTORC1 by Rheb-GTP, and negatively regulates the inhibitor of mTORC1 PRAS40. Alternatively, mTORC1 can be 
activated as a result of the inhibitory phosphorylation of TSC1/2 complex mediated by extracellular signal-
regulated kinase (ERK) or p90RSK. The phosphatase PTEN prevents activation of mTORC1 by PI3K while growth-
inhibiting conditions in the environment lead to mTORC1 inhibition through AMP kinase activation.  
mTORC1 phosphorylation of the 4E-BPs promotes the dissociation of eIF4E from 4E-BPs and the subsequently 
interaction with eIF4G and simultaneous stimulation of eIF4A helicase activity caused by S6K-mediated 
phosphorylation of eIF4B and PDCD4, an inhibitor of eIF4A. This cascade of events culminates in the assembly of 
the cap-binding complex eIF4F, composed of eIF4E, eIF4G, and eIF4A, stimulating cap-dependent translation. This 
figure was modified from “Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res. 2011 Dec 
15;17(24):7518-28. doi: 10.1158/1078-0432.CCR-11-1664. Epub 2011 Dec 5., Korets SB, Czok S, Blank SV, Curtin 






1.3.3 microRNAs and siRNAs, short non-coding RNAs that repress mRNA translation 
mRNA translation can also be tuned by non-coding RNAs. One such class of non-coding 
RNA that has been applied to reprogramming translation in CHO cells is that of microRNAs 
(also known as miRs or miRNAs). The potential application of microRNAs to CHO cell 
engineering has recently been reviewed elsewhere (Valdés-Bango Curell & Barron, 2018). 
These RNAs are transcribed as long primary transcripts but then processed to yield small 
(20-23 nucleotide) non-coding RNAs and were first described in C. elegans. MicroRNAs 
tend to act as repressors of translation of target mRNAs by interacting with the 
3’untranslated regions (3’UTRs) of such mRNAs (Figure 1.3). Functional complexes 
composed of miRNAs and Argonaute (AGO) proteins bind the target mRNA in the seed 
region (nucleotides 2 to 8 in the miRNA). These complexes repress the mRNA expression 
by inhibiting the initiation step of translation, likely through release of eukaryotic 
initiation factor 4 A-I (eIF4A-I) and eIF4A-II, and subsequently promoting mRNA 
deadenylation through interaction with protein GW182, which binds polyadenylate-
binding protein (PABPC), the deadenylation complexes poly(A)-nuclease deadenylation 
complex subunit 2 (PAN2)–PAN3 and carbon catabolite repressor protein 4 (CCR4)–NOT. 
This is then followed by decapping by the complex mRNA-decapping enzyme subunit 1 
(DCP1)–DCP2, finally leading to 5ʹ–3ʹ mRNA degradation (Figure 1.3). A given microRNA 
can in theory target multiple mRNAs via base pairing and hence modulate multiple mRNAs 
and pathways without placing an additional translational burden on the cell (Valdés-
Bango Curell & Barron, 2018). 
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Figure 1.3 - Schematic depicting the main mechanisms of action for microRNA-mediated mRNA repression 
in animals. 
A | Imperfect complementarity between the miRNA and the target mRNA leading to mRNA repression is the most 
common mechanism in animals. Complementarity in the seed region between nucleotides 2 to 8 of the miRNA 
(indicated in red) is necessary and sufficient to trigger the inhibition of target  mRNA translational initiation and 
stimulation of RNA decay. Complementarity on the 3’ supplementary sites between nucleotides 12 and 16 of the 
miRNA (indicated in green) can be present to enhance seed region binding. Although not shown in the figure, a 
single 3’ UTR region can be target of multiple miRNAs simultaneously. The second panel of this figure was adapted 
from: Regulation of microRNA function in animals, LFR. Gebert & IJ. MacRae, Nature Reviews Molecular Cell 
Biology, 2019. B | Extensive complementarity between the siRNA, loaded on the RISC complex, and the mRNA, 


















Early microRNA studies in CHO cells were limited by the lack of available Chinese hamster 
sequence annotation of microRNA primary transcripts, and hence chimeric microRNAs 
that contained the mature miR sequence but flanking sequences in the primary transcript 
from other species were used. Subsequent studies showed that endogenous CHO 
microRNA flanking sequences gave rise to higher expression when over-expressing 
microRNAs (Klanert et al., 2014). Recent engineering approaches harnessing microRNAs 
include studies that look to enhance the ability of CHO cells to produce so called ‘difficult 
to express proteins’. For example, one such study showed that a CHO cell line 
constitutively over-expressing miR-557 and a difficult to express antibody produced twice 
the antibody yield of cells engineered to express a negative control microRNA (Fischer et 
al., 2017). A further study reported that both transient and stable miR-143 over-
expression resulted in enhanced difficult to express protein production and targeted 
MAPK7 in CHO cells (Schoellhorn et al., 2017). The natural repertoire of microRNAs has 
also been harnessed to repress expression of the DHFR selection marker during cell line 
construction and allow the generation of higher producing cell pools (Jossé et al., 2018). 
Others have shown that microRNA fingerprints or signatures can be correlated with 
growth rate across a number of different CHO cell lines (Klanert et al., 2016). 
However, although microRNA engineering appears an attractive approach by which to 
tune translation of multiple mRNAs and translation of specific targets, the potential large 
number of predicted targets of any given microRNA means that the outcome of such 
engineering approaches can be difficult to predict as is identifying which targets a given 
microRNA interacts with. Barron and colleagues have described a system termed ‘miR-
CATCH’ that allows the investigator to identify those microRNAs that interact with a given 
target and thus validate these for potential cell engineering approaches (Griffith et al., 
2018). The authors had identified that the overexpression of the X-linked inhibitor of 
apoptosis (XIAP) enhanced CHO cell productivity, growth and culture longevity. To avoid 
overexpressing this gene and placing an additional translational burden on the cell, 
microRNA regulators of XIAP were identified using a biotin-labelled antisense DNA for 
XIAP resulting in the capture of interacting microRNAs. Inhibition of two of these 
microRNAs resulted in increased XIAP protein expression, validating the microRNA catch 
approach and the utility of this for identifying cell engineering targets.  
The use of small interfering RNAs (siRNAs) has also proved to be an effective strategy for 
CHO cell line engineering to selectively knockdown expression of target genes detrimental 
to cell growth or productivity. The advantage of knockdown, as opposed to knockout 
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strategies, is that essential genes can be reduced in their expression and the impact on 
cell phenotype assessed when knockout proves fatal. siRNAs mediate repression of a 
target mRNA translation by guiding its sequence-dependent slicing and subsequent 
degradation. siRNAs begin as long dsRNA molecules which are processed by the 
endonuclease Dicer into active ~21-25 nt constructs. These are then loaded on the multi-
protein RNA-induced silencing complex (RISC), where the guide strand pairs with its fully 
complementary target mRNAs. This triggers slicing of the target gene by RISC, which is 
then recycled for another few rounds of slicing, while the target mRNA is degraded (Figure 
1.3). One successful application of siRNA engineering has been the inhibition of lactate 
dehydrogenase-A (LDH-A) on its own (S. H. Kim & Lee, 2006), or in combination with 
pyruvate dehydrogenase kinases (PDHKs) (Zhou et al., 2011) to significantly reduce lactate 
accumulation in cultured CHO cells without negatively impacting cell growth and 
enhancing cell specific productivity. A further group undertook ribosomal profiling in CHO 
cells and identified the resistance marker NeoR as being highly transcribed and translated, 
and as expression of this exogenous gene in CHO cells is not required, used siRNA 
knockdown to reduce its expression with a resultant improvement in production and 
growth of the host observed (Kallehauge et al., 2017). Finally, a siRNA approach was used 
to knockdown the expression of the endoplasmic reticulum localized proteins ceramide 
synthase 2 (CerS2) and Rab1 GAP Tbc domain family member 20 (Tbc1D20) in CHO IgG 
producing cells with a subsequent observed increase in recombinant protein specific 
productivity and enhanced cell growth (Pieper et al., 2017). 
 
1.3.4 Long non-coding RNAs (lncRNAs) and their manipulation 
Recent genome wide analysis in mammalian cells estimates that 75% of the transcriptome is 
composed of non-coding sequences (Djebali et al., 2012) and led to the identification of a 
heterogeneous class of transcripts known as Long non-coding RNAs (lncRNAs) (Kapranov et 
al., 2007). LncRNAs are defined as transcripts longer than 200 nucleotides that lack a 
significant open reading frame (ORF) and are usually transcribed by RNA polymerase II and 
spliced, with or without, 3’ polyadenylation (Figure 1.4) (Wilusz, 2016). These molecules are 
emerging as key regulators in various biological processes both in the nucleus and the 
cytoplasm (Geisler & Coller, 2013), including epigenetic regulation, transcriptional control, 
splicing events, and mRNA translation. While most of our current understanding into 
lncRNAs and the underlying mechanism(s) by which they elicit their responses has come from 
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studies relating to disease and developmental studies, their potential as targets for cell 
engineering in mammalian cell factories remains largely unexplored.  
 
 
Figure 1.4 - Schematic depicting LncRNA transcription, localisation and functions in the cell 
While all lncRNA genes are transcribed by RNA polymerase II, only a subset undergoes co-translational 
polyadenylation. The transcripts are then spliced and remain in the nucleus, where they act at an epigenetic and 
transcriptional level to silence or to enhance the expression of single genes or even entire genomic regions and 
to regulate splice variants formation. Alternatively, transcripts are actively exported in the cytoplasm, where they 
selectively promote translation of specific transcripts or bind miRNAs working as a decoy to alleviate targeted 
mRNA repression.  
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Figure 1.5 - Graphical representation of the main known lncRNAs functions in the cell 
LncRNAs in the cell can act in the nucleus at an epigenetic level to silence or to enhance the transcription of entire 
genomic regions (A to D) and influence alternative splicing (E). When transported in the cytoplasm, they can bind 
to microRNAs and compete with their natural targets (H) or even interact directly with mRNAs to regulate their 
stability (F) and selectively promote translation (G,I). The figure is taken from: Long Non-Coding RNAs: New 
Players in Hematopoiesis and Leukemia, M. Morlando, M. Ballarino,  A. Fatica, 2015, Front Med, PMID: 25927065. 
 
The first analysis of the non-coding transcriptome in CHO cells under batch and fed-batch 
conditions has recently been published, unveiling a number of differentially regulated 
lncRNAs depending on feed and culture time which could be targets for cell engineering (Vito 
& Smales, 2018). One of the main challenges in identifying lncRNAs is the low sequence 
conservation between species. This, coupled with incomplete genome sequences and partial 
annotations of coding and non-coding genes of most vertebrates including Chinese hamster, 




Figure 1.6 - Summary of ENSEMBL number of genes for hamster, human and mouse 
The figure shows the number of genes for each annotated class in the ENSEMBL database for Chinese hamster 
(Cricetulus griseus, CriGri_1.0, GCA_000223135.1 and CHOK1GS_HDv1, GCA_900186095.1), mouse (Mus 
musculus, GRCm38.p6, GCA_000001635.8) and human (Homo sapiens, GRCh38.p12, GCA_000001405.27). While 
the number of coding genes is comparable between the four organisms, human contains 14,720 and mouse 9,443 
annotated long non-coding genes as compared to 2,563 for CriGri. 
 
A recently published study compared lncRNAs among 16 vertebrates and the echinoid sea 
urchin finding thousands of human lncRNA homologs with conserved genomic position 
sharing 5’-biased patches of sequence nested in rewired exonic architectures (Hezroni et al., 
2015). The FANTOM consortium applied a cap analysis of gene expression (CAGE) to data 
obtaining more than 27,919 human lncRNA genes with high-confidence 5ʹ ends and 
expression profiles across 1,829 samples from the major human primary cell types and 
tissues (Hon et al., 2017). Through the incorporation of conservation and expression data, 
the consortium was able to identify 19,175 potentially functional lncRNAs in the human 
genome. Due to the tissue-specificity of lncRNAs, comparing the expression among several 
cell types has led to a more robust identification of functional targets. By modelling their 
effects on the activity of transcription factors, RNA-binding proteins, and microRNAs in 5,185 
TCGA tumours and 1,019 ENCODE assays, it was possible to identify potential lncRNAs 
involved in dysregulated cancer pathways. This approach indicated OIP5-AS1, TUG1, NEAT1, 
MEG3, and TSIX, as synergic lncRNAs leading to dysregulated cancer pathways in multiple 
tumour contexts (Chiu et al., 2018). A similar effort using nascent RNA capture sequencing 
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identified 1145 temporally expressed S-phase-enriched lncRNAs across TCGA data sets in 
several cancer models showing effects on pathways including FGF/FGFR and its downstream 
PI3K/AKT and MAPK pathways (Ali et al., 2018).  
The NEAT1 lncRNA is a central component of paraspeckles, nuclear bodies that regulate 
multiple aspects of gene expression, promoting their formation through ATR signalling in 
response to replication stress and p53 activation (Adriaens et al., 2016). The RNA-binding 
NONO–PSF heterodimer binds a large number of expressed pri-miRNAs in the paraspeckles 
to promote processing by the Drosha–DGCR8 microprocessor. NEAT1 thus regulates efficient 
processing of potentially an entire class of small non-coding RNAs in the nucleus by 
interaction with the NONO–PSF heterodimer as well as other ribosome binding proteins 
(RBPs) (Jiang et al., 2017). 
The relationship between lncRNAs and the translational machinery was further elucidated 
with the discovery of a long nucleolus-specific lncRNA (LoNA) (D. Li et al., 2018). LoNA is 
expressed at high levels at resting state, suppressing rRNAs transcription in the nucleoli 
through the combined effects of its 5ʹ portion, which binds and sequesters nucleolin, and its 
snoRNA like 3ʹ end, which recruits and diminishes fibrillarin activity to reduce rRNA 
methylation. When the cell needs to sustain an elevated translational load, LoNA expression 
decreases leading to elevated rRNA and ribosome levels, an increased proportion of 
polysomes, mRNA polysome loading, and eventually protein synthesis. 
The first successful engineering of lncRNAs for enhanced recombinant protein production 
involved manipulation of SINEUPs, natural and synthetic antisense lncRNAs that can activate 
translation in a gene-specific manner using an inverted SINEB2 sequence (Carrieri et al., 
2012). A Binding Domain (BD) located towards the 5’ region of the SINEUP overlaps a target 
mRNA of choice conferring specificity, while an inverted SINEB2 element defined as the 
Effector Domain (ED) provides the translation activation function (Podbevšek et al., 2018). 
Synthetic SINEUPs have been used to increase translation and secretion of recombinant 
proteins in a range of mammalian cell lines, including CHO (Patrucco et al., 2015) and HEK293 
(Yao et al., 2015) cells. Translation of secreted proteins usually occurs on the endoplasmic 
reticulum after recognition of the nascent signal peptide by the signal recognition particle 
(SRP) (Reid & Nicchitta, 2015). Transiently transfected natural and synthetic SINEUPs 
targeting the secreting leader sequence of endogenous and exogenous transcripts have been 
shown to increase the secreted levels up to two-fold for a single chain variable fragment 
(scFV) directed against the human protein DPP6 (Patrucco et al., 2015).  
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SINEUPs can also be used for high-throughput gene function screenings with comparable 
results to RNAi in most higher eukaryotic expression systems, including HEK293T, HEK293A, 
HeLa and CHO cells (Yao et al., 2015). SINEUPs represent a unique tool to specifically enhance 
the expression of secreted recombinant proteins in CHO cells and other mammalian systems 
and to investigate potential targets for cell engineering. As further studies define those 
lncRNAs present in CHO cells and how these influence cell growth, fate and recombinant 
protein production, engineering of these non-coding RNAs is sure to offer potential to further 
tune and enhance mRNA specific and global mRNA translational efficiency.  
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1.3.5 tRNAs and mRNA translation 
The use of specific codons with high gene copy number and high codon bias coupled with 
the modulation of intracellular tRNA concentration has been shown to improve protein 
production in CHO cells (Ou et al., 2014). However, despite translational efficiency often 
being considered the mere result of codon optimization based on the correlation between 
codon bias and tRNA gene copy numbers (Figure 1.7), recent evidence suggests a 
considerably more intricate picture where ribosome collisions, co-translational folding, 
mRNA stability, composition, charge status and post-transcriptional modifications of the 
tRNA pool all contribute to finely tune protein production in response to the environment 
(Hanson & Coller, 2018).  
 
 
Figure 1.7 - Correlations between tRNA gene copy numbers and codon usage 
The gene copy numbers for each codon were retrieved from the genomic tRNA database (GtRNAdb) while the 
codon usage was sourced from either the Codon Usage Database (kazusa.or.jp/codon/), indicated as “Kazusa”, 
or the Codon Usage Table Database (hive.biochemistry.gwu.edu/review/codon), indicated as “Hive’. For each 
aminoacid, the summary of every single codon coding for the same aminoacid is shown as a % of the total. 
Cricetulus griseus (CriGri) is shown in blue, Human in grey, and Mouse in orange. The figure shows in panel A | 
the correlation between the Hive and gene copy number, panel B | shows the correlation between the Kazusa 
and gene copy number and panel C | shows the correlation between Kazusa and Hive. The two databases perform 
similarly, giving a significantly higher correlation (R = 0.68 - 0.70) with a lower p-value (0.0007 and 0.0004) for 







Controlling the translational capacity of an expression system through the use of 
alternative codon combinations modulates ribosome decoding speed, impacting protein 
quality as well as final yield (Zhao, Yu, & Liu, 2017). The use of suboptimal codons has 
been reported to slow translation at key structural motifs in order to facilitate correct 
co-translational polypeptide folding and signal recognition particle (SRP) recognition, 
which assists in protein translocation across membranes (Magistrelli et al., 2017). Thus, 
although recombinant genes are often ‘codon optimized’, we do not currently have all the 
information required around codon usage, context, tRNA abundance, modifications and 
charging to fully harness codon usage in recombinant sequences or to engineer tRNA 
abundance.  
Codon bias has been referred to as a secondary genetic code that impacts on the fidelity 
of translation, efficiency of translation, polypeptide/protein folding and mRNA 
stability/half-life (Hanson & Coller, 2017). The cell utilizes such codon effects to tailor the 
proteome and allow reprogramming, such as under cold stress whereby reprogramming 
and synthesis of specific proteins is enhanced through codon bias (Bastide et al., 2017). 
Codon bias or optimization is also linked to tuning mRNA stability and stable mRNAs are 
found to be enriched in codons that are considered optimal whilst also impacting on 
ribosome translocation (Presnyak et al., 2015). Specific combinations of adjacent codons in 
yeast and mammalian cells can have an effect on translation efficiency resulting in reduced 
expression, proving how the focus must be on global translation efficiency and codon context 
as opposed to single codons optimality (Ang, Kyriakopoulos, Li, & Lee, 2016; B. K.-S. Chung, 
Yusufi, Mariati, Yang, & Lee, 2013; Gamble et al., 2016). On top of this, mRNA secondary 
structure combined with tRNA abundance modulate translational elongation speed among 
different regions of the same transcript to avoid excessively slow or fast ribosome movement 
(Gorochowski, Ignatova, Bovenberg, & Roubos, 2015). As such, there remains enormous 
potential to enhance recombinant protein yields from further manipulation of codon usage. 
In order to further enhance recombinant protein yields by manipulation of codon usage it is 
necessary to further understand the abundance and modifications of tRNAs and the role 
these play in their activity. Determination of tRNA copy numbers can now be undertaken 
using RNA-Seq approaches. tRNA secondary structure and nucleotide modifications, mainly 
methylations, impair the efficiency of standard sequencing. Dedicated protocols based on an 
initial de-methylation step were recently developed to overcome this limitation, allowing for 
direct measurement of each tRNA abundance and detailed mapping of modifications (Cozen 
et al., 2015; Zheng et al., 2015). While some methods focus exclusively on mature tRNAs 
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(Shigematsu et al., 2017), partial alkaline RNA hydrolysis complemented with tRNA 
precursors enrichment identified tRNA leaders, trailers, and introns and showed that around 
half of all predicted tRNA genes are transcribed in human cells (Gogakos et al., 2017). While 
tRNA abundance is a major modulator of translational elongation, the aminoacylation state 
also has to be considered. The addition of chemical steps that specifically remove the 3’A 
residue in uncharged tRNA coupled with the aforementioned de-methylation RNA-Seq 
protocols showed most cytosolic tRNAs in HEK293T cells are charged at >80% levels, whereas 
tRNASer and tRNAThr are charged at lower levels (Evans, Clark, Zheng, & Pan, 2017). 
An additional layer of regulation during elongation is chemical modification of nucleotides 
among tRNAs (Figure 1.8) (T. Pan, 2018). One of the key enzymes to regulate the methylation 
state of tRNAs is the demethylase ALKBH1, which acts dynamically in response to specific 
conditions such as variations in glucose availability to impact translation at both the initiation 
and the elongation phases (F. Liu et al., 2016). These modifications can have different effects 
depending on the target tRNA and the position in the transcript, as it was shown ALKBH1 is 
required for the formation of essential methylations at position 34 of anticodon in 
cytoplasmic tRNALeu and mitochondrial tRNAMet (Kawarada et al., 2017). Advances in high-
throughput sequencing and data analysis have also allowed the identification of new classes 
of small non-coding RNAs derived from tRNAs: stress-induced tRNA halves (tiRs) and tRNA-
related fragments (tRFs). These RNAs act on cell proliferation, priming of viral reverse 
transcriptase, regulation of gene expression, RNA processing, modulation of the DNA 
damage response, tumour suppression, and stress response (Kumar, Kuscu, & Dutta, 2016). 
The application of such approaches to study tRNAs in CHO cells will further elucidate the 
mechanism(s) by which tRNAs and their modifications modulate translation.  
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Figure 1.8 - Summary of chemical modifications to nucleotides 
A | Known tRNA chemical modification to nucleotides in Human (left) and S. cerevisiae (right). The color indicates 
the percentage of modification frequency for each nucleotide on average considering all tRNAs in the Modomics 


























1.3.6 Challenges in modulation of translation for enhanced CHO cell biotherapeutic 
protein production 
Our understanding and ability to manipulate the translational machinery and harness non-
coding RNAs to enhance global and recombinant protein synthesis in CHO cells has advanced 
rapidly in the last decade. Further, the advent of the Chinese hamster and CHO cell line 
genomes has helped in the identification of non-coding RNAs such that these can be studied 
and manipulated. The ability of non-coding RNAs, in particular microRNAs, siRNAs, lncRNAs 
and tRNAs to tune both global and transcript specific translation, and hence protein 
synthesis, offers enormous opportunities to use these to enhance cell growth and 
proliferation, extend culture lifetimes, and increase recombinant protein yields and quality. 
However, our ability to harness these non-coding RNAs by engineering of CHO cells is 
currently limited by our knowledge of the mechanisms and targets by which many of these 
non-coding RNAs elicit their responses.  
The manipulation of microRNAs that can, in theory, tune multiple target transcripts appears 
an appealing approach, however this approach alone is unlikely to deliver new commercially 
viable host cells with dramatically enhanced phenotypes due to the fact these are ‘tuning’ 
molecules and tend to be negative regulators and off target approaches can be difficult to 
control. Where these might be more applicable is for the tuning of transcript targets with a 
specific role, such as enzymes involved in glycosylation or to harness modulation of the cells 
own endogenous microRNA pool as inducible controllers of exogenous gene circuits.  
The potential of lncRNA engineering is very much in its infancy and would appear to offer the 
potential to act as negative and positive regulators of gene expression. The limitation here is 
that many of these are, as the name suggests, long RNAs and thus the manipulation is more 
challenging and we do not yet understand what, if any, role many of these play in the cell. 
The control of gene expression via the elongation step of mRNA translation and tRNA 
availability, charging and modification, linked with improved predictive models for how such 
changes in abundance or modification change elongation rates of target mRNAs is likely to 
offer advances that can be directly applied industrially to engineering of the target 
recombinant gene(s) and of pathways in the cell to deliver new engineered host cell lines 
with improved growth, productivity and post-translational modification abilities. However, 
the major challenge will be to unravel the mechanisms by which the control on gene 
expression that these different non-coding RNAs provide are coordinated together, in order 
to reprogram the translational efficiency of current CHO cell chassis, under appropriate 
 42 
bioprocessing conditions (including continuous processes) to generate new chassis with 
enhance bioprocessing properties. 
 
1.4 Long non-coding RNAs are emerging as key regulators of cell biology 
While the majority of CHO cell line engineering development studies initially focussed upon 
manipulation of coding genes, the growing awareness of non-coding RNA as central 
regulators of cell biology has exponentially increased the interest towards these molecules. 
Although the manipulation of microRNAs in particular has been successfully used in the 
research laboratory to enhance CHO cells productivity of recombinant proteins, to the 
authors knowledge none of these approaches have yet to be translated into manufacturing 
host cell lines.  
The entire class of non-coding RNAs known as long non-coding RNAs (lncRNAs) remains 
poorly studied in CHO cells (Barron et al., 2011; Bort et al., 2012; Fischer et al., 2017; Stiefel, 
Fischer, Sczyrba, Otte, & Hesse, 2016). As described earlier, these transcripts are defined as 
RNAs longer than 200 nucleotides that lack a significant open reading frame (ORF), are 
usually transcribed by RNA polymerase II and spliced, with or without 3’ polyadenylation 
(Kashi, Henderson, Bonetti, & Carninci, 2016; Kung, Colognori, & Lee, 2013; Wilusz, 2016). 
They are merging as key regulators in various biological processes including, but not limited 
to, epigenetic regulation (Betancur, 2016), transcriptional control (Trimarchi et al., 2014), 
splicing events (Gonzalez et al., 2015), and mRNA translation (Carrieri et al., 2012), both in 
the nucleus and the cytoplasm (Geisler & Coller, 2013). Our understanding into lncRNAs and 
their mechanisms is constantly growing, but the majority of information around these comes 
from studies relating to disease (Schmitt & Chang, 2016) and developmental studies (Perry 
& Ulitsky, 2016). Therefore, in the work described in this thesis it was decided to obtain the 
first landscape of long non-coding RNA expression in multiple CHO cell lines under batch and 
fed-batch conditions with different feeding approaches to investigate the behaviour of these 
transcripts and identify new targets for manipulation (Chapter 3). We further expanded this 
study in collaboration with the Danish biotech company Symphogen, sequencing the whole 
transcriptome of six IgG productive CHO cell lines cultivated in an automated ambr®15 
system under controlled conditions (Chapter 4).  
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1.5 Translation is influenced by the codon sequence of mRNAs 
As mRNA translation is a complex process composed of sequential phases and requiring the 
assemble of cellular machinery containing multiple subunits, protein abundance control in 
the cell can be tuned at multiple levels depending on internal or external factors (Kelen, 
Beyaert, Inzé, & Veylder, 2009). Due to this central role of translation in controlling gene 
expression, numerous works in CHO cells have investigated this process, showing a 
dependence on the phosphorylation of key translation factors like eIF2a causing attenuation 
of global protein synthesis (Underhill et al., 2005), on global translation efficiency (Mead et 
al., 2012) and on culture temperature, which impacts on the quantity and quality of 
recombinant protein produced (Masterton et al., 2010; Underhill et al., 2005; K. Wang et al., 
2018). The interplay between these parameters and their variations throughout culture can 
have an impact with opposed effects for different transcripts.  
Under reduced temperature, translation elongator factor 2 (eEF2) becomes phosphorylated 
leading to a reprogramming of translation and causing global attenuation, which can be 
escaped by some transcripts by specific codon usage (Bastide et al., 2017). The degeneracy 
of the genetic code allows the use of different synonymous codon sequences to achieve the 
same polypeptide, providing the option to tailor an exogenous recombinant coding sequence 
to the codon usage of the expression system of choice (Welch, Villalobos, Gustafsson, & 
Minshull, 2009). Indeed, codon usage is routinely considered when designing a recombinant 
sequence for maximizing protein expression, leading to an increase of up to 1000-fold in 
protein yield, but much more modest effects in general (Gustafsson et al., 2012; Kimchi-
Sarfaty et al., 2013).  While this approach assumes that rare codons are rate limiting for 
mRNA translation and thus protein production (Mauro & Chappell, 2014), recent works 
suggest a much more complex picture, where mRNA stability, ribosome speed and folding 
are influenced by specific codons and codon combinations, especially in mammalian cells 
(Brule & Grayhack, 2017).  
A recent study used codon de-optimization of a bispecific antibody sequence through the 
introduction of less frequently occurring codons in CHO cells, showing an overall increase in 
final yield (Magistrelli et al., 2017). One of the reasons underpinning this different outcome 
could be the existence of distinct codon usage patterns depending on the cell type and phase, 
as reported in the case of proliferation and differentiation (Gingold et al., 2014; Plotkin, 
Robins, & Levine, 2004), or even among specific Gene Ontology (GO) sets of genes (Rudolph 
et al., 2016). On top of the intrinsic codon usage variability, mammalian cell factories carry 
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an additional burden on translation represented by the recombinant gene of interest and 
the selection marker used to generate the stable cell lines, which can account for up to 15% 
of the total ribosome capacity in the cell (Kallehauge et al., 2017).  
An additional layer of complexity is the determination of the tRNA pool, a key player of 
translation elongation. Whereas an accurate quantification of single tRNA species by high 
throughput sequencing techniques has been limited due to secondary structure and 
nucleotide modifications, new protocols have recently been developed to overcome most of 
the limitations these place upon using RNA-Seq to determine tRNA abundance (Gogakos et 
al., 2017; Shigematsu et al., 2017; Zheng et al., 2015). AlkB-facilitated RNA methylation 
sequencing (ARM-Seq) in particular takes advantage of the bacterial dealkylating enzyme 
AlkB to remove methyl groups from m1A, m3C and m1G residues in tRNAs allowing a much 
more accurate determination of tRNAs species present and their abundance (Cozen et al., 
2015; Hrabeta-Robinson, Marcus, Cozen, Phizicky, & Lowe, 2017). In Chapter 5 of this work 
is presented the first description of tRNA quantification in a host CHO-S cell line under batch 
and fed-batch conditions and both null and IgG1 producing CHO DG44 cell lines cultivated in 
an automated mini-bioreactor setting using two different feeding strategies. In addition, as 
cooling is known to globally repress translation and the elongation phase in particular 
(published work reported in Appendix), the ARM-Seq protocol was applied to Human 
Embryonic Kidney (HEK293) cells to investigate the effects of temperature on the tRNAs pool. 
1.5.1 Translation can be computationally modelled to predict decoding speed 
Progress in our knowledge of the concentrations and activities of biological components and 
the improvement of quantitative methods in high-throughput biology has enabled 
development of more accurate calculations of kinetic rate constants and other parameters 
to model mRNA translation. Many attempts to model mRNA translation are reported in 
literature, but the majority of these do not give a systems-wide and dynamic representation 
of the process (Dominique Chu, Barnes, & von der Haar, 2011; Gromadski & Rodnina, 2004; 
Reuveni, Meilijson, Kupiec, Ruppin, & Tuller, 2011; Romano, Thiel, Stansfield, & Grebogi, 
2009; Zouridis & Hatzimanikatis, 2007). Therefore, a tool was developed (D. Chu, Zabet, & 
von der Haar, 2012), and subsequently updated (Tarrant & Von Der Haar, 2014), using mixing 
agent-based techniques with event-driven stochastic simulation algorithms to address this 
(Gillespie, 1977). This tool is able to calculate the decoding speed of a given coding sequence 
and to predict the slowest and the fastest possible combinations of codons that code for the 
same amino acid sequence. Each transcript, represented as a string of codons with an initial 
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binding site summarizing a 5ʹ-UTR, can be occupied by multiple ribosomes at the same time, 
encapsulating information about the particular mRNA they are bound to, the position as well 
as information about the tRNA they are interacting with.  
The model assumes total numbers of tRNA, mRNA and ribosomes remain unchanged over 
the course of a simulation run. The following events drive the simulation: 
1. Binding of free ribosomes to an initial binding site on a transcript 
2. Binding of ribosomes located on an initial binding site to the first codon 
(AUG site) 
3. Binding of near/non-cognate aa-tRNAs to unoccupied bound ribosomes 
4. Unbinding of near/non-cognate tRNAs from a bound ribosome 
5. Translocation of ribosomes to the next codon 
6. Aminoacylation of uncharged tRNA 
7. Re-initiation/dissociation of ribosome once the ribosome has reached the end of 
the ORF 
In biological systems, translation initiation is composed of multiple steps, partially 
determined by structural properties of the 5ʹ-UTR, assembly of ribosomal subunits and 
scanning of the 5ʹ-UTR (von der Haar & McCarthy, 2002). The single parameters of these 
steps are poorly characterized, therefore this sequence of events was collapsed into a single 
initiation step (Event 1) following second-order kinetics with a mRNA-type specific rate 
constant. ORF specific translation rate starts with when the ribosome binds to the first AUG 
site (Event 2), which follows 0-th order dynamics. Events 3 to 5 summarize the movement of 
a ribosome from one codon to the next, requiring an aa-tRNA to bind to the ribosomal 
binding site, to pass a proof-reading step and to deliver the amino acid (Gromadski & 
Rodnina, 2004). Both cognate and near-cognate aa-tRNAs can bind to the ribosome in this 
model, then the tRNA is accepted or rejected depending on whether the aa-tRNA is cognate 
or near-cognate. The model loops into Event 4 if the tRNA is rejected, returning the aa-tRNA 
to the pool, while it proceeds to Event 5 if the tRNA is accepted, resulting in a de-
aminoacylation of the tRNA at the ribosomal P-site. When the next elongation cycle is 
completed, the uncharged tRNA unbinds and Event 6 summarizes an aminoacylation event 
using Gillespie's algorithm assuming first-order kinetics and a fixed rate constant that is equal 
for all tRNA species (Dominique Chu et al., 2011). This model of elongation was applied to 
mRNAs with roles in neuronal processes identified by polysome profiling to analyse 
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elongation over the initial 20 codons, showing that a subset of mRNAs, including RTN3 and 
Noggin, contained codons that require less abundant tRNAs in the 5’ end of the transcripts, 
allowing them to escape the repression of elongation occurring during temperature 
decrease. This work was published in Current Biology as follows, and is reported in the 
Appendix: 
Bastide A, Peretti D, Knight JR, Grosso S, Spriggs RV, Pichon X, Sbarrato T, Roobol A, Roobol 
J, Vito D, Bushell M, von der Haar T, Smales CM, Mallucci GR, Willis AE, (2017), RTN3 Is a 




Chapter 5 describes the application of this model to predict the decoding speed of model 
recombinant proteins based on tRNA gene copy numbers and the tRNA abundances 
measured with ARM-Seq to assess differences in codon combinations of the coding sequence 
in CHO under different conditions. 
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1.6  Aims of the work described in this thesis 
The aims and objectives of the work described in this thesis were therefore to; 
 
1. Obtain the first landscape of long non-coding RNA (lncRNA) expression in CHO cells in 
response to different culture conditions. 
2. Improve the annotation of lncRNAs in CHO cell databases and their connection to coding 
genes. 
3. Identify candidate non-coding genes to use for genetic manipulation to enhance desirable 
CHO cell properties, specifically growth and recombinant protein productivity. 
4. Quantify tRNAs in CHO cells for the first time using AlkB-facilitated RNA methylation 
sequencing. 
5. Assess the impact of recombinant protein expression, feed and time point sampling on the 
tRNA pool. 
6. Use the quantified tRNAs in a translational elongation phase computational model to 
calculate the predicted decoding speed of various recombinant transcripts and to predict the 
fastest and slowest possible codon combinations with the same primary amino sequence. 
 





Chapter 2 Materials and Methods 
 
2.1 Cell culture and RNA extraction 
2.1.1 CHO-S cell line 
A CHO-S host cell line (ThermoFisher Scientific, MA, USA) was cultured in a Lab-Therm LT-X 
(Kühner AG, Basel, Switzerland) shaking incubator at 37°C, 5% CO2, 125 rpm and 70% 
humidity in chemically deﬁned serum-free growth medium (CD CHO, ThermoFisher 
Scientific). Fed-batch cultures were supplemented with CHO CD Efficient Feed B Liquid 
Nutrient Supplement (ThermoFisher Scientific) immediately on Day 0 with 15% (v/v) of the 
initial starting volume, followed by 10% (v/v) supplementation on Day 3 and Day 6. Four 
biological replicates of each culture process (batch and fed-batch) were seeded at 3x105 
viable cells/mL from 20 mL cultures with a culture viability ≥ 98.5% in 120 mL CD CHO starting 
working volume in 500 mL polycarbonate Erlenmeyer flasks with vented caps (Corning). 
Viable cell concentrations and culture viability were determined daily using a Vi-CELL XR Cell 
Viability Analyzer (Beckman Coulter, Inc., Brea, CA, USA) on 1 mL culture samples. Cell 
samples of 1 x 107 viable cells were taken from each biological replicate flask after 96 hours 
(day 4) and 144 hours (day 7) of culture and small RNAs under 200 nt in length were 
immediately extracted using the commercially available mirVana miRNA Isolation Kit 
(ThermoFisher Scientific) and treated with RapidOut DNA Removal Kit (ThermoFisher 
Scientific) according to the manufacturers’ instructions. The recovered RNA was quantified 
using a NanoDrop ND-1000 (ThermoFisher Scientific) instrument and the small RNAs 
integrity and enrichment were assessed by standard denaturing agarose gel electrophoresis. 
S. cerevisiae was cultured in standard YPD media and the small RNAs extracted using the 
same described method. 
2.1.2 Symphogen cell lines 
Four Symphogen in-house mAb CHO cell clones (designated 3068, 3077, 3080, 4384 
producing the same IgG1 subtype) and two cell pools, of which one (3936) was IgG1-
producing and the other (3478) was a null-producer, were used in this study. All were 
generated from a modified dihydrofolate reductase-deficient (DHFR-) CHO DG44 host cell 
line (Urlaub et al., 1983) through transfection with a vector containing the DHFR gene and 
the genes for the antibody heavy (HC) and light chains (LC) and methotrexate (MTX) 
mediated stable selection . Clones were isolated by fluorescence activated cell sorting 
(FACS). Cells were routinely maintained and expanded in PowerCHO-2 CD (Lonza) as basal 
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media in shake flasks with shaking at190- 200 rpm in a 37°C humidified culture incubator 
supplied with 5% CO2. For upstream experiments to generate samples for analysis, cells were 
inoculated at a starting concentration of either 0.4x 106 viable cells/ml (DAVI experiments) 
or 0.6 x 106 viable cells/ml (JCE experiments, cell culture and RNA extractions executed by Dr 
Eriksen J.C. at Symphogen), in a total culture volume of 13 ml. The ambr15Ô micro 
bioreactor by Sartorius (Goettingen, Germany) was used to run fed-batch culture 
experiments for either 12 (DAVI) or 14 days (JCE). For feeding of cultures, HyClone Cell Boost 
6 Supplement (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) + 8% FunctionMAX™ 
TiterEnhancer (ThermoFisher Scientific, Massachusetts, United States) was used with a 
feeding regime of every 2nd or 3rd day for JCE experiments or daily from the 2nd day of culture 
for DAVI experiments. Culture viability and viable cell concentration (VCD) was measured 
using a Vi-CELL XR (Beckman Coulter, Brea, CA) instrument. For JCE experiments, glucose, 
glutamine, lactate, ammonium, glutamate, pH, and osmolality were measured using a 
Bioprofile 100plus (Nova BioMedical, Waltham, WA) instrument while IgG titer was 
determined by biolayer interferometry using an Octet QK384 instrument equipped with 
Protein G biosensors (ForteBio, Menlo Park, CA). For DAVI experiments, a Cedex Bio HT 
analyser (Roche, Basel, Switzerland) was used for all measurements. For seed train samples, 
cells were harvested 48 hours after adjusting their VCD to 0.3x106 viable cells/ml, when a 
steady doubling time and high culture viability were maintained. Cell suspensions from each 
seed-train in the JCE dataset were added to 15 ml Falcon tubes and centrifuged at 1000 rpm 
for 4 minutes, followed by Direct-zol RNA extraction (Zymo Research, California, USA) 
following the manufacturer’s instructions. For samples taken from the fed-batch cultures, 1 
x 107 viable cells were taken before feeding from each biological replicate ambr15™ 
bioreactor after 96 h of culture time (day 4, both DAVI and JCE experiments) and after either 
168 h (day 7, JCE experiment) or 288 h (day 12, DAVI experiment) of culture. Cells were lysed 
using TRI-Reagent (Sigma-Aldrich, Missouri, USA) followed by extraction of total RNA using a 
Direct-zol RNA Kit (Zymo Research) and in-column DNAse treated. Samples for tRNAs 
sequencing were extracted using the mirVana miRNA Isolation Kit (ThermoFisher Scientific) 
and eluted in RNase free water. The RNA quantity/quality was determined using a NanoDrop 
instrument (ThermoFisher Scientific) and RNA 6000 Pico Kit (Agilent, California, USA). 
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2.2 Whole transcriptome RNA-Seq on Symphogen samples 
2.2.1 RNA-Seq and Data analysis  
For DAVI experiments: the total RNA was sent to the Oxford Genomics Centre (Oxford, UK) 
where the Ribo-Zero ribosomal RNA (rRNA) removal kit (Illumina, California, USA) was used 
to remove rRNAs followed by multiplex barcoded sequencing on an HiSeq4000 by Illumina 
to generate 150 bp long paired ends reads, with coverage over 40M fragments per sample. 
The fastq files were initially checked for quality using the FastQC software on default settings, 
sorted using samtools, deduplicated using Picard MarkDuplicates then aligned with HISAT2 
to the CriGri_1.0 reference genome. Aligned files are publicly available on GEO, accession 
GSE140671. The gene counts were calculated using featureCounts, then the differential 
expression analysis was undertaken with the R/Bioconductor package DESeq2 (Love, Huber, 
& Anders, 2014).  
For JCE experiments: samples were sequenced at Genotypic (Bengaluru, India) to generate 
75 nt long paired end reads, with coverage over 20M fragments per sample. The fastq files 
were initially checked for quality using the FastQC software on default settings, then 
trimmed using Trim_Galore! and aligned to GCF_000419365.1 with STAR. The gene counts 
were calculated using featureCounts, then the differential expression analysis was 
conducted with the R package DESeq2 (Love et al., 2014) as described for the DAVI 
experiments. Genes with a fold change (FC) > 1.50 and Benjamini-Hochberg adjusted p-value 
<0.10 in both datasets were selected for GO and KEGG enrichment using the Bioconductor 
package gProfileR (Supplementary Material 1). 
2.2.2 RT-qPCR Validation of Differentially Expressed genes  
Primers for RT-qPCR experiments were designed using Primer-BLAST and synthetized by 
Integrated DNA Technologies (Illinois, USA). Primers used during this study are described in 
Supplementary Material 2. RT-qPCR reactions were conducted using a Mastercycler EP 
Realplex instrument (Eppendorf, Hamburg, Germany) using the PrecisionPLUS Onestep qRT-
PCR Master Mix kit by Primer Design (Southampton, UK). The specificity of amplification was 
checked by the generation of Tm curves and by analysis of the reaction products using 2% 
agarose gel electrophoresis to confirm the presence of a single amplicon of the expected 
size. The results were analysed applying the standard ΔCt method and normalized to B-actin 
and B2M housekeeping genes expression.   
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2.3 AlkB de-methylase production in E. coli 
2.3.1 Protein expression and purification 
The original AlkB-Facilitated RNA de-Methylation (ARM-Seq) workflow for tRNAs sequencing 
is described in detail here (Hrabeta-Robinson et al., 2017). A plasmid containing the wild-
type E. coli AlkB sequence, with the addition of a His-Tag, was kindly provided by the Phizicky 
group, based at the University of Rochester, NY, USA. The plasmid was amplified in DH5-
Alpha cells and expressed in BL21*(DE3) pLysS E. coli cells in the presence of chloramphenicol 
and ampicillin and induced with IPTG. Cells were harvested, resuspended in Binding Buffer 
(20 mM Tris-HCl pH 8, 500 mM NaCl, 5 mM Imidazole pH 8) and sonicated. A nickel affinity 
chromatography column was prepared by loading 5 mL of Chelating Sepharose to an empty 
column, washed with 20 mL of water, charged with 15 mL of Charge Buffer (100 mM NiSO4) 
and equilibrated with 25 mL of Binding Buffer. The cell lysate was loaded onto the column, 
then washed in succession with 20 mL of Binding Buffer, 10 mL of Wash Buffer I (20 mM Tris-
HCl pH 8, 500 mM NaCl, 50 mM Imidazole pH 8), 10 mL of Wash Buffer II (20 mM Tris-HCl pH 
8, 500 mM NaCl, 100 mM Imidazole pH 8) and eluted in 15 mL of Elution Buffer (20 mM Tris-
HCl pH 8, 500 mM NaCl, 400 mM Imidazole) divided in single 1 mL fractions. The purified 
AlkB was stored in a buffer composed of 20 mM Tris-HCl, 200 mM NaCl, 2 mM DTT, 50% 
Glycerol and RNase free water. 
2.3.2 SDS-PAGE protein characterisation  
2.3.2.1 Sample preparation procedure 
Samples were prepared adding to the eluted fractions a 5X sample buffer composed of 10% 
(v/v) glycerol, 120 mM Tris-HCl pH 6.8, 2% (w/v) SDS, a few grains of bromophenol bleu, a 
few grains of pyronin G diluted in distilled water to a 1X final buffer concentration, then 
vortexed thoroughly, boiled for 5 min at 95˚C and loaded into the polyacrylamide gel. 
2.3.2.2 Gel preparation and electrophoresis 
Sodium dodecyl sulphate (SDS) polyacrylamide gels were composed of a stack phase (5% 
acrylamide; 5% (v/v) acrylamide/Bis solution 37.5:1 (BioRad, USA), 125 mM Tris-HCl pH 6.8, 
1% (w/v) SDS, 1% (w/v) Ammonium persulfate, 0.1% TEMED) and a separating phase 
between 8 and 12% acrylamide (8-12% (v/v) acrylamide/Bis solution 37.5:1 (BioRad, USA), 
375 mM Tris-HCl pH 8.8, 1% (w/v) SDS, 1% (w/v) Ammonium persulfate, 0.06% TEMED) set 
in a Novex cassette (Life Technologies, USA). Samples were loaded on the gel and 
electrophoresis was performed in running buffer (200 mM glycine, 25 mM Tris-HCl, 0.1% 
(w/v) SDS, pH 8.8) at 100 V for 30 min and then at 150 V until desired migration.  
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2.3.2.3 Bradford assay 
To determine AlkB protein concentration, 1 mL of Bradford reagent (120 mM Coomassie Blue 
G250, 15% (v/v) ethanol, 8.5% (v/v) phosphoric acid) was added to 50 µL of sample, 
incubated 10 min at room temperature before using a calibrated spectrophotometer for the 
Bradford reagent used. 
 
2.3.3 MS-MS protein characterisation 
The SDS-PAGE gel was washed twice with water for 10 minutes, then the band corresponding 
to AlkB was excised using a clean scalpel, cut into 1 x1 mm squares and transferred to a 0.5 
mL centrifuge tube. The gel particles were washed with 100 µL of freshly prepared 50 mM 
NH4HCO3/acetonitrile (1:1) for 15 minutes, then the liquid was removed and 100 µL 
acetonitrile added for 15 minutes until the gel pieces had shrunk. After removing the liquid, 
the gel pieces were covered with 10 mM DTT in 50 mM NH4HCO3, incubated for 30 minutes 
at 56°C and briefly shrunk again in acetonitrile. The acetonitrile was then removed and 55 
mM Iodoacetamide in NH4HCO3 was added for 20 minutes in the dark at room temperature. 
The iodoacetamide solution was removed and the gel pieces washed two times with 100 µL 
of NH4HCO3 for 15 minutes, shrunk again with acetonitrile and dried in a vacuum centrifuge. 
The dried gel pieces were rehydrated in 20 µL of digestion buffer (10 mM NH4HCO3, 10% 
Acetonitrile) containing 10 ng/µL of trypsin at 4°C for 30 minutes, then the remaining 
supernatant was removed and 10 µL of digestion buffer without trypsin added to cover the 
gel pieces and keep wet during enzyme cleavage at 37°C overnight. 5 µL acetonitrile was then 
added to the gel pieces, followed by 15 minutes sonication, centrifugation, collection of the 
supernatant and addition of 50% acetonitrile with 5% formic acid. After additional 15 
minutes of sonication, the gel pieces were span down and the supernatant collected for 
MALDI TOF-TOF MS/MS analysis (Supplementary Figure 5.1). 
 
2.4 tRNA sequencing 
2.4.1 Small RNA de-methylation 
Between 4.0 and 7.2 ug of RNA were de-methylated at 37oC for 100 minutes using 10 µg of 
AlkB enzyme in a 100 µL reaction composed of a freshly prepared reaction buffer (50 mM 
HEPES KOH pH 8, 75 µM ferrous ammonium sulfate pH 5, 1 mM alpha-ketoglutarate, 2 mM 
ascorbate Na+, 50 µg/mL BSA). For each different condition, a single non-demethylated 
sample (AlkB-) was generated by substituting the volume of AlkB with the protein storage 
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buffer only. The RNA was then recovered using the Zymo Research RNA CleanUp kit (Zymo 
Research, California, USA), eluted RNase free water and quantified by Nanodrop. The 
samples collected at Symphogen were on-column DNase treated during RNA recovery. After 
the de-methylation treatment and before sequencing, an integrity control on the RNA 
samples was performed by the sequencing facility using RNA Screentape (Supplementary 
Figure 5.2). 
2.4.2 Library generation and sequencing 
For the CHO-S dataset and the yeast samples, the library was generated using a NEXTFLEX 
Small RNA-Seq Kit (Bioo Scientific, TX, USA) and sequenced on a HiSeq 2500 (Illumina), 
generating single end 50 bp long reads. For the Symphogen dataset, 150 ng of small RNAs 
where used to generate a library with the TruSeq Small RNA Library Prep kit (Illumina, 
California, USA). The standard protocol was followed with the exception of the reverse 
transcription step, changed to a 1-hour incubation at 60oC with SuperScript IV Reverse 
Transcriptase (ThermoFisher Scientific) and the purification of cDNA constructs, where the 
size window for the fragment was 140 to 250 bp to include all tRNAs fragments. cDNA 
fragments were checked with a High Sensitivity D1000 ScreenTape assay (Agilent, California, 
USA) and sequenced in biological duplicates on a NextSeq 500 (Illumina), generating single 
end 75 bp long reads. 
2.4.3 Alignment and differential expression 
Quality control on the fastq files was run using FastQC, adapters were trimmed using 
cutadapt 1.16 (Martin, 2011), discarding reads that were shorter than 16 bases after 
trimming. A reference set was created by downloading tRNA sequences from GtRNAdb (Chan 
& Lowe, 2016), removing any predicted intron sequences and adding a 3' terminal CCA to 
each tRNA. The reads were mapped to this reference set of tRNA sequences using Bowtie2 
2.3.1 (Langmead & Salzberg, 2012), using sensitive options and primary mappings. Reads per 
tRNA codon were counted using an in-house Perl script. Reads were also mapped, using 
Bowtie2 with the same options, to a reference set of all small RNA sequences. This reference 
set was created by using Ensembl (Zerbino et al., 2018) BioMart to retrieve all transcripts not 
labelled as protein coding, and adding in the sequences from the tRNA reference set 
described above. Reads were again counted using an in-house Perl script. Differential 
expression analysis was performed using DESeq2 1.18.1 (Love et al., 2014), using raw counts 




2.5 Codon Adaptation Index (CAI) and tRNA gene copy numbers 
The Codon Adaptation Index (CAI) of the selected coding sequences was calculated using the 
publicly available domain https://www.biologicscorp.com/tools/CAICalculator/ where the 
complete Chinese hamster genome was taken as a reference. The CAI for top and bottom 
500 most abundant coding sequences as a custom set of references was calculated using the 
CAI python package (B. D. Lee, 2018). Gene copy numbers for each tRNA were calculated in 
Chinese hamster genomes (CriGri_1.0, C_griseus_v1.0, CHOK1GS_HDv1) and Mesocricetus 
auratus (MesAur1.0), using the publicly available tool tRNAscan-SE 2.0 (Lowe & Chan, 2016). 
 
2.6 HEK293 cell line 
2.6.1 Cell culture and RNA extraction 
Four T175 flasks of HEK293 cells were grown at 37oC for 48 h then two of the flasks were 
transferred to 32oC for 24 h and two flasks were left at 37oC. After the 24 h, medium was 
removed from the cells, the flasks were washed with 10 mL PBS and then cells were detached 
with 2.5 mL trypsin-EDTA/flask (either at 37 or 32oC as appropriate) and the trypsin then 
quenched by adding 4.5 mL growth medium per flask. The two 37oC flask contents were 
pooled as were the 32oC flask contents into 15 mL falcon tubes. 20 uL samples were removed 
for cell counts and the remainder of the cell suspensions were harvested at 1000 rpm x 5min. 
The medium was removed from the cell pellets and the falcon tubes containing the cell 
pellets were immediately frozen in dry ice and stored at -80oC. The small RNAs samples were 
extracted following the mirVana protocol for small RNAs purification and subsequently 
treated using the bacterial demethylase AlkB as described in Section 2.4.1. After the de-
methylation treatment and before sequencing, an integrity control on the RNA samples was 
performed by the sequencing facility using RNA Screentape (Supplementary Figure 5.2). 
2.6.2 Library generation and sequencing 
150 ng of each RNA sample was processed using the Illumina TruSeq Small RNA library prep 
kit (Illumina). The standard protocol was followed with the exception of the reverse 
transcription step, changed to a 1-hour incubation at 55oC with SuperScript III Reverse 
Transcriptase (ThermoFisher Scientific), a 20 cycle PCR amplification step, and the 
purification of cDNA constructs between 146 bp and 200 bp. The libraries were then run on 
a NextSeq instrument, using the 75 bp single end read metric on one lane with the high-
output option, and analysed as described in Section 2.4.3. 
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2.7 Computational modelling of elongation 
Translation elongation rates on all indicated coding sequences were estimated using a 
published computational model (D. Chu et al., 2012; Dominique Chu et al., 2014), described 
in Section 1.5.1. The model was adapted for the Chinese hamster decoding system using 
relative sequenced tRNA abundances obtained as described in Section 2.4. 
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Chapter 3 The Long Non-Coding RNA 
Transcriptome Landscape in CHO Cells 
Under Batch and Fed-Batch Conditions 
 
While the biological functions and the use of coding genes has been investigated extensively 
for CHO cell engineering, the focus on non-coding RNAs has almost exclusively been on 
siRNAs and miRNAs. An emerging class of non-coding RNAs, defined as Long Non-Coding 
RNAs (lncRNAs), has in recent years shown a broad range of actions in cell biology, but the 
majority of our knowledge on these molecules is limited to diseases and model organisms. 
We evaluated lncRNA expression in a mammalian expression system (CHO cells) under 
industrially relevant conditions and assessed their potential as cell engineering targets. 
Through the use of a mouse microarray providing the surveillance of 24,881 mRNAs and 
35,923 lncRNAs, this work delivered to the community the first landscape of expression for 
both coding genes and lncRNAs in CHO cells under batch and fed-batch conditions at Day 4 
and Day 7 of culture. When comparing fed-batch against batch time points, I found 
thousands of differentially expressed mRNAs and lncRNAs. Single gene functions and their 
potential application as targets for cell engineering, as well as entire pathway variations, 
were identified and discussed in detail. This work was published in the Biotechnology journal 
as follows: 
Vito D, Smales CM (2018), The Long Non-Coding RNA Transcriptome Landscape in CHO Cells 
Under Batch and Fed-Batch Conditions, Biotechnol J., doi: 10.1002/biot.201800122, 
PMID:29781203 
 
This work is reported in the following pages and integrated with the rest of the PhD project 
described in the thesis.  
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3.1 Introduction 
Mammalian expression systems are widely used for the production of recombinant protein 
biopharmaceuticals, largely due to their ability to correctly fold, assemble, post-
translationally modify and secrete complex human like proteins (Walsh, 2010). Among these, 
the Chinese hamster ovary (CHO) cell is the most widely utilised expression platform used in 
industry, especially for the production of monoclonal antibodies (mAbs), and are used for 
the expression of more than 60% of biotherapeutic proteins made in mammalian cells 
(Dumont et al., 2016; Jayapal, Wlaschin, Hu, & Yap, 2007; J. Y. Kim et al., 2012; Kunert & 
Reinhart, 2016; Walsh, 2014). The most widely used bioprocess for the production of 
biopharmaceuticals from CHO cells involves fed-batch culture, this offering an advantage 
over batch culture in terms of cell growth, culture viability and product yields due to the 
supplementation of nutrients resulting in higher biomass accumulation, less build-up of toxic 
metabolic by-products and enhanced productivity (Durocher & Butler, 2009; X. Pan, 
Streefland, Dalm, Wijffels, & Martens, 2017; Wong et al., 2006).  
The prominence of CHO cell expression systems has driven innovation in the industry such 
that CHO expression systems and associated bioprocesses have been developed that can 
deliver yields of mAb in excess of 5-10 g/L in stably expressing, fed-batch systems (Povey et 
al., 2014; Reinhart, Damjanovic, Kaisermayer, & Kunert, 2015). Despite this, some 
biotherapeutic recombinant proteins, and particularly some of the non-mAb novel 
biotherapeutics in development, remain difficult to express in CHO cells or other mammalian 
cell expression systems (Alves & Dobrowsky, 2017; Jossé et al., 2016). Using a prior 
knowledge about cellular systems, various approaches have been taken to engineer cells to 
deliver enhanced product yields and quality including the engineering of chaperones (Josse, 
Smales, & Tuite, 2010; G. M. Lee, 2008), glycosylation machinery (Ferrara et al., 2006; 
Malphettes et al., 2010; Yamane-Ohnuki et al., 2004) and proliferation control strategies, 
including manipulation of the cell cycle (Bi, Shuttleworth, & Al-Rubeai, 2004; Fussenegger, 
Mazur, & Bailey, 1997), apoptosis (Choi, Rhee, Kim, & Park, 2006; N. S. Kim & Lee, 2002) and 
autophagy (Hwang & Lee, 2009; J. S. Lee, Ha, Park, & Lee, 2013).  
Alongside this approach, there have been studies to further our understanding of the 
potential cellular constraints on the production of mAbs (Mason, Sweeney, Cain, Stephens, 
& Sharfstein, 2012; Pybus et al., 2014), other recombinant biotherapeutics (Johari, Estes, 
Alves, Sinacore, & James, 2015) and difficult to express recombinant proteins (Thoring et al., 
2016) in order to identify bottlenecks in the recombinant gene expression pathway and to 
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develop new bioprocesses or adapt/engineer novel hosts for enhanced production and/or 
quality of such molecules (Mead et al., 2012, 2015). The majority of these studies to date 
have focussed upon manipulation of coding genes, however with the discovery and improved 
understanding of non-coding RNA in the control of cellular processes, there has been much 
interest in the last decade or so in these non-coding RNAs in CHO cells. In particular, the 
manipulation of microRNAs to enhance the ability of CHO cells to produce biotherapeutic 
proteins has attracted much attention (Barron et al., 2011; Bort et al., 2012; Fischer et al., 
2017; Stiefel et al., 2016). An advantage of manipulating such non-coding RNAs for 
modulating CHO cell phenotypes is that such engineering does not place an addition protein 
synthetic burden upon the host cell (Hackl, Borth, & Grillari, 2012), unlike engineering of 
coding genes, and often such non-coding RNAs can modulate whole pathways rather than 
individual steps or processes as when manipulating many coding genes. 
It has been estimated that at least 75% of transcripts originate from non-coding sequences 
(Djebali et al., 2012). Investigations into these transcripts has resulted in the identification of 
a class of transcript collectively known as Long non-coding RNAs (lncRNAs) (Kapranov et al., 
2007). LncRNAs are defined as transcripts longer than 200 nucleotides that lack a significant 
open reading frame (ORF), are usually transcribed by RNA polymerase II and spliced, with or 
without 3’ polyadenylation (Kashi et al., 2016; Kung et al., 2013; Wilusz, 2016). A number of 
lncRNA molecules have been shown to play key regulatory roles in various biological 
processes including epigenetic regulation (Betancur, 2016), transcriptional control (Trimarchi 
et al., 2014), splicing events (Gonzalez et al., 2015), and mRNA translation (Carrieri et al., 
2012). Indeed, lncRNAs are capable of modulating a wide range of cellular processes and 
mechanisms both in the nucleus and the cytoplasm (Geisler & Coller, 2013). The majority of 
our understanding into lncRNAs and the mechanism(s) by which they elicit their responses 
has come from studies relating to disease (Schmitt & Chang, 2016) and developmental 
studies (Perry & Ulitsky, 2016). LncRNAs elicit their effects by acting as competing 
endogenous RNAs (ceRNAs) by binding to and sequestering microRNAs (Tay, Rinn, & 
Pandolfi, 2014), by acting as architectural RNAs (arcRNAs) whereby they form functional 
structures (Chujo, Yamazaki, & Hirose, 2016), act as cis molecules to enhance (eRNAs) coding 
gene expression (Melo et al., 2013) or as trans protein binding RNA molecules that can recruit 
chromatin modifying (Gomez et al., 2013; Koziol & Rinn, 2010), as microRNA precursors 
(Keniry et al., 2012), modulators of mRNA stability (Rashid, Shah, & Shan, 2016) and to impact 
upon post-translational modifications (Bodu Liu et al., 2015; P. Wang et al., 2014).  
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Despite the importance of lncRNAs in controlling cellular processes, and unlike small non-
coding RNAs (e.g. siRNAs, microRNAs), the impact(s) of lncRNA expression on CHO cell 
bioprocessing with regard to growth/proliferation and recombinant protein yields and 
quality has barely been explored, with only a small number of studies reported (Patrucco et 
al., 2015; Tabuchi, 2013). However, these two studies show that manipulation of lncRNAs 
can impact upon recombinant protein production from CHO cells. One of the reasons for the 
small number of studies on lncRNAs in CHO cells is the lack of a comprehensive annotation 
of non-coding transcripts in CHO, hampering their identification, genome wide assessment 
of their expression and modulation during culture, functional studies and hence 
identification of target lncRNAs for cell engineering. One way to address this problem is to 
take advantage of the reported similarities between the Chinese hamster, CHO cell and 
mouse genomes (Becker et al., 2011), where the number of well annotated non-coding 
transcripts is much higher. The similarity between CHO cells and mouse has already been 
utilised for the identification of 416 ncRNAs based on sequenced transcripts from a pooled 
CHO sample compared to the fRNAdb database of non-coding RNAs using BLAST, with most 
hits coming from mouse (X Xu et al., 2011). Here, I report the first analysis in CHO cells of 
both the coding and the non-coding transcriptome (specifically the lncRNAs) during batch 
and fed-batch culture at two different time points. I report on the identification of 
differentially expressed lncRNAs and mRNA, their interconnections and their potential 
impact on cellular pathways. This has allowed the mapping of the lncRNA landscape in CHO 
cells and identification of lncRNAs targets in CHO for further manipulation with a view to 
increase proliferation and to sustain viability throughout batch and fed-batch culture.  
3.2 Materials and Methods 
3.2.1 Model Cell Line and Cell Culture Conditions 
The CHO-S Freestyle host cell line (ThermoFisher Scientific, MA, USA) was used as a model 
CHO cell line for this study. Cells were routinely cultured in a Lab-Therm LT-X (Kühner AG, 
Basel, Switzerland) shaking incubator at 37°C, 5% CO2, 125 rpm and 70% humidity in 
chemically deﬁned serum-free growth medium (CD CHO, ThermoFisher Scientific, MA, USA). 
Fed-batch cultures were supplemented with CHO CD Efficient Feed B Liquid Nutrient 
Supplement (ThermoFisher Scientific, MA, USA). Initial supplementation testing was 
conducted in duplicate following Conditions 3 and 9 as described in the CHO CD Efficient 
Feed manual. Cultures with a viability >98% were used to seed initial fed experiments at 
3x105 viable cells/mL in a 50 mL working volume in 250 mL polycarbonate Erlenmeyer flasks 
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with vented caps (Corning, Wiesbaden, Germany). From the initial feeding experiments, 
Condition 3 was used for all future fed-batch cultures and for generating samples analysed 
during this study. This adopted feeding strategy consisted of a 15% (v/v) supplementation of 
CHO CD Efficient Feed B to the CD CHO starting volume immediately on Day 0, followed by 
10% (v/v) supplementation on Day 3 and Day 6. Four biological replicates of each culture 
process (batch and fed-batch) were seeded at 3x105 viable cells/mL from 20 mL cultures with 
a culture viability ≥ 98.5% in 120 mL CD CHO starting working volume in 500 mL 
polycarbonate Erlenmeyer flasks with vented caps (Corning). Viable cell concentrations and 
culture viability were determined daily using a Vi-CELL XR Cell Viability Analyzer (Beckman 
Coulter, Inc., Brea, CA, USA) on 1 mL culture samples.  
3.2.2 Sampling from Cell Cultures and Subsequent RNA Extraction 
Samples of 1 x 107 viable cells were taken from each flask after 96 hours (day 4) and 144 
hours (day 7) of culture and total RNA immediately extracted using the commercially 
available mirVana miRNA Isolation Kit (ThermoFisher Scientific, MA, USA) and treated with 
RapidOut DNA Removal Kit (ThermoFisher Scientific, MA, USA). The RNA quantity and quality 
were determined using a NanoDrop ND-1000 (ThermoFisher Scientific) instrument and the 
integrity of RNA assessed by standard denaturing agarose gel electrophoresis. 
3.2.3 lncRNA and Coding RNA Microarray and Data Analysis  
3.2.3.1 Microarray Details 
Three of the 4 cultures were selected for analysis. Analysis of extracted RNA for coding and 
lncRNAs was undertaken using the commercially available ArrayStar Mouse lncRNA 
Microarray V3.0 (Rockville, MD, USA). RNA labelling and array hybridization were performed 
according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol 
(Agilent Technologies, Santa Clara, CA, USA) with minor modifications. Ribosomal RNAs were 
removed from total RNA using the mRNA-ONLY Eukaryotic mRNA Isolation Kit, (Epicentre, 
Madison, WI, USA). Each sample was then amplified and transcribed into fluorescent cRNA 
along the entire length of the transcripts without 3’ bias utilizing a mixture of oligo(dT) and 
random primers using the Arraystar Flash RNA Labelling Kit (Arraystar). The labelled cRNAs 
were purified by RNeasy Mini Kit (Qiagen, Hilden, Germany). The concentration and specific 
activity of the labelled cRNAs were determined by NanoDrop ND-1000 (ThermoFisher 
Scientific). A total of 1 μg of each labelled cRNA was then fragmented by adding 5 μL of 10 × 
Blocking Agent and 1 μL of 25 × Fragmentation Buffer before heating at 60°C for 30 min. 
 61 
Finally, 25 μL of 2 × GE Hybridization buffer was added to dilute the labelled cRNA. A sample 
of 50 μL of the hybridization solution was then dispensed into the gasket slide and assembled 
to the LncRNA expression microarray slide. The slides were incubated for 17 hours at 65°C in 
a Microarray Hybridization Oven (Agilent Technologies). The hybridized arrays were then 
washed, fixed and scanned using the G2505C DNA Microarray Scanner (Agilent 
Technologies). 
3.2.3.2 Microarray Data Analysis  
Agilent Feature Extraction software (version 11.0.1.1) was used to analyse acquired array 
images. Quantile normalization and subsequent data processing were performed using the 
GeneSpring GX v12.1 software package (Agilent Technologies). After quantile normalization 
of the raw data, lncRNAs and mRNAs that were present in ³3 of 12 samples were selected 
for further data analysis. Raw p-values were calculated by unpaired t-test, then the 
differentially expressed lncRNAs and mRNAs with statistical significance between compared 
groups were filtered for a FC ≥ 2 and a false discovery rate (FDR) ≤ 0.10 calculated by the 
Benjamini–Hochberg procedure. GO analysis was performed using the Bioconductor package 
topGO (Alexa & Rahnenfuhrer, 2016) and with a raw p-value cut-off of 0.05 calculated by 
Fisher’s exact test, subsequently filtered for an FDR ≤ 0.10. Pathway analysis for differentially 
expressed mRNAs was performed based on the KEGG database 
(http://www.genome.jp/kegg) with a raw p-value cut-off of 0.05 calculated by Fisher’s exact 
test, subsequently filtered for an FDR ≤ 0.10. 
3.2.4 RT-qPCR Validation of lncRNAs Identified as Differentially Expressed by Microarray 
Primers for RT-qPCR were designed using OligoPerfect Designer (ThermoFisher Scientific) 
and synthetized by Eurofins Scientific (Luxembourg) (listed in Appendix). RT-qPCR reactions 
were conducted using a Mastercycler EP Realplex instrument (Eppendorf) following the 
QuantiFast SYBR Green RT-PCR Kit protocol (Qiagen). Specificity of amplification was checked 
by the generation of Tm curves and by analysis of the reaction products by 2% agarose gel 
electrophoresis to confirm the presence of a single amplicon of the expected size. The results 
were analysed applying the standard ΔCt method and normalized to GAPDH, B-actin and 




3.3.1 Growth Characteristics and Sampling of CHO-S Cells Throughout Batch and Fed-
Batch Culture for (Non)-Coding RNA Analysis 
The steps followed to generate the results presented in this work are summarized in Figure 
3.1. Initially, growth comparisons and supplementation testing were undertaken using CD 
CHO and the associated commercially available feds (Efficient Feds A and B). From these 
preliminary experiments, I selected Efficient Feed B Liquid Nutrient Supplement for 
experimental Fed-batch cultures as this gave the highest viable cell concentrations across a 
10-day process from the feed strategies investigated (data not shown). Cells under Fed or 
Batch culture grew almost identically up until day 4 of culture whereupon their growth 
characteristics differed (Figure 3.2A). Whilst growth of the Batch cultures slowed 
dramatically after day 4, with a mean peak viable cell concentration on day 6 of 
approximately 1 x 107 cells/mL, in the Fed-batch cultures growth and proliferation continued 
until day 6 where a mean peak viable cell concentration of almost 2 x 107 cells/mL was 
obtained (Figure 3.2A). After day 6 the viable cell number and viability of both cultures 
decreased with time, however while culture viability rapidly declined in the Batch culture 
such that by day 9 culture viability was close to 0%, in the Fed-batch mode cultures had a 
mean viability of 83.6% at day 10 (Figure 3.2A). The first-time point at which samples were 
harvested was Day 4, when both types of culture had grown in a similar way and were still in 
the exponential growth phase (late exponential for batch), whilst the second time point at 
which cells were harvested for RNA analysis was on Day 7, corresponding to the end of the 
stationary phase/first day of decline for both cultures. In the case of the Fed-batch cultures, 
these two sampling points were also 24 hours after addition of the Efficient Feed B. 
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Figure 3.1 - Experimental workflow for transcriptomics analysis of CHO-S cell line 
Summary of the experimental workflow. Growth and culture viability of a CHO-S cell line in Batch and Fed-batch cultures were measured for 10 days and samples for RNA extraction taken at 
Day 4 and at Day 7. The samples were analysed on a mouse array containing all the coding and non-coding transcripts stored in the main public databases. The measured intensities were log-
normalized and differentially expressed transcripts/genes were filtered for a fold change (FC) ≥ 2 and an FDR ≤ 0.10. A selected group of genes was validated through RT-qPCR (Supplementary 
Table 3.1). Due to the poor annotation of lncRNAs in CHO, the identification of potential targets with a described biological role required the comparison of human and mouse literature and 
databases, followed by alignment against the Chinese hamster genome, leading to predicted lncRNAs transcripts and previously un-annotated genomic regions (Table 3.1). At the same time, 
GO and pathway enrichment was implemented on mRNAs. 
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Figure 3.2 - Results of CHO-S batch and fed-batch cultures 
A | Growth profiles for the model CHO-S host cell line throughout Batch and Fed-batch culture. Viable cell 
concentration (VCC) and culture viability are shown (red for Batch and blue for Fed-batch). The percentage of 
CHO CD Efficient Feed B Liquid Nutrient Supplement added to the existing working volume are shown for each 
feeding day (days 0, 3 and 6). The arrows indicate when samples for microarray analysis were harvested (Day 4 
and Day 7). B | Hierarchical clustering heatmaps arranging samples into groups based on their averaged log-
normalized expression levels. Only transcripts/genes with an expression variance between each group above the 
80th percentile are shown. The dendrogram shows the relationships for lncRNAs (left panel) and mRNAs (right 
panel). C | Down-regulated (green bars) and up-regulated (red bars) mRNAs (full bars) and lncRNAs (textured 
bars) in CHO-S cells during batch and fed-batch culture for each of the compared pairs showing a fold change ≥ 2 
and an FDR ≤ 0.10. D) Venn diagrams showing the number of lncRNAs and mRNAs differentially expressed (DE) in 
Fed-batch vs Batch (FC ≥ 2, FDR ≤ 0.10). Genes DE at both Day 4 and Day 7 are represented in the overlaps while 










3.3.2 Microarray Analysis of mRNA and lncRNA Transcripts in Batch and Fed-Batch 
Culture  
The Arraystar Mouse LncRNA Microarray V3.0 used in this study is based on publicly available 
databases and publications, allowing for the potential simultaneous surveillance of 35923 
lncRNAs and 24881 coding transcripts. The lncRNAs collection is based on Mus musculus 
gene expression in all tissues as stored in the NCBI Refseq, UCSC Known Gene 6.0, Ensembl 
38.71, Fantom3, RNAdb 2.0, NRED databases, a number of literature publications, T-UCRs, 
and evolutionary constrained lncRNAs (Amaral, Clark, Gascoigne, Dinger, & Mattick, 2011; 
Bejerano et al., 2004; Benson, Karsch-Mizrachi, Lipman, Ostell, & Wheeler, 2004; 
Cunningham et al., 2015; Guttman et al., 2009; Mercer, Dinger, Sunkin, Mehler, & Mattick, 
2008; Pruitt, Tatusova, & Maglott, 2007; Rinn et al., 2007). Positive probes for housekeeping 
genes and negative probes are printed onto the array for hybridization quality control. After 
quantile normalization of the raw data, 24603 unique lncRNAs and 19617 mRNAs were 
selected for analysis. Firstly, I implemented Principal Component Analysis (PCA) on the log2 
transformed intensities and plotted the first 3 components against each other, where 
lncRNAs and mRNAs showed very comparable results, especially where for the first two 
components samples from Batch cultures at both days grouped closely compared to Fed-
batch samples, which showed a wider separation even between the same condition 
(Supplementary Figure 3.1). Then I applied hierarchical clustering, arranging samples into 
groups based on their averaged log-normalized expression levels to show the relationships 
among gene expression patterns of samples for both lncRNAs and mRNAs (Figure 3.2B). We 
continued performing differential expression analysis (DE) where I compared Fed-batch 
against Batch at Day 4, Fed-batch against Batch at Day 7, Fed-batch at Day 7 against Fed-
batch at Day 4 and Batch at Day 7 against Batch at Day 4.  At this point, the expression of a 
selected number of the identified DE transcripts was confirmed by RT-qPCR, that showed 
these transcripts were present but that lower fold-changes were observed between samples 
than from the array analysis (Supplementary Table 3.1). The genes identified as DE were then 
filtered based on a threshold fold change (FC) ≥2 and a false discovery rate (FDR) ≤ 0.10 
(Supplementary Tables 3.2, 3.3). When I compared Batch Day 7 to Batch Day 4 samples, I 
found surprisingly low numbers of mRNAs or lncRNAs where the expression changed beyond 
the set thresholds, with 0 mRNAs being up and 19 down regulated between the two days 
whilst for the lncRNAs there were no transcripts that changed about the thresholds set 
(Figure 3.2C). To check whether this lack of identified transcripts changing was due to the FC 
≥ 2 threshold, we repeated the analysis for FC ≥ 1.5 and FC ≥ 1.25, FDR ≤ 0.10 (Supplementary 
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Tables 3.4-3.11). For a FC ≥ 1.25, 99 mRNAs were down and 30 were up-regulated while none 
met the threshold for the lncRNAs. I then carried on with the FC ≥ 2, FDR ≤ 0.10 thresholds 
for the remaining comparisons. Fed-batch Day 7 vs Day 4 revealed 693 mRNAs up-regulated 
and 421 down-regulated whilst for the lncRNAs I found 545 up-regulated and 200 down-
regulated genes (Figure 3.2C). When I compared Fed-batch against Batch at Day 4 and Day 
7, 1048 and 1875 lncRNAs were up-regulated respectively in addition to 856 down-regulated 
at day 4 and 1018 down-regulated at day 7. For the same comparisons I saw more down-
regulated mRNAs at day 4 (1538) and day 7 (1397) while there were 716 up-regulated mRNAs 
at day 4 and 1121 at day 7 (Figure 3.2C).  
3.3.3 Identification of lncRNAs Differentially Expressed as Potential Engineering Targets 
for Modulation of Cell Growth 
As one of the aims of this work was to identify new transcripts for manipulation in CHO cells, 
I reduced the list of potential targets to a manageable group for further experimental 
validation. Firstly, I aligned all the 60 nucleotide mouse probes corresponding to the 
differentially expressed genes identified for each comparison against the Chinese hamster 
(CH) genome using the discontiguous megablast algorithm to check how many transcripts 
had an annotation in CHO. Only 16-28% of the probes corresponding to differentially 
expressed lncRNAs had a matching transcript in CH, as opposed to 58-80% of the mRNAs 
(Supplementary Table 3.12). This is likely due to the poor annotation of the CH transcriptome 
compared to mouse, where the number of described lncRNAs is significantly higher. If we 
consider the ENSEMBL 91 database release alone, 2563 lncRNAs and 446 pseudogenes are 
listed for Chinese hamster as opposed to 9308 lncRNAs and 12363 pseudogenes in mouse. 
To address this issue, I complemented this approach with literature and databases mining 
(NCBI, ENSEMBL, lncRNAdb, LNCipedia) to identify differentially expressed lncRNAs already 
described in mouse but not in Chinese hamster, revealing genomic positions that align with 
potential lncRNAs (Supplementary Figures 3.2-3.4). The identified sequences were then 
examined using the Rfam database (Kalvari et al., 2018) to assess their resemblance to 
existing non-coding RNA families. A list of potential lncRNAs found using the described 
approaches is reported in Table 1, along with literature references describing their biological 
function. 
The role of lncRNAs in diseases is well established, especially linked to cell proliferation in 
cancer (W. Sun, Yang, Xu, & Guo, 2017) and several of those identified here have been 
investigated in such systems. NEAT1 (nuclear-enriched abundant transcript 1) and MALAT1 
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(also known as NEAT2), found to be up-regulated at both days in our Fed-batch cultures 
(Table 3.1), are among the most well characterized lncRNAs and have been reported to 
promote cell proliferation through regulation of gene expression at the nuclear level. 
MALAT1 is a mostly un-spliced transcript around 6.7 kb in mouse, with a long half-life due to 
the tRNA-like structure adopted at the 3’ end (Wilusz, 2016). This structure is cleaved to 
generate a 61 nt mascRNA (MALAT1-associated small cytoplasmic RNA) exported to the 
cytoplasm where it is subjected to canonical CCA nucleotides addition and accumulates in 
the cytoplasm (Wilusz, 2015; Wilusz, Freier, & Spector, 2008). I was able to identify the 
JH002628.1 genomic region in Chinese hamster using the abovementioned complementary 
approaches and we could recognize all of its main conserved domains (Supplementary Figure 
3.2). The structure of this genomic region is conserved in the most recent CHOK1GS_HDv1 
genome and resembles the pattern found in human and mouse, where close to MALAT1 is 
the NEAT1 locus. The NEAT1 locus is regulated by alternative 3ʹ end processing, where the 
primary transcript can be cleaved and polyadenylated to generate a 3.2 kb long MENε 
isoform or cleaved and non-polyadenylated to generate the 20.8 kb long MENβ isoform 
(Wilusz, 2016). We were able to identify a predicted 3.2 kb long non-coding transcript (NCBI 
Ref XR_478750.2) arising from a locus (LOC103159497, C_griseus_v1.0) with similar primary 
structure to both the 3.2 kb and the 20.8 kb isoforms (E-value 0.0, Identity 80%, algorithm 
megablast). MALAT1 and NEAT1 both localize to the paraspeckles stress-responsive nuclear 
bodies in the cell (Nakagawa & Hirose, 2012), where they are reported to influence the 
splicing machinery (W. Sun et al., 2017; Tripathi et al., 2010) and the DNA repair machinery 
(Adriaens et al., 2016). The Plasmacytoma Variant Translocation 1 (PVT1) lncRNA is 
considered a biomarker for various cancers due to its ability to promote cell proliferation 
with a range of proposed mechanisms (Colombo, Farina, Macino, & Paci, 2015a; Tseng & 
Bagchi, 2015; F. Wang et al., 2014; Shikai Zhu et al., 2017). I identified a predicted non-coding 
RNA in Chinese hamster (NCBI Ref XR_478426.2) which contained the PVT1_3 RFAM domain 
and was up-regulated at both Day 4 (FDR = 1.2E-01) and Day 7 in the Fed-batch compared to 
Batch (Table 3.1).  
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Table 3.1 - Selected differentially expressed lncRNAs 
 
Summary of the lncRNAs identified using the described approaches, consisting in a direct alignment of the 
differentially expressed gene probe against the Chinese hamster genome to literature search and RNA families 
conservation in RFAM. From left to right, the columns show the gene symbol, the NCBI accession reference, the 
fold-change measured for Fed-batch vs Batch samples respectively at Day 4 and Day 7, with the corresponding 
FDRs, the ID of the non-coding RNA family found for the sequence in Rfam database with the corresponding ID 
and E-value and the references describing the biological function of the gene. 
3.3.4 Comparison of mRNAs with Existing Datasets 
I compared our Fed-batch against Batch dataset with previous work to identify coding genes 
related to growth in CHO. Although all these works used different approaches and cell lines, 
I saw the opportunity to find common patterns of expression in CHO across various 
conditions. The first dataset compared was Clarke 2011 (Clarke et al., 2011), where I 
observed 10 of their reported down-regulated genes at Day 4 and 7 at Day 7 of our dataset 
(Supplementary Table 3.13). On comparing our data to Clarke 2012 (Clarke et al., 2012), only 
the kinesin family member C1 (KIFC1) gene, up-regulated at both Day 4 and Day 7, was 
observed to behave in the same way. Lastly, when I considered the translatome analysis in 
Courtes 2013 I identified 3 genes at Day 4 and 8 genes at Day 7 among our down-regulated 
transcripts, together with 1 gene at Day 4 and 2 genes at Day 7 among the up-regulated 
transcripts (Courtes et al., 2013). Interestingly, a group of the common genes between the 
selected works and our dataset (CDC20, MAD2L1, MCM7, MCM4, GTF2H4) are involved in 
cell cycle and DNA replication, supporting the findings in the pathway enrichment analysis 
(described in Section 3.3.5) (Buch et al., 2012; Yu, 2002; Zhai et al., 2017). In addition, I found 
single genes in consistently enriched pathways in our pathway analysis such as HNRNPC, 
involved in RNA molecule binding or LGMN, participating in protein degradation in the 
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lysosome (Dall & Brandstetter, 2016). Interestingly, HNRNPs proteins are well known to bind 
and mediate the functions of lncRNAs, and HNRNPC in particular has been reported to 
interact with MALAT1 in a tightly regulated N6-methyladenosine-dependent manner (N. Liu 
et al., 2015; X. Sun, Haider Ali, & Moran, 2017). 
3.3.5 GO analysis and Pathway Enrichment 
I performed GO term analysis on the differentially expressed mRNAs with an FDR cut-off of 
0.10 calculated by the BH method, followed by pathway enrichment analysis based on the 
KEGG database (Supplementary Tables 3.14-3.29), allowing the determination of the 
significantly enriched biological pathways filtered for an FDR ≤ 0.10 and grouped based on 
KEGG class annotation (Table 3.2). The pathway enrichment identified 22 pathways 
containing down-regulated genes at Fed-batch vs Batch Day 4 and 24 at Fed-batch vs Batch 
Day 7 while only 1 contained up-regulated genes (Lysosome, ID: 04142) at either day. This is 
most likely a reflection of the lower number of up-regulated genes compared to down-
regulated (Figure 3.3). The Metabolism domain includes 7 enriched pathways at Day 4 while 
only 1 of these was still enriched at Day 7, suggesting a central role of metabolism together 
with p53 signalling predominantly during the exponential growth phase. On the contrary, 
towards Day 7 I see the prevalent enrichment of pathways related to translation regulation 
and RNA interaction at different levels, from transport to splicing. The most evident pattern 
of enrichment between Day 4 and Day 7 is represented by the Replication and Repair class, 
where the majority of the pathways involved in genome maintenance and diverse repair 
mechanisms are consistently enriched, indicating an early and sustained regulation of these 
genes throughout culture. DNA damage is reported to stimulate the expression of NEAT1 
and, together with MALAT1, to promote the formation of paraspeckles, which regulate 
alternative splicing and promote proliferation (Adriaens & Marine, 2017; Adriaens et al., 
2016; Nakagawa & Hirose, 2012). I then compared our results with relevant KEGG pathway 
enrichment datasets available for CHO (Harreither et al., 2015) and found 4 common 
pathways, which were enriched exclusively at Day 7 in our dataset: RNA Transport (ID: 
03013), mRNA surveillance (ID: 03015), RNA degradation (ID: 03018), Spliceosome (ID: 
03040). Taken together, these results suggest the importance of cell cycle and genome repair 
mechanism control likely due to the high proliferation of the fed-batch system. In addition, 
the active regulation of RNA transport, RNA maintenance and splicing seem to be particularly 
important towards the later stages of our Fed-batch cultures.
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Figure 3.3 - Graphical summary of the enriched KEGG pathways based on differentially expressed genes 
Graphical representation of the enriched KEGG pathways listed in (Table 3.2), hierarchically grouped based on KEGG Pathway Maps. Each filled rectangle (in red for Day 4, in blue for Day 7) 
contains the corresponding enriched pathways, with pathways enriched at both Day 4 and Day 7 enclosed in the overlaps between the filled rectangles. The enrichment is based on genes 




Table 3.2 - Enriched KEGG pathways based on differentially expressed genes  
 
Summary of the enriched pathways based on the list of up-regulated (lysosome) and down-regulated (lower tables) transcripts in Fed-batch vs Batch comparison at Day 4 (left panel) and Day 
7 (right panel). The columns show from left to right the ID from KEGG, the pathway name, the FDR associated with the enrichment (FDR ≤ 0.10 threshold), the number of differentially expressed 







By taking advantage of a comprehensive commercially available mouse microarray 
containing 35923 lncRNAs and 24881 mRNAs, I have provided the first mapping of the CHO 
lncRNA landscape, together with the coding transcriptome. Previous reports have shown 
that more than 70% of the assembled CHO transcriptome is similar to mouse (Mus musculus) 
and closely related to rat (Rattus norvegicus) transcriptomes (Becker et al., 2011) suggesting 
that this approach was likely to be valid for lncRNAs as well. Due to the species and tissue-
specificity of lncRNAs compared to mRNAs, the number of detectable lncRNAs in CHO is likely 
to be lower than the 35923 probes included in the array. Nevertheless, using this approach I 
was able to detect 24603 lncRNAs (68.5% of the total probes) and 19617 mRNAs (78.8% of 
the total probes), and found that several hundreds of lncRNAs exhibit changing expression 
profiles on different days of culture and between Batch and Fed-batch culture in a model 
CHO-S system. This was especially true for the Fed system, where comparing Day 4 and Day 
7 we observed 1114 differentially expressed mRNAs and 745 lncRNAs, as opposed to the 
Batch, were we saw only 19 differentially expressed mRNAs and no lncRNA for the same 
comparison, suggesting a prevalent variability induced by the Fed supplement as compared 
to time only.  
Among the differentially expressed genes, between 16-28% of the lncRNAs probes had a 
matching transcript in CH, as opposed to 58-80% of the mRNAs. This required a specific 
approach where the Chinese hamster genome, literature search and databases mining were 
combined to detect lncRNAs differentially expressed in my system with an established 
biological function. Within these lncRNAs, we focused on MALAT1, NEAT1 and PVT1 to 
provide a comparison between the mouse gene and the Chinese hamster putative 
homologues. The number of lncRNAs with a fully understood role in the cell remains small, 
however these three non-coding genes are among the most well characterized (Kopp & 
Mendell, 2018). MALAT1 and NEAT1 in particular are associated with increased proliferation 
and participate in the regulation of alternative splicing and DNA repair, which I found to be 
strongly regulated in our pathway enrichment analysis. This suggests a potential role for 
these lncRNAs in CHO, although further experimental studies on the single genes are now 
required to assess the actual effects on the cell under different conditions.  
Several approaches to investigate and confirm the functional annotation of lncRNAs in other 
organisms have been described, including the perturbation of lncRNA expression by 
overexpression, knockout or knockdown (S. J. Liu et al., 2016; Shiyou Zhu et al., 2016), in 
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addition to complementary strategies (Kashi et al., 2016). Future developments in CHO will 
have to proceed with a mix of functional prediction tools to assess the properties of the 
transcriptome and evaluate the degree of conservation with other species (Iwakiri, Hamada, 
& Asai, 2015; Signal, Gloss, & Dinger, 2016; Ulitsky, 2016) and of targeted approaches to 
ameliorate the annotation and propose mechanisms of action for the single transcripts 
(Cabili et al., 2015; Clark et al., 2015; Lai, Blumenthal, & Shiekhattar, 2016; Mercer et al., 
2014). Further, the data reported here is for both lncRNAs and mRNAs and hence will allow 
investigators to further probe the relationships between the expression and regulation of 
these two classes of RNA. As the majority of the lncRNAs reported in the literature are 
discussed and related to human or model organism systems, our work aimed at unveiling the 
role of lncRNAs in CHO under industrially relevant conditions to identify new targets for 
manipulation to sustain proliferation. Examples of successful cell engineering of lncRNAs to 
selectively enhance translation (Zucchelli, Patrucco, Persichetti, Gustincich, & Cotella, 2016) 
and product yield (Tabuchi, 2013) have already been reported in CHO, demonstrating the 
potential of manipulation of lncRNAs for enhancing industrial processes. Moreover, since it 
was reported up to 15% of the total ribosome occupancy can be occupied by a single 
recombinant mRNA, the intrinsic characteristics of lncRNAs place them as ideal candidates 
for cell line engineering of protein production cell factories, as they do not add any 
translational burden on top of the coding gene of interest (Kallehauge et al., 2017).  
My work has identified potential lncRNA targets differentially expressed in Fed-batch 
compared to Batch culture from which we selected a group of molecules to be 
experimentally studied (Table 3.1). In addition to the expression of lncRNAs I also looked at 
expression of mRNAs (coding transcripts) and found a consistent change in differentially 
expressed mRNAs when comparing batch and fed-batch cultures. Pathway enrichment 
analysis (Figure 3.3) underlined the importance of genes involved in cell cycle and genome 
maintenance pathways along with the regulation of lysosome formation as potential targets 
for cell engineering to enhance proliferation. My approach allowed the identification of 
previously undescribed lncRNAs in CHO along with mRNAs to identify the connections 
between them and compared these with existent literature. This network of reciprocal 
interactions is beginning to be unveiled in other organisms (Han & Chang, 2015; Kornienko, 
Guenzl, Barlow, & Pauler, 2013; Mallory & Shkumatava, 2015) and my work will help pave 
the way for the definition of new layers of regulation involving single transcripts or even 
entire pathways in CHO. 
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3.5 CONCLUSIONS 
He I report on the lncRNA landscape and how this changes in CHO cells, presenting a full 
dataset of those lncRNAs present as determined from an array study and how these change 
through a Batch and Fed-batch culture and between the two culture systems. From analysis 
of the data, I have determined those lncRNAs whose expression changes the most between 
2 days in culture and between fed and batch culture that are attractive targets for cell 
engineering. This resource will now provide the community with the opportunity to 
undertake functional validation studies by undertaking single or multiple knock downs/outs, 
or by the up-regulation of target lncRNAs, and determine the impact on growth, and 
productivity, characteristics of CHO cells. Ultimately, I anticipate such a resource will be 
incorporated into wider genome analysis datasets including coding mRNAs and other non-
coding RNAs to develop a wider appreciation of the role of RNAs in controlling recombinant 
CHO cell line growth and productivity characteristics. 
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Chapter 4 Defining lncRNAs that Underpin 




In Chapter 3 is described the use of a mouse microarray to obtain a transcriptomic landscape 
of expression in CHO cells and the identification of candidate lncRNAs for cell engineering. 
Based on this work, we further explored lncRNAs expression in six CHO cell lines in 
collaboration with an industrial partner, Symphogen. Small-scale bioreactors used in Chinese 
hamster ovary (CHO) cell line development allow transcriptomic studies on multiple cell 
lines. Here I define the CHO cell long non-coding RNA (lncRNA) transcriptome from cells 
grown in controlled miniature bioreactors under fed-batch conditions using RNA-Seq to 
identify lncRNAs and how the expression of these changes throughout growth and between 
IgG producers. I identify lncRNAs associated with productivity and growth characteristics, 
finding that Adapt15, linked to ER stress, GAS5, linked to mTOR signalling/growth arrest, and 
PVT1, linked to Myc expression, are differentially regulated during fed-batch culture and 
whose expression relates to productivity (Adapt15) or growth (GAS5, PVT1). Changes in 
(non)-coding RNA expression between the seed train and the equivalent day of fed-batch 
culture are also reported, showing large differences in gene expression between these. 
Collectively, I present a comprehensive lncRNA CHO cell profiling and identify targets for 
engineering growth and productivity characteristics of CHO cells.  
This work has been submitted to the scientific journal iScience as a research manuscript 
titled:  
“Defining lncRNAs that Underpin CHO Cell Growth and IgG Productivity by RNAseq”,         
Vito D, Eriksen JC, Skjødt C, Weilguny D, Rasmussen SK, Smales CM; 
and is currently under revision after initial review at the time of submitting this thesis.  
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4.1 Introduction 
Many recombinant protein biopharmaceuticals are expressed in mammalian expression 
systems due to the ability of such systems to correctly fold, assemble, and undertake 
‘human-like’ post-translational modifications and secrete the target protein out of the cell 
(Walsh, 2010). Of mammalian cell expression systems one predominates, with more than 
60% of mammalian made biotherapeutic proteins produced from cultured Chinese hamster 
ovary (CHO) cells (Kunert & Reinhart, 2016; Leu, Dumont, Hafey, Murphy, & George, 2004; 
Mead et al., 2015; Povey et al., 2014; Walsh, 2010). Fed-batch culture is currently the most 
common bioprocess used for the industrial production of proteins in CHO cells, generating 
increased cell concentrations (and hence biomass) and sustained culture viability compared 
to batch culture, ultimately resulting in higher productivity and final product yields (Durocher 
& Butler, 2009; X. Pan et al., 2017; Wong et al., 2006). The introduction of small-scale parallel 
bioreactors allowing automated sampling and continuous control of fundamental culture 
parameters, including pH, stirring and temperature has enhanced the ability to screen a 
wider range of culture parameters and cell lines leading to improved upstream development 
timelines and experimental throughput (Bareither & Pollard, 2011).  
The ambr15Ô cell culture system (Sartorius Stedim Biotech) has been shown to give similar 
cell growth and productivity data to those achieved in larger scale stirred bioreactors, 
enabling more accurate predictions compared to shake flasks on the behaviour of a cell line 
at larger scale (Alsayyari et al., 2018; V. Janakiraman, Kwiatkowski, Kshirsagar, Ryll, & Huang, 
2015; Nienow et al., 2013; Rouiller et al., 2016). This capacity to conduct small scale 
experiments under controlled conditions, of a highly predictive nature at larger scale, allows 
the investigation of the behaviour of different cell lines under alternative feeding regimes to 
determine how each respond. Indeed, recent reports state that the ambr15Ô small-scale 
automated and controlled bioreactor system provides an excellent scale down model to 
facilitate studies on multiple cell lines under controlled industrially relevant conditions to 
identify robust targets linked to productivity for cell engineering and material and data for 
future regulatory submissions (Sandner et al., 2018). 
Despite advancements in the ability of CHO cells to reach higher cell concentrations and 
generate increasing amounts of target biotherapeutic proteins, particularly monoclonal 
antibodies (mAbs), there remains a desire to further understand the limitations upon CHO 
cell phenotypes and to engineer cells for the production of more difficult to express products 
(Godfrey et al., 2017; Jossé et al., 2018; Mead, Chiverton, Smales, & Von Haar, 2009). One 
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approach that has been applied towards improving our understanding of the limitations on 
CHO cell growth and recombinant protein production is the field of transcriptomics 
(Tamošaitis & Smales, 2018). Transcriptomic studies in particular could benefit from 
generating material from controlled miniature bioreactors that predict behaviour at larger 
scale, as an issue of such previous studies is reproducibility and robustness across different 
transcriptomic datasets, given the high heterogeneity of CHO cell lines and their intrinsic 
genetic instability (Chen, Le, & Goudar, 2017; F. M. Wurm, 2013; F. Wurm & Wurm, 2017).  
The availability of CHO cell and Chinese hamster genome sequences (Lewis et al., 2013; X Xu 
et al., 2011) has greatly enabled omics-based studies (Faustrup Kildegaard, Baycin-Hizal, 
Lewis, & Betenbaugh, 2013), and since there has been an increasing number of publicly 
available databases for different CHO cell lines. However, the focus of these studies has been 
on either coding genes or microRNAs (miRNAs) with few studies investigating other classes 
of RNAs and their impact on CHO cell behaviour (Singh, Kildegaard, & Andersen, 2018; 
Tamošaitis & Smales, 2018).  
Here I investigate the long non-coding transcriptome in CHO cells during fed-batch culture 
under controlled bioreactor conditions. Since the unravelling of multiple organisms 
genomes, particularly eukaryotic genomes, associated with the development of high 
throughput sequencing technologies, new classes of non-coding RNA have been identified 
(Djebali et al., 2012). Among these, a class of transcripts known as long non-coding RNAs 
(lncRNAs) was identified. LncRNAs are defined as transcripts longer than 200 nucleotides that 
lack a significant open reading frame (ORF), are usually transcribed by RNA polymerase II, 
and are spliced with, or without, 3’ polyadenylation (Kashi et al., 2016; Kung et al., 2013; 
Wilusz, 2016). In the nucleus, cis-acting lncRNAs regulate the chromatin state and 
transcription of nearby genes while trans-acting lncRNAs can recruit RNA binding proteins to 
form chromatin modifying complexes, modulate splicing or organise functional nuclear 
domains (Kopp & Mendell, 2018). When transported to the cytoplasm, lncRNAs act at a post-
transcriptional level by promoting specific mRNA translation or turnover and by 
competitively binding microRNAs (miRNAs), attenuating the repression of target genes 
(Geisler & Coller, 2013). The wide range of processes involving lncRNAs suggests that some 
of these may be potential cell engineering targets to rewire CHO cell phenotypes for 
enhanced cell growth and/or recombinant protein production and quality without placing a 
translational burden on the cell compared to overexpression of coding genes. However, the 
majority of our knowledge around lncRNAs comes from studies in model organisms related 
to disease and development (Perry & Ulitsky, 2016; Schmitt & Chang, 2016) with lncRNAs 
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poorly annotated in the CHO cell genome and little known about their role in defining CHO 
cell phenotypes.  
A recent report described the first study into the lncRNA landscape in CHO cells, showing 
regulated expression of thousands of lncRNAs under batch and fed-batch conditions over 
time (Vito et al 2018). Others have demonstrated the potential power of lncRNA cell 
engineering to manipulate the cells ability to produce target recombinant proteins with the 
first reports of engineering of a class of lncRNAs named SINEUPs to enhance the translation 
of specific target mRNAs in various mammalian cell factories (Patrucco et al., 2015; Zucchelli, 
Patrucco, Persichetti, Gustincich, & Cotella, 2016). However, the limited number of studies 
and poor annotation of non-coding regions in the Chinese hamster genome means that 
transcriptomics across multiple cell lines associated with phenotypes of interest under 
industrially relevant and controlled conditions is required to identify lncRNAs whose 
manipulation may enhance mammalian cell factories ability to generate secreted target 
products (Vishwanathan, Le, Le, & Hu, 2014). Here I present a comprehensive coding and 
non-coding, particularly lncRNAs, transcriptome analysis using RNA-Seq of 5 IgG1 producing 
CHO cell lines and 1 stable pool harbouring the plasmid cassette without genes encoding for 
the IgG1, cultivated under fed-batch conditions in an ambr15Ô system to unveil regulated 
lncRNA targets for cell engineering. The RNA-Seq datasets and analyses are made openly 
available to the community to promote further studies and comparisons and provide a first 
CHO cell lncRNA transcriptomic resource. 
 
4.2 Results and Discussion  
I set out to provide the first analysis of the long noncoding RNA (lncRNA) transcriptome using 
RNA-Seq in CHO cells producing three different model monoclonal antibodies during fed-
batch culture, defining those lncRNAs expressed in CHO cells and the flux of these during 
culture and between cell lines. To do this, I undertook RNA-Seq analysis on a panel of IgG 
expressing CHO DHFR cell lines, sampling throughout fed-batch cultures in an ambr15™ 
microbioreactor system generating profiles of the flux of coding RNAs and lncRNAs. 
4.2.1 Analysis of fed-batch culture samples  
The DAVI dataset included the 3068, 3080 and 3077 IgG1 producing cell lines and the null 
pool 3478 (Summarised in Table 4.1). These cell lines showed comparable culture viability, 
maintaining a culture viability >80% throughout the 12 days of fed-batch culture. However, 
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there was a diverse range of viable cell concentrations achieved across the cell lines with cell 
line 3077 reaching the highest maximum viable cell concentration of 14.48 x 106 viable 
cells/mL with the other cell lines reaching lower concentrations of 10.66 x 106 (for 3478), 
9.38 x 106 (for 3068) and 8.56 x 106 (for 3080, Figure 4.1A). The overall product titres and Qp 
for the producer cell lines at Day 12 were 1.96 g/L and 23.05 pg/cell/day (3077), 1.48 g/L and 
26.53 pg/cell/day (3068), and 1.80 g/L and 31.71 pg/cell/day (3080) respectively (Figure 
4.1B,D). The glutamate, glutamine and ammonia profiles were similar across all cell lines 
(Supplementary Figure 4.1), while lactate accumulated during the first few days of culture, 
with a peak concentration of 2.2 g/L for 3080 at Day 5 and 3478 at Day 12 and <1.5 g/L for 
3068 and 3077 (Figure 4.1C). 
Table 4.1 - Symphogen cell lines used in DAVI and JCE experiments 
DAVI Experiment 





3478 Pool 10.66 x 106 - - 
3068 Clone 9.38 x 106 1.48 26.53 
3077 Clone 14.48 x 106 1.96 23.05 
3080 Clone 8.56 x 106 1.80 31.71 
JCE Experiment 





3068 Clone 8.52 x 106 2.64 35.20 
3080 Clone 6.94 x 106 2.25 35.81 
4384 Clone 11.01 x 106 2.43 23.39 
3936 Pool 10.67 x 106 1.23 13.25 
Cell line detail/name, clonality, peak viable cell number (VCD), the IgG yield at Day 12 for DAVI and 
Day 14 for JCE and the cell specific productivity for the model IgG1 expressing cells used in the 





Figure 4.1 - Cell culture parameters for the DAVI and JCE datasets  
The parameters measured and monitored during fed-batch culture of model IgG1 expressing CHO cell clones and a null pool for the DAVI dataset (A, B, C, D) and the JCE 
dataset (E,F,G,H). A |E | viable cell density (VCD) and viability over time. B |F | yield of IgG1 antibody over time. C |G | Lactate concentration over time. D |H | productivity 
(Qp) for each cell line. 
A EB F
C D G H
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The JCE dataset included the 3068, 3080 and 4384 IgG1 producing cell lines and the 3936 
IgG1 producing pool (Table 4.1). The 3068 cell line reached a maximum viable cell 
concentration of 8.52x106 viable cells/mL, while the 3080 cell line obtained a maximum 
viable cell concentration of 6.94x106 viable cells/mL. The 4384 cell line reached the highest 
maximum viable cell concentration of the cells used in this experiment of 11.01x106 viable 
cells/mL followed closely by the 3936 cell line at 10.67x106 viable cells/mL (Figure 4.1E). The 
culture viability profiles were broadly comparable across the cell lines, being within the range 
of 60-80% on the last day of culture (Figure 4.1E). The highest IgG titre reached at the end of 
culture on Day 14 was achieved by the 3068 cell line of 2.64 g/L, followed closely by 2.43 g/L 
and 2.25 g/L achieved by the 4384 and 3080 cell lines respectively. The 3936 cell line 
generated the lowest titre of only 1.23 g/L, as would be expected from a pool of clones 
(Figure 4.1F). When the Qp was calculated, the 3068 and 3080 cell lines had cell specific 
productivities of 35.20 and 35.81 pg/cell/day respectively, while the 4384 cell line had a Qp 
of 23.39 pg/cell/day and 3936 a Qp of 13.25 pg/cell/day (Figure 4.1H). The glutamate, 
glutamine and ammonia profiles were broadly similar across the cell lines while lactate never 
accumulated over 2 g/L for 3068 (Figure 4.1), while the lactate in the culture supernatant for 
the other cell lines fluctuated above this value, with a peak at approximately 3.5 g/L for the 
3080 cell line (Figure 4.1G). 
4.2.2 RNA sequencing of ambr15™ generated samples and subsequent analysis of the 
data: The DAVI experiment  
As described in the methods section, cell pellet samples in biological duplicates for RNA 
sequencing were collected in duplicate at Day 4 and Day 12 of fed-batch culture from the 
ambr15™ reactors. Clustering analysis of the RNA-Seq data revealed that the samples 
showed a consistent hierarchical clustering for the biological replicates and an evident 
separation between the two time-points based on gene expression (Figure 4.2A, B). This 
separation was confirmed by Principal Component Analysis (PCA), however an additional 
layer of clustering emerged among the producers upon PCA with a difference in Qp, clearly 
showing clusters formed of 3077 and 3068 (23.05 and 26.53 pg/cell/day), that were 
distanced from cell line 3080 (31.71 pg/cell/day) and the null-pool 3478 (Figure 4.2C). 
Overall, this preliminary cluster analysis based on total gene expression suggests a grouping 
of cell lines directly related to differences in Qp more than maximum viable cell 
concentrations for this dataset. Differential transcript expression (DE) analysis was then 
conducted using the DESeq2 R software package, setting a fold change (FC) threshold of 1.50. 
DE genes were considered significant if the adjusted p-value for this FC threshold calculated 
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in DESeq2 using the Benjamini-Hochberg method was below 0.10. Comparing DE within the 
same cell line between Days 12 and Day 4 identified the highest numbers of DE genes, with 
the producing clones 3068, 3077 and 3080 having 2295, 2538 and 2255 DE genes 
respectively, while there was a much higher number of DE genes identified between these 
two days in the null-pool 3478 (4464 DE genes) (Figure 4.3). When comparing the gene 
expression between the different producers on the same culture day, a comparison of cell 
line 3077 against 3068 revealed 224 (Day 4) and 281 (Day 12) DE genes, while a comparison 
of cell line 3077 against 3080 revealed 883 (Day 12) and 604 (Day 4) and for 3080 against 
3068 revealed 813 (Day 12) and 570 (Day 4) (Figure 4.3). The number of identified DE genes 
using the criteria outlined when comparing the producer cell lines to the null-pool 3478 was 
much larger than when comparing the producers to each other. As such, when comparing 
the null to cell line 3068 there were 371 (Day 4) and 1653 (Day 12) identified DE genes, whilst 
for cell line 3077 there were 509 (Day 4) and 2255 (Day 12) and for cell line 3080 there were 
491 (Day 4) and 813 (Day 12) (Figure 4.3). Within the identified DE genes, lncRNAs made up 
10-30% of the total number identified (Figure 4.3). A representative group of differentially 
expressed coding and non-coding RNAs were then selected (see Section 4.2.6) for RT-qPCR 
validation, resulting in a positive correlation between the fold changes measured by RNA-




Figure 4.2 - Clustering and PCA analysis based on gene expression 
Coding and non-coding gene expression measured with RNA-Seq. From left to right, clustering based on the distance between each sample, clustering based on the top 30 
most differentially expressed genes expression and PCA of normalized gene expression for the first two principal components. Figures A to C show the DAVI dataset. The 
type indicates whether the samples are from the non-producing pool (Null) or from producing clones (Producer) while the condition groups replicates of the same cell line 
and time point. Figures D to F show the JCE dataset. The type indicates whether the samples are from fed-batch culture (FB) or from the seed-train (ST) while the condition 




Table 4.2 - Identified potential lncRNA genes for cell engineering 









100689050 NR_045124.1 Adapt15 
3068 D12 v D4, -1.80 
3080 D12 v D4, 3.36 
3478 D12 v D4, -5.21 
D12 3068 v 3478, 2.86 
D12 3077 v 3478, 3.36 
D12 3080 v 3478, 1.88 
- - - 0.023 NR_040384.1 5e-11 
linked to oxidative 
lipotoxicity, resulting in 
ER stress and cell death 
103158913 XR_478428.1 GAS5 
3077 D12 v D4, -1.98 
3478 D12 v D4, -2.47 
D12 3068 v 3478, 2.17 
- SNORD44 SNORD78 
RF00287 
RF00592 0.023 NR_002840.2 1e-65 
snoRNA host gene 
tumour suppressor 
103158906 XR_478426.2 PVT1 
3068 D12 v D4, 1.91 
3080 D12 v D4, 3.59 
D4 3077 v 3478, 2.70 
D12 3068 v 3478, 2.71 
D12 3077 v 3478, 3.59 
D12 3080 v 3478, 2.13 
D4 3068 v 3936, 2.53 
D4 3936 v 3080, -2.63 
D4 4384 v 3080, -2.04 
D7 3068 v 3936, 2.53 
PVT1_3 RF02166 0.029 NR_003368.2 2e-53 
Oncogene, interacts 
with miR200 family and 
Myc 
Three identified potential lncRNAs targets for cell engineering with an established function in the literature and a homologue in mouse. From left to right, the table indicates 
the GeneID and NCBI RefSeq accessions, the gene name, the statistically significant differential expression in DAVI and JCE datasets, the RFAM secondary structure family 
and accession numbers, the coding probability measured in the Coding Potential Calculator 2 (CPC2) (Kang et al., 2017), the mouse homologue transcript with the 




Figure 4.3 - Differentially expressed genes in the DAVI and JCE datasets 
The number of differentially expressed genes with a FC ³ 1.5, adj p-value < 0.1. In blue is shown the 
DAVI dataset and in red is shown the JCE dataset while the size of the dot indicates the % of lncRNAs 
for each comparison. For each comparison, the exact number of genes is indicated on the right. 
 
4.2.3 RNA sequencing of ambr15™ generated samples and subsequent analysis of the 
data: The JCE Experiment  
In the JCE experiment, samples for RNA sequencing were collected in biological triplicate 
from the seed train (ST) flasks and at Day 4 and Day 7 of fed-batch culture. The samples 






































as observed in the DAVI experiment was not as evident (Figure 4.2D, Figure 4.2E). PCA 
revealed a similar pattern where only a cluster composed of the 4384 cell line samples was 
distinguishable from the other samples with the other clones not grouping separately, with 
the exception of the seed-train samples, based upon analysis of the complete RNA-Seq 
datasets (Figure 4.2F). The clustering of the 4384 cell line samples as different from the 
others (as observed by PCA) was confirmed by the high number of DE genes identified when 
comparing this cell line (4384) against the others on Day 4 (vs 3068, 701 DE genes; vs 3080, 
1015 DE genes; vs 3936, 472 DE genes). When the other cell lines were compared to each 
other on Day 4 the number of identified DE genes was much lower than when comparing to 
the 4384 cell line, indicating the gene expression profiles of these cell lines was closer than 
to that of 4384 (3068 vs 3080, 301 DE genes; 3068 vs 3936,170 DE genes; 3936 vs 3080, 316 
DE genes). The number of DE genes identified between the cell lines was much lower when 
the profiles at Day 7 were compared (220 DE genes for 3068 vs 3080; 152 DE genes for 3068 
vs 3936; 228 DE genes for 3936 vs 3080; 489 DE genes for 4384 vs 3068; 525 DE genes for 
4384 vs 3080, 314 DE genes for 4384 vs 3936; see Figure 3).  
When comparing changes in gene expression within cell lines between days 4 and 7 of fed-
batch culture there was a large difference in the total number of DE genes. When comparing 
Day 7 against Day 4 of culture there were 181 DE genes identified in cell line 4384 whereas 
in cell line 3068 there were 417 DE genes identified, for cell line 3080 there were 516 DE 
genes and for cell line 3936 there were 615 DE genes. I then compared the gene expression 
profiles of the seed-train cultures that were used to start the fed-batch process, obtained 
from cells during logarithmic growth phase, to the Day 4 gene expression profiles of the fed-
batch culture experiments. Although cells from the seed train and fed-batch day 4 ambr15™ 
bioreactor might be expected to be in a similar growth and metabolic state, there were 
changes in gene expression identified between the samples. The seed train samples gene 
expression when compared to the Day 4 bioreactor sample comparison for the 3936 cell line 
revealed the fewest DE genes with 140 genes changing in expression between the samples. 
The same comparison for the 4384 and 3080 cell lines revealed 306 and 307 genes DE 
respectively between the seed train and fed-batch reactor samples whilst for the 3068 cell 
line there was more than double the number of DE genes identified (761). Overall, the 
hierarchical clustering, PCA and DE analysis suggest the 4384 cell line has a different gene 
expression profile to the other cell lines whilst the 3068, 3936 and 3080 cell lines have a 
much closer gene expression profile. Further, the seed train samples of each cell line show, 
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to varying degrees, different gene expression profiles than that of cells taken from the fed-
batch cultures in an equivalent growth phase.  
4.2.4 Investigating Pathway Enrichment in DE Genes  
KEGG pathway functional enrichment of the RNA-Seq datasets based on statistically 
significant differentially expressed genes showed two distinct patterns across the datasets. 
Firstly, a major theme of enrichment in the DAVI dataset was in the Replication and Repair 
area, where DE genes were found to be enriched in DNA replication, base excision repair, 
nucleotide excision repair, mismatch repair, homologous recombination and Fanconi anemia 
pathways among the 3077, 3068 and 3478 cell lines when comparing Day 12 v Day 4 
expression profiles within the same cell line (Figure 4.4). Interestingly, the only cell line in 
the DAVI dataset in which none of these pathways was enriched was the 3080 cell line. In 
the DAVI dataset this was the cell line with the highest Qp and also the cell line that was 
distinct from the others when the RNA-Seq data was analysed by PCA. On the other hand, 
comparing the different cell lines gene expression profiles between Day 4 or Day 12 to each 
other did not reveal any enriched pathways related to genome maintenance (Supplementary 
Figure 4.2). Thus, within a given cell line changes in genome maintenance pathways were 
observed between days 4 and 12 of culture, however when Day 4 or Day 12 of different cell 
lines were compared this was not observed. 
I then applied the same enrichment analysis to the JCE dataset and surprisingly none of the 
pathways involved in genome maintenance were enriched within the DE genes between Day 
4 and Day 7 (Supplementary Figure 4.3). An analysis of the seed train v fed-batch DE genes 
for the 3080 and 3068 cell lines revealed enrichment of the DNA replication pathway and for 
the seed train v 4384 cell line enrichment of the nucleotide excision repair, mismatch repair 
and DNA replication pathways (Supplementary Figure 4.4). The pathway enrichment analysis 
also consistently revealed the enrichment of the PI3K-Akt signalling pathway, focal adhesion 
and ECM-receptor interaction pathways in the DE genes across both the DAVI and JCE 
datasets. Overall, the enrichment suggests a prominent regulation of genome maintenance 
mechanisms is conserved across different cell lines at the passage from seed train to fed-
batch culture and towards the end of culture, while the most differentially regulated 
pathways at the same stage in culture for the same cell lines are the PI3K-Akt signalling, focal 
adhesion and ECM-receptor pathways. 
When considering the differential expression of individual genes involved in the Replication 
and Repair domain, I identified Exonuclease 1 (Exo1), Rad51, Essential Meiotic Structure-
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Specific Endonuclease 1 (Eme1) and FA Complementation Group B (Fancb) in common 
among the top 30 most differentially expressed genes in both the DAVI and JCE datasets 
(Supplementary Figure 4.5). These genes are involved in a wide range of genome repair 
mechanisms from mismatch repair to homologous recombination and DNA double-strand 
break repair, suggesting a co-regulation of multiple facets of genome maintenance and the 
importance of high fidelity in these pathways to maintain cell integrity, viability and growth 













Figure 4.4 - Enriched KEGG pathways based on differentially expressed genes in the DAVI dataset 
Enriched KEGG pathways based on differentially expressed genes for each comparison among the same cell line at day 12 against day 4 in the DAVI dataset. Each dot 
represents a pathway, with colour shade representing the p-value, size proportional to the overlap size (differentially expressed genes in the pathway) and x-coordinate 
recall (overlap size divided by the total number of genes in the pathway). 
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4.2.5 Mapping of Long non-coding RNA expression during fed-batch culture  
As outlined in the introduction section, a key aspect of this study was to generate a detailed 
description of lncRNA expression under controlled bioreactor conditions in different IgG 
producing CHO cells and to identify lncRNAs whose manipulation may enhance the CHO cell 
factory ability to generated secreted target products. In order to investigate and identify 
non-coding RNAs, all the significant differentially expressed non-coding genes were filtered 
based on NCBI annotation and are shown as a percentage of the total number of 
differentially expressed genes for each comparison in  
Figure 4.3 and in Supplementary Table 4.1. The complete RNA-Seq dataset is provided 
reporting those lncRNAs identified as being expressed in CHO cells and hence providing a 
reference for the community to investigate individual lncRNAs in CHO cells (Supplementary 
Material 4.1).  
The DAVI dataset showed a higher percentage of ncRNAs on average (22.2%) compared to 
JCE (14.0%) as a percentage of the total DE RNAs identified, most likely due to the higher 
coverage in the sequencing data for the DAVI dataset. Among the DAVI dataset, comparisons 
listing the highest number of DE genes, in particular Day 12 v Day 4 for each cell line, 
contained the lowest percentage of lncRNAs on average at 14.8% while the opposite was 
true for comparisons at Day 4 and partly at Day 12, where the lower number of DE genes 
resulted in a higher percentage of ncRNAs respectively at 28.7% and 20.6% on average. I then 
calculated how many ncRNAs were differentially expressed at both time points in the two 
datasets to assess the variability of lncRNAs expression as culture progresses (Supplementary 
Material 4.1). When comparing producers against non-producers in the DAVI dataset, 
between 33.4% and 44.4% ncRNAs were differentially expressed at both day 4 and day 12, 
while the percentages raised to 56.6-71.1% when comparing producers. The JCE dataset 
showed a narrower range, between 38.6% and 53.1% ncRNAs differentially expressed at 
both day 4 and day 7. Overall, these results confirm the higher coverage for the DAVI dataset 
resulting in a higher number of identified ncRNAs. 
4.2.6 Identification of differentially expressed lncRNAs as potential cell engineering 
targets  
I then looked to filter and refine the list of DE lncRNAs by counting the occurrence of each 
transcript in all the DE comparisons, assessing sequence conservation across mammalian 
species through the discontiguous megablast algorithm and secondary structure prediction 
based on the RFAM database (Kalvari et al., 2018). Each lncRNA identified via this strategy 
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was then experimentally validated by RT-qPCR to confirm the differential expression 
between conditions in CHO cells (Supplementary Material 4.2). The first lncRNA identified 
via this approach was Adapt15. LncRNA Adapt15 (also known as growth arrested DNA-
damage inducible gene 7, Gadd7) was discovered in hamster cells, with homologs identified 
in the closely related Long-tailed Dwarf Hamster (C. longicaudatus) with sequence 
conservation across rodents (Crawford, Schools, Salmon, & Davies, 1996). More recently 
Adapt15 has been linked to oxidative lipotoxicity, with knockdown alleviating ER stress and 
cell death (Brookheart, Michel, Listenberger, Ory, & Schaffer, 2009). In the DAVI dataset at 
Day 12, Adapt15 was upregulated compared to day 4 in the 3077, 3068 and 3080 cell lines 
with a fold change in expression of 3.36, 2.86 and 1.88 respectively compared to the null 
pool 3478. Conversely, within the JCE dataset, which is focused only on producers and 
comparison of earlier stages of culture, there was no significant DE of Adapt15 identified, 
suggesting DE expression of this transcript is observed in producer cell lines compared to a 
non-producing control later in fed-batch culture (Table 4.2). This observation of increased 
Adapt15 transcript expression at day 12 relative to day 4 of fed-batch culture in the DAVI 
dataset was confirmed by qPCR experiments. 
A second lncRNA that showed significant DE was growth arrest specific transcript 5 (GAS5), 
a non-protein-coding multiple small nucleolar RNA (snoRNA) host gene (C. M. Smith & Steitz, 
1998) with a short ORF and a well-known tumour suppressor lncRNA in human cancer biology 
(Ma et al., 2016). As a result of cell growth arrest and mTOR pathway activity repression, 
translation of the GAS5 short ORF is blocked and the transcript accumulates, escaping the 
nonsense-mediated decay (NMD) pathway which depends on active translation (Ma et al., 
2016; Tani, Torimura, & Akimitsu, 2013). I identified the uncharacterized gene 
LOC103158913, upregulated in its expression at Day 12 in 3068 compared to 3478 null pool 
with a fold change in expression of 2.17 and an adj p-value = 7.23 x 10-5, as a homologue of 
mouse GAS5 in CHO using BLAST. I suggest this lncRNA is upregulated in CHO cell lines 
whereby growth has been arrested and mTOR signalling attenuated and may be a 
characteristic of such cell lines. 
A 3rd well characterised lncRNA in other systems that was identified in our system as 
differentially regulated was plasmacytoma variant translocation 1 (PVT1). PVT1 is a non-
coding oncogene related to poor prognosis in different cancer types (Shikai Zhu et al., 2017) 
with reports of competing endogenous RNA (ceRNA) activity on the miR200 microRNA family 
and direct interaction with the MYC oncogene (Colombo, Farina, Macino, & Paci, 2015b). In 
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a previous work (Vito & Smales, 2018), we identified the uncharacterized gene 
LOC103158906 as a homologue of mouse PVT1 in CHO using BLAST  and secondary structure 
prediction in RFAM. PVT1 is annotated in C_griseus_v1.0 as LOC103162981, giving the same 
BLAST alignment scores and RFAM. Myc proto-oncogene protein is predicted to be encoded 
in CHO as LOC100758352, containing Myc amino-terminal region (Myc_N), Helix-loop-helix 
DNA-binding domain (HLH) and a Myc leucine zipper domain (Myc-LZ). The expression of 
Myc and PVT1 in DAVI was inversely correlated, with a Pearson coefficient of -0.73 and a p-
value of 0.0015. In particular, PVT1 was expressed at lower levels at Day 4 for all cell lines 
and at Day 12 for the null pool 3478 and 3080, when Myc expression was at its highest levels. 
Interestingly, when PVT1 expression increased at Day 12 for 3077, Myc levels decreased to a 
similar extent. By contrast, the correlation between PVT1 and Myc in the JCE dataset was 
positive, with a Pearson coefficient of 0.60 and a p-value = 0.0001. When only the seed train 
samples were considered, the coefficient was 0.93, indicating a very strong correlation at the 
early stage of fed-batch culture, when PVT1 expression is lower (Supplementary Figure 4.6). 
This suggests a change in PVT1 expression as culture progresses that relates to cell growth 
and Myc expression. 
PVT1 expression was upregulated with a two-fold change at Day 12 in every producer 
compared to the null pool in the DAVI dataset and it was upregulated a fold-change of 2 at 
both Day 4 and Day 7 in the 3068 cell line compared to 3936, the clone with the highest yield 
and the pool with the lowest yield respectively in the JCE dataset. When assessing the direct 
interaction probability of CHO PVT1 (XR_478426.2) and Myc (XP_003516054.2) using lncPro 
and RPISeq prediction tools, the output suggested a strong likelihood of interaction, scoring 
respectively 85.1 and 0.9 (Lu et al., 2013; Muppirala, Honavar, & Dobbs, 2011). Collectively 
these data suggest that PVT1 is likely to be related to Myc expression and hence cell growth 
and proliferation in CHO cells during fed-batch culture. 
4.2.7 Comparison of data presented here with existing datasets  
A recent meta-analysis publication compared transcriptomics studies in CHO cells, 
commenting on the difficulty in comparing these datasets but also identifying the most 
recurrent genes identified as related to Qp and growth (Tamošaitis & Smales, 2018). Here, I 
find that of the coding genes in this study a number were regulated in agreement with this 
meta-analysis study. The gene ranking first in the list of the meta-analysis was Cd36, a 
multifunctional glycoprotein acting as receptor for a broad range of ligands of proteinaceous 
or lipidic nature (Yang et al., 2017), and was consistently downregulated in producers in this 
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study compared to the 3478 null pool in the DAVI dataset, with a fold-change between 2.53 
- 3.41 at Day 4 and 4.14 - 6.64 at Day 12. Cd36 was also downregulated in 3068 and 3080, 
the cell lines with the highest Qp in the JCE dataset, compared to 3936 and 4384 at both Day 
4 and Day 7, with a fold change down in expression > 4.29. Heat Shock Protein Family A 
Member 8 (Hspa8), a molecular chaperone implicated in the protein quality control system 
and protection of the proteome from stress (Stricher, Macri, Ruff, & Muller, 2013), was 
downregulated at Day 12 against Day 4 in the DAVI dataset among every producer cell line 
and when compared to the null 3478 cell line at Day 12. The same pattern of differential 
expression was shown by both Serpinh1, a collagen-specific molecular chaperone localized 
to the endoplasmic reticulum (Ito & Nagata, 2017), and vimentin (Vim) a type III intermediate 
filament protein responsible for maintaining cell shape and stabilizing cytoskeletal 
interactions (Musaelyan et al., 2018). A summary of all the common genes between the meta 
study and the current one is provided in Supplementary Material 4.3. Overall, Cd36, Hspa8, 
Serpinh1 and Vim were consistently downregulated in cell lines with higher Qp in my datasets 
in agreement with previous transcriptomics studies summarised in the meta-analysis 
(Tamošaitis & Smales, 2018). 
4.3 Summary  
In this work I present and make available to the community two RNA-Seq derived 
transcriptomic datasets that comprehensively detail coding and non-coding transcript 
expression analysis of 5 IgG1 producing CHO cell lines and 1 null pool at different time points 
cultivated under fed-batch conditions in an ambr15™ system. In particular, I provide the first 
CHO RNA-Seq study detailing the lncRNA profile of such cells, confirming the expression of 
lncRNAs in CHO cells and identifying those whose expression is differentially regulated 
throughout fed-batch culture and between cell lines with different characteristics. The 
different time points for sample collection throughout culture and Qp of cell lines was clearly 
reflected in the PCA clustering of the transcript expression analysis and in the numbers of 
differentially expressed genes for the DAVI dataset. In addition, feeding was shown to be a 
significant source of variability even at early stage of culture, as shown by the comparison of 
seed train flask data used to inoculate the fed-batch process. This data shows for the first 
time that there is a significant change in gene expression after only 4 days of culture among 
the same clone when the cells are still rapidly growing and dividing and before the major 
phase of production of the protein of interest.  
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KEGG functional enrichment analysis confirmed a tendency of pathways in the Replication 
and Repair domain to be differentially regulated in response to feeding when the seed train 
is inoculated in the fed-batch process and towards Day 12 in particular. The only exception 
was the clone with the highest Qp at Day 12, 3080, which interestingly did not show any 
differentially regulated pathways in the Replication and Repair domain. These data suggest 
that those cell lines that can maintain genome integrity and its surveillance may be better 
suited to prolonged culture and recombinant protein productivity. Although our datasets 
contained 6 different cell lines, I wanted to identify coding genes related to an increase in 
Qp across literature to improve robustness across different systems, leading to the 
identification of Cd36, Hspa8, Serpinh1 and Vim as genes negatively correlated with Qp in 
both our datasets and the most recent transcriptomics meta-analysis in CHO cells (Tamošaitis 
& Smales, 2018). Although the functions of those genes are heterogenous, the conserved 
pattern of expression among very different experimental settings and cell lines suggests 
conserved roles with detrimental effects on Qp. Knock-Out (KO) or Knock-Down (KD) 
strategies on the aforementioned genes with CRISPR or RNA interference could be 
implemented to investigate these effects (J. S. Lee et al., 2015; Wu, 2009). 
In conclusion, while many studies in CHO cells have investigated coding genes, my work 
aimed to unveil the non-coding transcriptome variation, specifically lncRNAs. I identified 
Adapt15, GAS5 and PVT1 among many others as lncRNAs linked to Qp, although there is a 
lack of their annotation in Chinese hamster genomes there is a well-established effect of 
these in model organisms and human diseases (Colombo et al., 2015b; Hollander, Alamo, & 
Fornace, 1996; Ma et al., 2016). While Adapt15 was initially identified in hamster and later 
linked to ER stress and cell death, its role in CHO cells has never been further investigated. 
Adapt15 upregulation in producing cell lines towards day 12 of culture indicates an 
increasing stress on the ER as the recombinant protein is produced, suggesting Adapt15 as a 
target for knock-down with RNAi or knock-out with CRISPR. GAS5 transcript accumulation 
occurs as a result of mTOR signalling repression, suggesting its use as a marker of translation 
repression and cell growth arrest in specific cell lines. My data also suggests a close link 
between the expression of the lncRNA PVT1 and of Myc, the relationship between the two 
depends on the stage of fed-batch culture. When compared to an existent public database 
of gene expression (Singh et al., 2018), these lncRNAs are constitutively expressed in 
different CHOS, CHOK1 and DG44 cell lines, suggesting a conserved functional role which 
could be exploited for cell engineering. Although secondary structure and RNA-protein 
interaction predictions can suggest functional mechanisms of action, focused experimental 
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studies on single transcripts will be required to assess their effects in mammalian cell 
factories.  
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Chapter 5 tRNA Expression in CHO and 
HEK293 Cells and the Impact on Transcript 




The majority of approved recombinant biopharmaceuticals, including monoclonal antibodies 
(mAbs), are produced in mammalian cell expression systems, predominantly in Chinese 
hamster ovary (CHO) cells under fed-batch culture conditions (Butler & Spearman, 2014; 
Dumont et al., 2016; Mauro, 2018). CHO cells are the current leading system due to their 
demonstrated ability to produce complex correctly folded proteins with post-translational 
modification (PTMs) compatible with human coupled with an effective secretion of the 
protein produced (J. Y. Kim et al., 2012). In addition, CHO cells can grow in suspension in 
chemically defined serum-free media, on a large scale and produce secretory yields of 
monoclonal antibody in fed-batch culture in excess of 5 g/L (Povey et al., 2014). The secretory 
yield from such an expression system results from the combination of the number of cells 
across culture (the integral of viable cell concentration or IVC) and the average amount of 
material expressed by each cell (cell specific productivity, Qp) (Kunert & Reinhart, 2016). 
These attributes can be positively influenced by selecting the most appropriate culture 
conditions and by engineering cell clones, but mRNA translation remains the main biological 
processes determining global and protein specific synthesis, and hence controlling most 
cellular activities, impacting on IVC, Qp and protein quality (McLeod et al., 2011; Mead et al., 
2015; Schwanhäusser et al., 2011). As mRNA translation is a complex process composed of 
sequential phases and requiring the assemble of cellular machineries with multiple subunits, 
protein abundance control in the cell can be tuned at multiple levels depending on internal 
or external dynamics, such as the availability of translation factors in the cell or extracellular 
signalling stimulating growth (Kelen et al., 2009). Due to this central role of translation, 
numerous works in CHO cells have investigated this process showing a dependence on the 
phosphorylation of key translation factors such as eIF2a causing attenuation of global 
protein synthesis (Underhill et al., 2005), on global translation efficiency (Mead et al., 2012; 
O’Callaghan et al., 2010; Roobol et al., 2015) and on culture temperature, which impacts on 
quantity and quality of recombinant protein produced (Underhill et al., 2005). The interplay 
of these parameters and their variations throughout culture can have a huge impact with 
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opposed effects for different transcripts. Under reduced temperature, translation elongator 
factor 2 (eEF2) becomes phosphorylated leading to a reprogramming of translation and 
causing global attenuation which can be escaped by transcripts with a specific codon usage 
(Bastide et al., 2017). The degeneracy of the genetic code allows the use of different 
synonymous codon sequences to achieve the same polypeptide, providing the option to 
tailor an exogenous recombinant coding sequence to the codon usage of the expression 
system of choice (Welch et al., 2009). 
Indeed, codon usage is routinely considered when designing a recombinant sequence for 
maximizing protein expression, leading to a peak increase up to 1000 fold in protein yield, 
but much more modest effects in general (Gustafsson et al., 2012; Kimchi-Sarfaty et al., 
2013). While this approach assumes that rare codons are rate limiting for protein production 
(Mauro & Chappell, 2014), recent work suggests a much more complex picture, where mRNA 
stability, ribosome speed and folding are influenced by specific codons and codon 
combinations, especially in mammalian cells (Brule & Grayhack, 2017; Hanson & Coller, 
2017). A recent report used codon de-optimization of a bispecific antibody sequence through 
the introduction of less frequently occurring codons in CHO, showing an overall increase in 
final yield (Magistrelli et al., 2017). One of the reasons underneath this different behaviour 
could be the existence of distinct codon usage patterns depending on the cell type and 
growth phase, as reported in the case of proliferation and differentiation (Gingold et al., 
2014; Plotkin et al., 2004), or even among specific Gene Ontology (GO) sets of genes 
(Rudolph et al., 2016). On top of the intrinsic codon usage variability, mammalian cell 
factories bare an additional burden on translation represented by the recombinant gene of 
interest, which can account for up to 15% of the total ribosome capacity in the cell 
(Kallehauge et al., 2017).  
An additional layer of complexity is the determination of the tRNAs pool, key players in 
translation elongation. Whereas an accurate quantification of single tRNAs species by high 
throughput sequencing techniques has been limited due to secondary structure and 
nucleotide modifications, new protocols recently emerged to overcome most of the 
limitations (Gogakos et al., 2017; Shigematsu et al., 2017; Zheng et al., 2015). AlkB-facilitated 
RNA methylation sequencing (ARM-Seq) in particular takes advantage of the bacterial 
dealkylating enzyme AlkB to remove methyl groups from m1A, m3C and m1G residues in 
tRNAs allowing a much more accurate determination of tRNAs species (Cozen et al., 2015; 
Hrabeta-Robinson et al., 2017). Here I present the first attempt of tRNA quantification in a 
host CHO-S cell line under batch and fed-batch conditions and in both null and IgG1 
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producing CHO DG44 cell lines cultivated in an automated mini-bioreactor setting using two 
different feeding strategies, and I compare these to HEK293 cells cultivated at 37oC and 32oC. 
In addition, I calculate the speed of elongation of selected IgG1 sequences and Etanercept 
based on the computational model of elongation described in Section 1.5.1. 
 
5.2 Results 
5.2.1 Culture of CHO-S cells for tRNA analysis; Fed-batch culture shows a sustained 
higher proliferation and culture viability compared to batch culture 
A CHO-S host cell line was used as a model CHO cell host expression system to accurately 
measure tRNA species abundance and variation throughout culture at different time points, 
and to allow a comparison between tRNA abundancies and their variation during batch or 
fed-batch culture processes. The CHO-S batch and fed-batch culture growth characteristics 
are described in detail in Chapter 3. Cell growth under fed or batch culture was almost 
identical up until day 4 of culture ; after this time cell growth of the batch cultures started to 




Figure 5.1 - CHO-S and Symphogen cell culture results 
A | Growth profiles of the CHO-S host cell line throughout batch and fed-batch culture over time. Viable cell 
concentration (VCC) and culture viability are shown (red for Batch and blue for Fed-batch). This data was used in 
Chapter 3 and is reported for the convenience of the reader. The percentages of CHO CD Efficient Feed B Liquid 
Nutrient Supplement added to the existing working volume are shown for each feeding day (days 0, 3 and 6). The 
arrows indicate when samples for tRNA sequencing were harvested (Day 4 and Day 7). B to H | Main parameters 
of the three Symphogen IgG1 producing cell clones (3068, 3080, 3077) and one null producer cell pool (3478) 
cultured in an ambr15Ô system under fed-batch culture with feeding using either the Cell Boost 6 (CB6) or Cell 
Boost 7 (CB7) protocol. B | Viable cell density (VCD) and culture viability over time. C | IgG1 titer over time. D | 
Specific productivity (Qp) for each cell line. E | Lactate accumulation over time F | Ammonia accumulation over 








Fed-batch cultures growth continued with an increase in viable cell concentrations observed 
until day 6 where a mean peak viable cell concentration of approximately 2 x 107 cells/mL 
was obtained. After this time point the viable cell number and culture viability of both 
cultures started to decrease, albeit at different rates, such that the cultures were terminated 
with a culture viability of 0% at day 9 for the batch cultures as opposed to a 83.6% mean 
culture viability at day 10 for the fed-batch cultures (Figure 5.1A). The first-time point at 
which samples were harvested for tRNA analysis was on day 4, when cell growth and culture 
viability were high and maintained in both cultures. On-the-other-hand, the second time 
point at which cells were harvested for RNA analysis was on day 7 of culture, corresponding 
to the end of the stationary phase/first day of decline for both cultures. In the case of the 
fed-batch cultures, these two sampling points were also 24 hours after addition of the 
Efficient Feed B. 
 
5.2.2 Culture of Symphogen cells for tRNA analysis; Comparison of growth and 
productivity characteristics of different IgG1 producing cell lines cultivated in an 
automated ambr15TM system with Cell Boost 6 and Cell Boost 7 feeding 
As described in Chapter 4, three Symphogen DG44 derived in-house IgG1-producing CHO cell 
clones (3068, 3080, 3077) and one non-producing cell pool (3478) were used in this study 
(Table 5.1). This cell lines showed a comparable culture viability, well above 80%, throughout 
the 12 days of culture, while the VCD (viable cells/mL) peaked at 14.48 x 106 for cell line 3077, 
10.66 x 106 for cell line 3478, 9.38 x 106 for cell line 3068 and 8.56 x 106 for cell line 3080 
(Figure 5.1B). The IgG titres and Qp (cell specific productivity) for the producer cell lines at 
Day 12 were 1.96 g/L and 23.05 pg/cell/day respectively for cell line 3077, 1.48 g/L and 20.82 
pg/cell/day for cell line 3068, and 1.80 g/L and 31.71 pg/cell/day for cell line 3080 (Figure 
5.1C). Monitoring of the extracellular glutamate, glutamine and ammonia concentrations 
throughout culture did not reveal any significant differences in concentrations between the 
cell lines (Figure 5.1F,G,H). There were some differences observed in lactate concentrations 
throughout culture between the cell lines with lactate accumulating to a peak concentration 
slightly over 2 g/L for cell line 3080 at Day 5 and for cell line 3478 at Day 12 whilst the peak 
lactate concentration observed was below 1.5 g/L for cell lines 3068 and 3077 (Figure 5.1E). 
To allow a comparison of any impact between different feeds on tRNAs in particular, the 
3478 (non-producing cell line) and 3068 cell lines were cultured with Cell Boost 7a + b (CB7) 
supplement in parallel to Cell Boost 6 (CB6). In this case, when using the Cell Boost 7 fed, the 
peak VCDs were 10.09 x 106 viable cells/mL for cell line 3478 and 9.21 x 106 viable cells/mL 
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for cell line 3068. When grown in fed-batch culture mode with Cell Boost 7, a Qp of 29.03 
pg/cell/day was observed for cell line 3068 with a final IgG titre of 1.98 g/L being achieved 
(compared to a titre of 1.48 g/L and a Qp of 20.82 pg/cell/day using Cell Boost 6). After day 
7 of culture, lactate formation for both cell lines was decreased when using the CB7 feed 
compared to CB6, ending below 0.70 g/L at day 12 (Figure 5.1E). However, although the 
lactate concentration was reduced in CB7 fed cultures compared to CB6 fed cultures, the 
accumulation of the remaining measured metabolites was increased substantially in both 
the 3478 and 3068 cell line cultures when using CB7 compared to CB6 fed-batch culture, 
reaching concentrations respectively of 12.14 (cell line 3478) and 12.64 (cell line 3068) mM 
for ammonia (Figure 5.1F), 5.05 and 4.78 mM for glutamate (Figure 5.1G), and 2.65 and 2.19 
mM for glutamine (Figure 5.1H). 
 
Table 5.1 - Summary of the cell lines used in the Symphogen dataset 





3478 Pool Cell Boost 6 10.66 x 106 - - 
3478 Pool Cell Boost 7 10.09 x 106 - - 
3068 Clone Cell Boost 6 9.38 x 106 1.48 26.53 
3068 Clone Cell Boost 7 9.21 x 106 1.98 29.03 
3077 Clone Cell Boost 6 14.48 x 106 1.96 23.05 
3080 Clone Cell Boost 6 8.56 x 106 1.80 31.71 
The cell line number, clonality (not assessed for Pool, assessed by FACS for Clone), the peak viable cell 
concentration (VCD), the total IgG yield at Day 12 and the cell specific productivity.  
 
5.2.3 AlkB de-methylation treatment on extracted small RNAs increases the detection of 
full length tRNAs up to 5-fold  
Once cell pellet samples had been taken from the cultures at the appropriate days for 
analysis, it was necessary to extract the RNA, and then for tRNA RNA-Seq analysis, specifically 
to remove modification of tRNAs that can interfere with sequencing. Thus, it was necessary 
to assess the efficiency of tRNA de-methylation treatment (as described in section 2.4.1) we 
included one negative control sample for each condition, where the AlkB protein that 
undertakes the demethylation reaction was not added (AlkB). On top of this, as tRNA gene 
copy number is known to correlate strongly with codon usage and tRNA abundance in yeast 
(Iben & Maraia, 2012), we de-methylated and sequenced small RNAs from S. cerevisiae to 
use as a reference for the assessment of the technical accuracy of the RNA-Seq analysis.  
After adapter and short read (<16 nt) trimming, between 28.9% and 48.9% of the total reads 
aligned to tRNAs in the different AlkB treated samples, as opposed to only 5.8-12.2% 
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obtained in the no AlkB added samples, and therefore no demethylation, controls (Figure 
5.2A). Therefore, using the demethylase treatment and ARM-Seq allowed the identification 
of 4- to 5-fold more tRNAs compared to standard small RNA sequencing. Interestingly, 
optimizing the library generation protocol for the DAVI dataset with the use of a more 
processive Reverse Transcriptase and a longer reaction time (see Materials and Methods) 
led to an even higher percentage of reads aligning to tRNAs, ranging from 74.3% to 88.5% 
(Table 5.2). As expected, the yeast samples showed a strong correlation between the tRNA 
abundances measured by sequencing and the gene copy numbers (r = 0.75, p-value = 5.1e-
09, Figure 5.2B). Taken together, these results show a much higher identification of tRNAs 
following the AlkB treatment protocol to detect tRNAs, with a 4 to 5-fold increase, and a 
reliable accuracy, as shown by the S. cerevisiae samples used as a reference. 
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Table 5.2 - Mapping efficiencies for Symphogen dataset 
Sample Reads mapping to tRNA [%] 
Reads mapping 
to sRNA [%] 
Reads not 
mapped [%] 
3478 D4 CB6 86 8 6 
3478 D12 CB6 86 9 5 
3068 D4 CB6 84 10 6 
3068 D12 CB6 82 13 5 
3478 D4 CB7 86 8 6 
3478 D12 CB7 81 13 6 
3068 D4 CB7 88 7 5 
3068 D12 CB7 77 16 7 
3077 D4 84 10 6 
3077 D12 83 11 6 
3080 D4 80 13 7 
3080 D12 82 11 7 
For each sequenced Symphogen cell line sample, the table shows from left to right the percentage of 




Figure 5.2 - Small RNA-Seq reads alignments and yeast correlation 
A | Pie chart summary of the CHO-S cell small RNAs sequenced dataset mapping to GtRNAdb for tRNAs and 
ENSEMBL for the other small RNAs. In blue is indicated the proportion of reads mapping to tRNAs, in orange the 
proportion of reads mapping to small RNAs and in grey the proportion of reads unassigned. Samples indicated 
with the suffix –n (first row of graphs) were not demethylated before sequencing, while the corresponding 
samples below were treated with the bacterial de-methylase AlkB before library generation. B | Pearson 
correlation between the sequenced S. cerevisiae tRNAs and the tRNAs gene copy numbers in the genome. The 










Figure 5.3 - Clustering and PCA based on tRNA sequencing 
From top to bottom: clustering of samples based on the Euclidean distance between each sample, clustering 
based on the top 30 most differentially expressed genes and the PCA of normalized gene expression for the first 






5.2.4 The CHO-S and the Symphogen datasets both cluster based on culture time point 
sampling as opposed to feeding regime 
The calculation of the Euclidean distances between samples provides an effective visual 
representation of a datasets global heterogeneity. When this was calculated for the CHO-S 
dataset, we observed two main clusters composed respectively of samples collected at Day 
4 and those collected on Day 7 of culture. The one exception to this was for one of the 
replicates for Batch culture Day 7 (Figure 5.3A). The Symphogen dataset showed a similar 
trend, with a main block composed of samples collected at Day 12 of culture and two blocks 
formed from samples collected at Day 4 of culture (Figure 5.3B). While for Day 4 I noticed a 
preferential separation for CB7 fed samples, with the exception of 3478_D4_CB7_2, this was 
not the case at Day 12 of culture.  
Focusing the analysis on the 30 tRNAs with the highest expression variance across samples 
gives a more accurate overview of the single gene behaviours and global clustering. The CHO-
S dataset showed a clear clustering based on time point sampling, while there was no clear 
separation between batch and fed-batch culture (Figure 5.3E). The three tRNA genes with 
the highest variance were ThrGGT, ValTAC and LeuCAG, while the most represented amino 
acids were Arg (ArgCCG, ArgCCT, ArgTCG, ArgTCT), Leu (LeuAAG, LeuCAA, LeuCAG, LeuTAA), 
Ser (SerAGA, SerCGA, SerGCT, SerTGA), Thr (ThrAGT, ThrCGT, ThrTGT), and Val (ValAAC, 
ValCAC, ValTAC).  
Clustering for the Symphogen dataset followed a similar pattern showing distinct Day 4 and 
Day 12 culture clusters, with the exception of 3080_D12_CB6_1 and 3080_D12_CB6_2, while 
feeding and cell line did not group together (Figure 5.3B,D). The three tRNAs with the highest 
variance in this data set were AlaGGC, ThrGGT and GlyACC, while the most represented 
amino acids were Arg (ArgACG, ArgCCG, ArgCCT, ArgTCG, ArgTCT), Gly (GlyACC, GlyCCC, 
GlyTCC), Leu (LeuAAG, LeuCAA, LeuCAG, LeuTAA), and Ser (SerAGA, SerGCT, SerTGA). Thus, 
Arg, Leu and Ser were commonly observed as the most represented amino acids across both 
datasets. 19 tRNA genes were observed as being the most differentiated in both datasets: 
AlaGGC, ArgCCG, ArgCCT, ArgTCT, GlnCTG, GluTTC, GlyACC, GlyCCC, IleAAT, iMetCAT, 
LeuAAG, LeuCAA, LeuCAG, LeuTAA, SerAGA, SerGCT, SerTGA, ThrGGT, TrpCCA. 
A useful method to visualize grouping of different samples is to reduce the dimensionality of 
the dataset using Principal Component Analysis (PCA). PCA for the CHO-S dataset confirmed 
a clear separation between the Day 4 and Day 7 culture samples, while there was no evident 
clustering based on feeding (Figure 5.3E). The same trend was observed for the Symphogen 
dataset, with two main clusters corresponding to Day 4 and Day 12 culture samples and no 
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obvious clustering based on cell line or feeding type (Figure 5.3F). For both datasets, more 
than 69% of the variation was explained by the first two components. 
 
5.2.5 The de-methylation treatment does not impair the detection of other small RNAs 
In addition to tRNAs, the sequencing protocol allows the identification and quantification of 
most small RNAs, including in order of abundance: small nucleolar RNAs (snoRNAs), 
microRNAs, mitochondrial tRNAs, ribosomal RNAs and small nuclear RNAs. When these were 
included in the alignment, the percentage of reads mapping to either tRNAs or small RNAs 
increased to 92.1-95.3% of the total in the DAVI dataset, leaving a very small proportion of 
non-aligned reads (Table 5.2). Although my analysis focused primarily on cytosolic RNAs, the 
sequencing protocol allows the identification of mitochondrial small RNA species, including 
mitochondrial tRNAs (mt-tRNAs) and mitochondrial rRNAs (mt_rRNAs). Both species were 
consistently overexpressed in the DAVI dataset at Day 12 compared to Day 4, and the same 
trend was observed in the CHO-S dataset at Day 7 compared to Day 4 (Figure 5.4). 
Unfortunately, ENSEMBL annotation does not specify the type of mitochondrial tRNA for 
Chinese hamster except ENSCGRT00000000009 as tRNA methionine, and blasting each 




Figure 5.4 - mt-tRNA and mt-rRNA sequencing 
Sequenced mitochondrial transfer RNAs (mt-tRNA) and mitochondrial ribosomal RNAs (mt-rRNA) for the CHO-S 
dataset (Panel A) and the Symphogen dataset (Panel B). The plots show a noticeable increase in the expression 
of mt-tRNAs and mt-rRNAs towards Day 7 and Day 12 of culture compared to Day 4 in both datasets. 
 
5.2.6 The use of different Chinese hamster genomes does not significantly alter the tRNA 
gene copy number predictions 
The tRNAscan-SE algorithm allows the identification of tRNA genes in DNA sequences using 
two previously described tRNA detection programs as fast, first-pass prefilters to identify 
candidate tRNAs, followed by a highly selective tRNA covariance model (Lowe & Chan, 2016). 
As tRNA prediction in the GtRNAdb only included those from the CriGri_1.0 genome 
assembly, I decided to assess the variability of tRNA gene copy numbers across the different 
ENSEMBL publicly available Chinese hamster genomes and the related species Mesocricetus 
auratus (Table 5.3) (Lewis et al., 2013). The majority of the genes showed comparable 
numbers across Chinese hamster, with the biggest discrepancies measured for LysCTT and 
CysGCA, the tRNAs with the highest copy numbers (36-41 and 109-124 respectively). The 
number of genes for each tRNA shows a higher variability when comparing Chinese hamster 




Table 5.3 - tRNA gene copy numbers in hamster 
Anticodon Type CriGri_1.0 C_griseus_v1.0 CHOK1GS_HDv1 MesAur1.0 
AGC Ala 19 21 20 10 
CGC Ala 3 3 3 5 
GGC Ala 1 1 1 2 
TGC Ala 13 14 14 5 
ACG Arg 6 7 6 7 
CCG Arg 3 3 3 3 
CCT Arg 7 6 7 7 
TCG Arg 6 5 6 3 
TCT Arg 4 4 5 6 
ATT Asn 1 0 1 0 
GTT Asn 14 16 15 13 
GTC Asp 14 13 13 13 
GCA Cys 41 36 41 25 
CTG Gln 12 12 12 10 
TTG Gln 5 5 5 4 
CTC Glu 14 13 16 6 
TTC Glu 7 7 8 6 
CCC Gly 7 7 7 6 
GCC Gly 11 12 13 8 
TCC Gly 6 4 8 6 
GTG His 13 11 12 5 
AAT Ile 13 14 14 9 
TAT Ile 3 4 4 4 
CAT iMet 8 8 8 10 
AAG Leu 5 5 5 4 
CAA Leu 3 3 4 3 
CAG Leu 9 8 8 7 
TAA Leu 3 3 3 2 
TAG Leu 4 4 5 4 
CTT Lys 109 111 124 31 
TTT Lys 16 16 17 11 
CAT Met 8 8 8 7 
GAA Phe 8 7 8 8 
AGG Pro 7 6 8 9 
CGG Pro 3 4 3 3 
TGG Pro 6 5 6 5 
TCA SeC 2 2 2 1 
AGA Ser 6 7 7 5 
CGA Ser 2 3 3 3 
GCT Ser 8 9 9 9 
TGA Ser 3 3 3 3 
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Anticodon Type CriGri_1.0 C_griseus_v1.0 CHOK1GS_HDv1 MesAur1.0 
AGT Thr 7 7 8 8 
CGT Thr 4 5 5 3 
TGT Thr 4 5 4 3 
CCA Trp 6 6 7 5 
GTA Tyr 11 11 11 12 
AAC Val 11 12 11 6 
CAC Val 8 8 8 4 
TAC Val 5 5 5 8 
Summary of the gene copy numbers for each tRNA and the correspondent aminoacid type in three 
Chinese hamster genomes (CriGri_1.0, C_griseus_v1.0, CHOK1GS_HDv1) and Mesocricetus auratus 
(MesAur1.0), predicted using tRNAscan-SE 2.0. 
 
5.2.7 IgG1 light chain, EPO and Etanercept codon sequences show a strong agreement 
with the CHO codon bias even when a subset of sequences is considered 
As discussed in the introduction of this thesis, the proportion of specific synonymous codons 
for the same amino acids can significantly impact translation efficiency. The codon 
adaptation index (CAI) is a score ranging from 0 to 1 which measures the codon usage bias 
of a sequence based on a set of reference coding genes (Sharp & Li, 1987). A significant 
advantage of the Symphogen dataset is the availability of total RNA-Seq results for the 3478, 
3080, 3068 and 3077 cell lines at Day 4 and Day 12 of culture, along with the sequenced 
tRNAs. Therefore, I used the CAI python package (B. D. Lee, 2018) to calculate the index of 
adaptation for the 3068 and 3080 cell lines with respect to the IgG light and heavy chain 
sequence/codon usage, along with the publicly available Etanercept and EPO sequences, 
reported in the Appendix. To assess whether highly expressed genes show a different codon 
usage bias to genes expressed at a lower level, I decided to split the CAI calculation using the 
whole CHO genome and the 500 most and least expressed coding genes measured by RNA-
Seq (Table 5.4). While the heavy chain sequences showed a strong CAI between 0.84 and 
0.87, the IgG light chain CAI for both cell lines was always above 0.91, with a peak around 
0.95. The EPO and Etanercept sequences displayed a CAI similar to the IgG light chain, while 
the use of the reference set of genes sequenced from different cell lines did not produce 
significant variations in the CAI of any of the coding sequences.  Overall, all the coding 
sequences showed a strong agreement with the CHO codon bias, with little variation when 
considering only part of the expressed genes as a reference and a higher adaptation for the 
light chain compared to the heavy chain for both 3068 and 3080 IgGs. 
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Table 5.4 - Codon adaptation index calculations 









HC 3068 0.86 0.85 0.84 0.84 0.84 
HC 3080 0.87 0.86 0.85 0.84 0.85 
LC 3068 0.95 0.94 0.92 0.91 0.91 
LC 3080 0.95 0.94 0.92 0.91 0.92 
EPO 0.96 0.96 0.96 0.91 0.93 
Etanercept 0.95 0.95 0.95 0.89 0.91 
Summary of the Codon Adaptation Index (CAI) for the 3068 and 3080 cell line IgG heavy (HC) and light 
(LC) chains, EPO and Etanercept coding sequences. From left to right, CAI was calculated using a 
reference set of sequences from either the whole Chinese hamster coding genome or the top and 
bottom 500 coding genes ordered by transcript abundance based on the whole transcriptome RNA-
Seq dataset described in Chapter 4. 
 
5.2.8 The CHO-S RNA-Seq tRNA dataset shows a strong correlation with tRNA gene copy 
numbers and codon usage 
The correlation between tRNA gene copy numbers and codon usage in Chinese hamster, 
human and mouse are discussed in Chapter 1 (see section 1.3.5). The sequenced tRNA 
datasets add a new layer of data where actual quantified tRNA abundances in the cell were 
determined and are compared to codon usage and gene copy number (Summarized in Table 
5.5). As opposed to data from yeast (described in Section 5.2.3 and Figure 5.2B), the 
Symphogen CHO cell sequenced tRNAs indicated a weak Pearson correlation with gene copy 
numbers, showing coefficients (r) ranging between 0.14 and 0.20 and p-values above 0.1 
(Figure 5.5A for day 12). Thus, for the Symphogen CHO cell samples there appears little 
correlation between tRNA gene copy number and tRNA abundance which could have 
implications when designing recombinant gene sequences and codon usage when based 
upon gene copy number alone.  
To the contrary, the CHO-S cell samples showed a much stronger correlation between tRNA 
abundance and gene copy number than the Symphogen CHO cell samples, with a range 
between 0.32 and 0.38 with p-values all below 0.025 (Figure 5.6), although this is still much 
lower than observed with the yeast samples. A similar pattern was observed when 
comparing sequenced tRNAs to codon usage between CHO cell samples, where the 
correlation coefficient was between 0.13 and 0.19 for the Symphogen dataset (Figure 5.5B 
for day 12), while it was between 0.41 and 0.48 for CHO-S samples (Figure 5.6).  
We further assessed the codon usage among the heavy and light IgG chain in the 3068 and 
3080 cell lines and compared this to the tRNA gene copy numbers and codon usage in CHO 
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cells. The heavy chain sequence showed a statistically significant correlation with tRNA gene 
copy numbers at r = 0.29, p-value = 0.018 in cell line 3080 and r = 0.28, p-value = 0.023 in cell 
line 3068. The correlation with codon usage was much stronger at r = 0.68, p-value = 9.5e-
10 in cell line 3080 and r = 0.66, p-value = 4.6e-09 for cell line 3068. The light chain sequence 
showed a weaker correlation with the tRNA gene copy numbers with an r = 0.25, p-value = 
0.044 in cell line 3080 and r = 0.19, p-value = 0.14 in cell line 3068 while the correlation with 
codon usage was again much stronger at r = 0.66, p-value = 4e-09 in cell line 3080 and r = 
0.61, p-value = 1.1e-07 in cell line 3068. When comparing the IgG codon usage to the 
sequenced tRNAs at Day 12 of culture, when recombinant protein production is at its peak, 
we found a better correlation for the heavy chain (r between 0.16 and 0.23, p-value between 
0.07 and 0.18) compared to the light chain (r between 0.09 and 0.13, p-value between 0.32 
and 0.49) (Summarized in Table 5.5).  
In summary, the tRNA analysis in the different cell lines has shown that; 
• Symphogen CHO cell line sequenced tRNAs show a positive but not statistically 
significant correlation with gene copy numbers, while CHO-S cell samples showed a 
statistically significant correlation.  
• CHO-S sequenced tRNAs showed a strong correlation to codon usage while this was 
non-significant for the Symphogen dataset.  
• Correlation between the codon usage among the 3080 and 3068 cell lines for the HC 
and LC sequences with tRNA gene copy numbers and CHO cell codon usage was 
statistically significant except for the case of the 3080 cell line LC v tRNA gene copy 
number. 
• The HC codon usage correlated more strongly than LC codon usage with the 




Figure 5.5 - Correlations between sequenced tRNAs, gene copy number and codon usage in the Symphogen 
dataset 
Pearson correlation between the sequenced Symphogen tRNAs sampled at day 12 of culture and the 
tRNA gene copy numbers (Panel A) and the codon usage (Panel B) in CHO cells. The coefficients (r = 
0.13 - 0.19) coupled with the p-values (p = 0.14 - 0.32) indicate a weak statistically non-significant 






Figure 5.6 - Correlations between sequenced CHO-S tRNAs, gene copy numbers and codon usage 
Pearson correlation between the sequenced CHO-S cell tRNAs, sampled at day 4 and day 7 of batch 
or fed-batch culture, and the tRNA gene copy numbers (Panel A) and the codon usage (Panel B) in 
CHO. The coefficients (r = 0.32 - 0.48) indicate a positive correlation for all the comparisons, with a 
stronger correlation showed between the sequenced tRNAs and the codon usage.  
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Table 5.5 - Correlation coefficients for the sequenced tRNAs 











3478 D4 CB6 0.16 0.16 0.19 0.09 0.17 0.07 
3478 D12 CB6 0.17 0.16 0.19 0.10 0.17 0.08 
3068 D4 CB6 0.18 0.18 0.21 0.11 0.19 0.09 
3068 D12 CB6 0.17 0.16 0.20 0.12 0.18 0.10 
3478 D4 CB7 0.15 0.15 0.19 0.10 0.17 0.08 
3478 D12 CB7 0.18 0.19 0.20 0.11 0.18 0.10 
3068 D4 CB7 0.14 0.15 0.19 0.11 0.17 0.08 
3068 D12 CB7 0.19 0.18 0.23 0.13 0.20 0.11 
3077 D4 CB6 0.20 0.17 0.21 0.10 0.19 0.09 
3077 D12 CB6 0.16 0.13 0.20 0.10 0.16 0.09 
3080 D4 CB6 0.18 0.18 0.21 0.13 0.19 0.11 
3080 D12 CB6 0.17 0.16 0.19 0.10 0.17 0.09 
Batch D4 0.33 0.41 0.19 0.01 0.19 0.05 
Batch D7 0.35 0.46 0.21 0.04 0.20 0.08 
Fed-batch D4 0.38 0.48 0.23 0.07 0.22 0.10 
Fed-batch D7 0.32 0.48 0.23 0.06 0.22 0.09 
Summary of the correlation coefficients between the sequenced tRNAs and the corresponding gene 
copy numbers, codon usage in Chinese hamster, codon usage among the 3068 and 3080 IgG1 coding 
sequences for the heavy and the light chain. 
 
5.2.9 Differential expression of tRNAs among the CHO-S dataset shows variability at Day 
7 regardless of the type of culture 
Among the CHO-S dataset, comparing batch v fed-batch at Day 4 did not reveal any 
statistically significant differential expression. On the contrary, the same comparison at Day 
7 indicated Phe, Ala, Leu, Gln, Leu, Thr, Arg, Met, His, Arg, Asn, Ile as differentially expressed 
tRNA isotypes (Table 5.6). When considering the same type of culture at Day 4 v Day 7, batch 
cultures showed HisGTG, GlyGCC, AsnGTT, LeuTAG, AspGTC, SerGCT, SeC(e)TCA, ProTGG, 
CysGCA, GluTTC, LeuAAG as being upregulated and TrpCCA, LeuCAA, LeuCAG, GlnCTG, 
ArgACG, ArgTCG, TyrGTA, ThrTGT, AlaAGC, LysTTT, AlaCGC, AlaTGC, ThrAGT, GlnTTG as being 
downregulated (Table 5.6). Day 4 v Day 7 among fed-batch cultures presented PheGAA, 
GlyTCC, SeC(e)TCA, GlyCCC, LeuTAA, SerGCT, LeuTAG, AspGTC as upregulated tRNAs while 
ThrCGT, ThrAGT, GlnCTG, TyrGTA, ArgTCG, LysCTT, AlaAGC, ArgACG, GlnTTG resulted 
downregulated (Table 5.6).  
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Table 5.6 - Differentially expressed tRNAs in CHO-S dataset 
Comparison tRNA log2FC adj p-value 
Batch v Fed-batch D4 - - - 
Batch v Fed-batch D7 PheGAA 0.65 2.86E-29 
 AlaCGC 0.34 7.67E-08 
 AlaTGC 0.32 4.52E-08 
 LeuTAA 0.15 2.12E-02 
 GlnTTG 0.14 4.05E-03 
 LeuCAG 0.13 2.08E-05 
 ThrAGT 0.10 2.12E-02 
 ArgTCT -0.09 2.01E-02 
 ArgTCG -0.20 4.08E-02 
 MetCAT -0.23 2.45E-03 
 HisGTG -0.25 3.29E-02 
 ArgACG -0.27 1.54E-05 
 AsnGTT -0.30 1.02E-12 
 IleTAT -0.31 1.54E-05 
D4 v D7 Batch HisGTG 0.37 5.01E-09 
 GlyGCC 0.34 1.09E-07 
 AsnGTT 0.31 8.22E-16 
 LeuTAG 0.29 5.77E-05 
 AspGTC 0.28 8.65E-07 
 SerGCT 0.27 1.43E-06 
 SeC(e)TCA 0.26 5.89E-05 
 ProTGG 0.22 4.93E-05 
 CysGCA 0.19 1.38E-02 
 GluTTC 0.17 1.79E-02 
 LeuAAG 0.14 6.06E-03 
 TrpCCA -0.09 4.90E-02 
 LeuCAA -0.10 1.79E-02 
 LeuCAG -0.11 4.79E-02 
 GlnCTG -0.13 4.90E-02 
 ArgACG -0.14 1.99E-02 
 ArgTCG -0.17 3.63E-03 
 TyrGTA -0.21 2.07E-04 
 ThrTGT -0.24 5.21E-07 
 AlaAGC -0.26 3.82E-09 
 LysTTT -0.27 4.90E-02 
 AlaCGC -0.32 1.67E-05 
 AlaTGC -0.33 9.52E-07 
 ThrAGT -0.33 1.20E-10 
 GlnTTG -0.41 1.62E-24 
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Comparison tRNA log2FC adj p-value 
D4 v D7 Fed-batch PheGAA 0.47 4.92E-09  
GlyTCC 0.29 1.09E-02  
SeC(e)TCA 0.27 1.61E-02  
GlyCCC 0.25 6.28E-04  
LeuTAA 0.25 8.51E-05 
 SerGCT 0.16 4.23E-02 
 LeuTAG 0.16 1.25E-02 
 AspGTC 0.15 3.77E-02 
 ThrCGT -0.20 2.35E-02 
 ThrAGT -0.22 1.76E-02 
 GlnCTG -0.27 3.46E-02 
 TyrGTA -0.30 1.09E-02 
 ArgTCG -0.31 1.09E-02 
 LysCTT -0.32 6.22E-03 
 AlaAGC -0.33 1.45E-04 
 ArgACG -0.38 1.93E-06 
 GlnTTG -0.38 7.92E-04 
Summary of the log2 fold change (log2FC) and adjusted p-value calculated with DESeq2 for each tRNA 
among the indicated comparison for the CHO-S dataset. Only adj p-values below 0.05 are reported, 
with no threshold for fold change. 
 
5.2.10 Differential expression analysis among the Symphogen dataset shows the tRNA 
pool between cell lines at the same time point is consistent whilst there is a higher 
variability in the tRNA pool across culture  
When comparing the tRNA abundancies from Day 12 of culture against those from Day 4 of 
culture from the same cell line, I found several differentially expressed tRNAs (Table 5.7). 
CysGCA was consistently downregulated in all comparisons except in the case of the 
Symphogen 3080 cell line, the cell line showing the highest Qp. Interestingly, PheGAA was 
upregulated at Day 12 of culture in the 3068 cell line with the CB7 feeding protocol and in 
the 3080 cell line, the two cell lines with the highest Qp. The CB6 feeding regime appears to 
generate wider variations in the tRNAs pool when compared to the CB7 feeding protocol, in 
particular among the proline codons ProAGG, ProCGG, ProTGG; all of these were 
upregulated at Day 12 of culture in both the 3478 and 3068 cell lines under CB6 feeding only 
(not in CB7 and likely reflects the differences in the feeding).  
When comparing across the different cell lines at Day 4 of culture there were few changes in 
tRNA abundance with the exception of a small number of cell line comparisons when fed 
with the CB6 protocol. For the comparison of the 3478 v 3080 cell line tRNA abundancies 
under fed-batch CB6 day 4 of culture, the GluCTC, GluTTC, GlyGCC, HisGTG, LeuTAG, LysCTT, 
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ThrTGT, TyrGTA codons were observed to be differentially expressed. A comparison of the 
tRNA abundancies for the 3068 v 3080 cell lines on day 4 of culture with CB6 feeding revealed 
that the GluCTC, HisGTG, PheGAA were up-regulated whilst a comparison of the 3077 v 3080 
cell lines with CB6 feeding revealed that the GluCTC and PheGAA codons were upregulated.  
An analysis of the differential expression of tRNAs at Day 12 of culture revealed that the 
variations were even more limited than those observed at day 4 of culture. The PheGAA 
codon was found to be upregulated in 3478 cell line v 3068 cell line under CB7 feeding 
conditions, whilst this codon was also upregulated in the 3478 cell line v 3077 cell line on 
D12 of culture with CB6 feeding, and in the 3077 cell line v 3080 cell line on D12 with CB6 
feeding. However, the PheGAA codon was downregulated in the 3068 cell line v 3077 cell 
line on D12 with CB6 feeding. When comparing the 3068 cell line and 3478 cell line tRNA 
expression under CB7 v CB6 feeding at both culture time points, only two codons, the GluCTC 
and GlyGCC, were observed to be differentially regulated. Overall, these results indicate a 
generalized stability of the available tRNA pool when comparing the same time point among 
different cell lines, while the 3068 and 3478 cell lines showed a higher variability under the 
CB6 feeding compared to CB7 feeding protocol. 
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Table 5.7 - Differentially expressed tRNAs in Symphogen dataset 
Comparison tRNA log2FC adj p-value 
D12 v D4 3478 CB6 ProCGG 0.78 2.45E-22 
 ThrCGT 0.76 1.47E-27 
 ProTGG 0.73 8.80E-13 
 ProAGG 0.69 2.28E-11 
 TyrGTA -0.62 5.84E-04 
 GluCTC -1.06 1.35E-24 
 CysGCA -1.93 1.90E-03 
D12 v D4 3478 CB7 ProCGG 0.63 2.11E-10 
 CysGCA -0.7 4.06E-02 
 GluCTC -0.87 1.98E-07 
D12 v D4 3068 CB6 ProCGG 0.76 4.43E-50 
 ProAGG 0.68 2.24E-17 
 ProTGG 0.67 7.57E-18 
 ValTAC 0.64 3.75E-46 
 ThrTGT 0.62 2.88E-48 
 SeC(e)TCA -0.64 1.58E-27 
 eMetCAT -0.71 2.63E-06 
 GlnCTG -0.71 6.03E-09 
 HisGTG -0.76 7.47E-12 
 TyrGTA -0.88 1.33E-12 
 GluCTC -1.02 6.98E-04 
 CysGCA -1.08 3.34E-85 
D12 v D4 3068 CB7 PheGAA 0.85 1.44E-02 
 CysGCA -1.55 3.40E-51 
D12 v D4 3080 CB6 PheGAA 0.6 5.37E-09 
 AspGTC -0.72 5.37E-09 
D12 v D4 3077 CB6 GlnCTG -0.65 4.13E-04 
 CysGCA -1.55 8.73E-39 
3478 v 3068 D4 CB6 - - - 
3478 v 3068 D4 CB7 - - - 
3478 v 3077 D4 CB6 GluCTC -0.70 1.37E-14 
3478 v 3080 D4 CB6 LeuTAG 0.61 9.72E-26 
 ThrTGT 0.59 7.33E-16 
 GluTTC -0.69 1.44E-22 
 HisGTG -0.7 4.07E-07 
 LysCTT -0.72 1.56E-09 
 TyrGTA -0.74 3.80E-08 
 GlyGCC -0.92 3.76E-12 
 GluCTC -1.5 2.70E-63 
3068 v 3077 D4 CB6 - - - 
3068 v 3080 D4 CB6 GluCTC 0.97 5.12E-08 
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Comparison tRNA log2FC adj p-value 
 HisGTG 0.64 1.29E-05 
 PheGAA 0.63 1.12E-03 
3077 v 3080 D4 CB6 GluCTC 0.76 1.66E-15 
 PheGAA 1.03 3.80E-20 
CB7 v CB6 3478 D4 GluCTC 0.70 6.92E-04 
CB7 v CB6 3068 D4 - - - 
CB7 v CB6 3478 D12 GlyGCC 0.87 3.08E-04 
CB7 v CB6 3068 D12 - - - 
3478 v 3068 D12 CB6 - - - 
3478 v 3068 D12 CB7 PheGAA 0.59 5.00E-03 
3478 v 3077 D12 CB6 PheGAA 0.90 3.34E-11 
 LeuTAG 0.75 7.06E-20 
3478 v 3080 D12 CB6 GlyGCC -0.59 7.68E-03 
3068 v 3077 D12 CB6 PheGAA -1.06 3.04E-15 
3068 v 3080 D12 CB6 - - - 
3077 v 3080 D12 CB6 PheGAA 1 1.16E-134 
 GluCTC 0.64 2.24E-08 
 CysGCA -0.95 1.37E-17 
Summary of the log2 fold change (log2FC) and adjusted p-value calculated with DESeq2 for each tRNA 
among the indicated comparison in the Symphogen dataset. Only adj p-values below 0.05 and fold 
changes equal or above an absolute value of 1.5 are reported. 
 
5.2.11 The use of tRNA abundancies to predict elongation speed shows longer decoding 
times than using tRNA gene copy numbers 
In Section 1.5.1, the use of kinetic rate constants coupled with high-throughput techniques 
to calculate the decoding speed of a given coding sequence through the use of an elongation 
phase model was described. The sequenced tRNA abundancies were used to calculate the 
decoding times of each codon under different conditions, then based on either tRNA gene 
copy numbers or the tRNA abundance, the time required for the elongation of two 
Symphogen IgG1 molecules (expressed in the clones 3068 and 3080) and Etanercept 
(sequence reported in Appendix) was predicted using the model for both the heavy and the 
light chain (Table 5.8). The tRNA abundance model might be considered more accurate as 
this uses the actual abundancies of the different tRNAs available rather than the gene copy 
number. The elongation times based on gene copy number resulted in the shortest predicted 
elongation time for each molecule, predicting an elongation time of 211.3 s for the 3068 
heavy chain (HC 3068), 212.8 s for the 3080 heavy chain (HC 3080), 112.5 s for the 3068 light 
chain (LC 3068) and 114.7 s for the 3080 light chain (LC 3080). When using tRNA abundance 
as determined in this study and collected for the CHO-S dataset at day 4 and day 7 of either 
batch or fed-batch culture, the predicted times to decode the full mRNA were between 237.8 
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and 247.4 s for HC 3068, between 241.0 and 250.1 s for HC 3080, between 127.4 and 132.7 
s for LC 3068 and between 129.5 and 135.1 s for LC 3080. Interestingly, Batch D4 consistently 
yielded the slowest predicted decoding times for each coding sequence. 
In addition to calculating the predicted total decoding time of a coding sequence, the model 
generates the fastest and the slowest possible codon combinations with the same amino 
acid output for the protein of interest. Once again, the predicted elongation times based on 
gene copy numbers resulted in the fastest for both the slowest and the fastest possible 
sequences, with the model calculating the decoding speeds using the gene copy numbers to 
be respectively 83.4 s for HC 3068, 84.2 s for HC 3080, 46.4 s for LC 3068, 45.5 s for LC 3080 
and 374.8 s for HC 3068, 375.8 s for HC 3080, 199.4 s for LC 3068, 198.8 s for LC 3080. 
Sequenced tRNAs abundance based decoding time predictions when using the CHO-S 
dataset resulted in predictions of 103.0-109.1 s for HC 3068, 104.1-110.3 s for HC 3080, 54.5-
57.2 s for LC 3068 and 54.5-57.5 s for LC 3080 for the fastest possible codon sequence while 
the times were 419.5-437.2 s for HC 3068, 422.7-440.2 s for HC 3080, 217.1-226.0 s for LC 
3068 and 217.9-226.7 s for LC 3080 for the slowest possible sequence. 
Collectively these results reveal a slower predicted decoding speed for all the considered 
coding sequences when using the quantified tRNAs pool as determined by sequencing as 
opposed to those predicted using gene copy numbers. While Batch culture D4 data 
consistently generated the slowest overall predicted decoding times, differences between 
batch and fed-batch culture at day 4 or day 7 were always under 5% of the total time. When 
focusing on the Etanercept sequence and overall decoding speeds, the model predicted 
187.6 s based on tRNA gene copy numbers, 220.6 s based on batch day 7 and 212.6 s based 
on fed-batch day 7 tRNA abundancies, confirming the trend observed for the IgG1 sequences 
where the sequenced tRNA pool generated longer predicted decoding times compared to 
those from gene copy numbers. When investigating each individual tRNA decoding speed as 
depicted as a single dot in the prediction plot along with a regression trendline makes it 
possible to follow the decoding speed profile along the original coding sequence, and 
visualise the fastest and the slowest possible combinations of codons (Figure 5.7, Figure 5.8, 
Figure 5.9). For every simulation, the presence of short regions with a slower decoding speed 
followed by faster regions is evident in the original coding sequence, in particular in the first 
half of the transcript for the heavy chains and Etanercept sequences. This pattern is 
conserved in the slowest possible sequence, while the use of the fastest codons generates a 
smooth regression fit line along the entire transcript length.   
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Figure 5.7 - Decoding speed simulations for 3068 IgG1 
Decoding speeds in seconds for each codon of the 3068 IgG1 heavy chain (HC3068) and light chain 
(LC3068) coding sequences, calculated based on tRNA gene copy number (GCN), sequenced tRNA 
abundance at batch day 4 (B4), batch day 7 (B7), fed-batch day 4 (FB4) and fed-batch day 7 (FB7). For 
each graph, in green is indicated the fastest and in red the slowest possible combinations of codons 
generating the same amino acid sequence, while grey represents the original coding sequence. The 
dots indicate the decoding speed associated with each single codon while the lines are loess fit 
regression of the individual codons. 
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Figure 5.8 - Decoding speed simulations for 3080 IgG1 
Decoding speeds in seconds for each codon of the 3080 IgG1 heavy chain (HC3080) and the light chain 
(LC3080) coding sequences, calculated based on tRNA gene copy number (GCN), sequenced tRNAs at 
batch day 4 (B4), batch day 7 (B7), fed-batch day 4 (FB4) and fed-batch day 7 (FB7) of culture. For each 
graph, in green is indicated the fastest and in red the slowest possible combination of codons 
generating the same amino acid sequence, while in grey is represented the original coding sequence. 
The dots indicate the decoding speed associated with each single codon while the lines are loess fit 
regression of the individual codons. 
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Figure 5.9 - Decoding speed simulations for Etanercept 
Decoding speeds in seconds for each codon of the Etanercept coding sequence, calculated based on 
tRNA gene copy number (GCN), sequenced tRNAs at batch day 7 (B7), and fed-batch day 7 (FB7) of 
culture. For each graph, in green is indicated the fastest and in red the slowest possible combinations 
of codons generating the same aminoacidic sequence, while in grey is represented the original coding 
sequence. The dots indicate the decoding speed associated with each single codon while the lines are 
loess fit regression of the individual codons. 
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Table 5.8 - Decoding speeds for Symphogen antibodies and Etanercept sequences 





HC 3068 GCN 83.4 211.3 374.8 
HC 3068 Batch D4 109.1 247.4 437.2 
HC 3068 Batch D7 104.1 237.8 419.5 
HC 3068 Fed-batch D4 105.5 241.5 427.8 
HC 3068 Fed-batch D7 103.0 240.0 428.6 
LC 3068 GCN 46.4 112.5 199.4 
LC 3068 Batch D4 57.2 132.7 226.0 
LC 3068 Batch D7 55.5 127.4 217.1 
LC 3068 Fed-batch D4 55.2 128.4 220.1 
LC 3068 Fed-batch D7 54.5 127.6 220.6 
HC 3080 GCN 84.2 212.8 375.8 
HC 3080 Batch D4 110.3 250.1 440.2 
HC 3080 Batch D7 105.5 241.0 422.7 
HC 3080 Fed-batch D4 106.6 244.4 430.9 
HC 3080 Fed-batch D7 104.1 242.8 431.8 
LC 3080 GCN 45.5 114.7 198.8 
LC 3080 Batch D4 57.5 135.1 226.7 
LC 3080 Batch D7 55.4 129.5 217.9 
LC 3080 Fed-batch D4 55.4 130.6 220.4 
LC 3080 Fed-batch D7 54.5 129.7 221.4 
Etanercept GCN 87.3 187.6 398.3 
Etanercept Batch D7 109.2 220.6 450.2 
Etanercept Fed-batch D7 104.9 212.6 439.2 
Summary of the decoding speed times in seconds predicted by the elongation model for the original 
coding sequence, the fastest and the slowest possible combination of codons with the same amino 
acid output of the heavy (HC) and light (LC) chains in the 3068 and 3080 IgG1s or Etanercept. Each 
decoding speed is simulated based on tRNA gene copy numbers, CHO-S cell tRNA abundancies from 
sequenced data at batch day 4 and day 7 or fed-batch day 4 and day 7. 
 
 
5.2.12 HEK293 cold shock dataset 
In addition to investigating tRNA abundance in CHO cells, during this study I also investigated 
tRNA abundance using the sequencing method described above in HEK293 cells and whether 
this changed upon cold-shock in these cells. Indeed, cooling cell cultures for a limited amount 
of time has been shown to alter translational efficiency, influencing the elongation phase in 
particular (Bastide et al., 2017). To assess if there were any variations induced on the tRNA 
pool by a 24 h temperature shift from 37oC to 32oC in Human Embryonic Kidney (HEK293) 
cells, we therefore applied the same ARM-Seq protocol described for the CHO cell lines. The 
HEK293 samples showed a correlation between tRNA gene copy numbers and sequenced 
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tRNAs very similar to the CHO-S samples described in paragraph 1.1.8, with r = 0.35, p-value 
= 0.0051 at 37oC and r = 0.31, p-value = 0.012 at 32oC (Figure 5.10). On the contrary, the 
correlation between codon usage in human and sequenced tRNAs was not statistically 
significant with r = 0.19, p-value = 0.13 at 37oC and r = 0.18, p-value = 0.16 at 32oC (Figure 
5.10), mirroring the behaviour of the Symphogen cell lines described in Section 5.2.8. Thus, 
sequence design and codon usage based upon gene copy number should be improved in 
terms of elongation speed using tRNA abundancies as opposed to gene copy number based 
upon these data. Furthermore, both the 37oC and 32oC HEK293 samples showed a strong 
correlation with the Symphogen dataset (between 0.62 and 0.91) while the correlation with 
the CHO-S dataset was considerably lower (between 0.24 and 0.27). This difference was 
mainly due to two single tRNAs, MetCAT, whose quantification can be challenging as a result 
of the initiator-elongator ratio, and PheGAA. When these two tRNAs were excluded from the 
analysis, the correlation coefficient with the CHO-S dataset increased to 0.73-0.83, while the 
correlations measured against codon usage and gene copy numbers did not change 




Figure 5.10 - Correlations between sequenced tRNAs, gene copy number and codon usage in HEK293  
Pearson correlation between the sequenced HEK293 tRNAs, sampled at 37oC (Panel A) or 32oC (Panel 
B), and the tRNA gene copy numbers (left) or codon usage (right) in human. The coefficients for the 
gene copy number (r = 0.31, 0.35) indicate a positive correlation for the two samples while the 
correlation with codon usage is not significant (p = 0.13, 0.16). 
 
5.3 Discussion 
Translation is a key regulative step composed of three main phases (initiation, elongation, 
termination) resulting from the interaction of protein factors with RNAs in the translational 
machinery (Summarized in Figure 1.1). Codon optimization based on tRNA gene copy 
numbers and codon usage is widely used in recombinant protein production (Mauro, 2018), 
although the actual abundance of tRNA molecules in the cell is often overlooked due to 
technical limitations in their detection. The details and application of an adapted ARM-Seq 
protocol were described here to accurately measure tRNAs in a CHO-S and a variety of 
industrial CHO cell lines under different culture parameters, in addition to yeast and HEK293 
cells. The results showed 4 to 5 fold improved detection of tRNAs compared to standard 




Yeast showed a strong correlation between sequenced tRNAs and gene copy numbers 
(Figure 5.2B), while only the CHO-S and HEK293 datasets presented statistically significant 
correlations (Figure 5.6A, Figure 5.10), with the Symphogen dataset suggesting a complete 
lack of correlation (Figure 5.5A).  
When considering the correlation between sequenced tRNAs and codon usage among CHO 
cells (Figure 5.5A, Figure 5.6A) or human (Figure 5.10), I obtain a comparable outcome, 
where only CHO-S and HEK293 show statistically significant correlation. These discrepancies 
between the datasets could be due to the high genetic variability of CHO cells, leading to 
variable tRNA pools, although using alternative reference genomes to predict tRNA gene 
copy numbers did not impact the analysis (summarized in Table 5.3). In addition, between 
74.3-88.5% of the total reads aligned to tRNAs in the Symphogen datasets compared to 28.9-
48.9% in the CHO-S dataset, reflecting an actual biological difference in the tRNA pools or a 
disparity along the sequencing protocol, at the level of the initial de-methylation or further 
down during library generation. The expression of an IgG1 in the industrial CHO cell lines is 
unlikely to be the source of variation in the tRNAs pool as the null-producer 3478 did not 
deviate from the rest of the Symphogen samples with regard to correlations between 
sequenced tRNAs with tRNA gene copy numbers or codon usage.  
When looking at statistically significant fold-changes, most of the variability arose from 
comparisons involving later stages in culture, either at Day 7 or Day 12, regardless of the type 
of feeding strategy. The availability of two CHO datasets allowed us to find common patterns 
between the heterogenous CHO cell lines considered in this study. We found AspGTC, 
CysGCA, GlnCTG, GluCTC, HisGTG, PheGAA, ProAGG, ProCGG, ProTGG, SeC(e)TCA, ThrCGT, 
ThrTGT, TyrGTA as differentially regulated in both datasets at the latest time point. While in 
the CHO-S dataset all significant log2 fold-changes were in the range between 0 and 0.65 
(Table 5.6), in the Symphogen dataset the variability reached -1.93 log2 fold-change for 
CysGCA in 3478 CB6 Day 12 v Day 4 (Table 5.7) and was in general higher than the 
aforementioned CHO-S dataset. Although this could be due to the presence of a recombinant 
protein to produce in the Symphogen cell lines, the absence of a specific deviation of the 
null-producer 3478 from the rest of the cell lines suggests this does not impact the results. 
Nonetheless, this higher variability could be due to the specific steps required for industrial 
cell line selection and the intrinsic genetic instability of CHO cells, suggesting the importance 
of a tailored approach to codon optimization, particularly in industrial systems.  
Indeed, what I investigated next is the impact of variations in the tRNAs pool on the 
translation of the heavy and light chain of Symphogen IgG1s and Etanercept using a 
 128 
computational elongation model able to calculate the decoding speed of any coding 
sequence based on tRNA gene copy numbers or tRNA abundances (introduced in Section 
1.5.1). I found a sustained trend towards longer decoding times for every considered coding 
sequence when sequenced tRNA abundances were used for the calculations (Table 5.8). The 
main reason behind this trend is the balance among cognate/near-cognate tRNAs, a 
parameter used in the model to predict the speed of elongation of each codon. Differences 
of over 35 seconds in the decoding speeds of the heavy chain found for both 3068 and 3080 
IgG1s could heavily impact on tRNA availability, ribosome occupancy and recycling, mRNA 
stability, eventually influencing the overall productivity. The use of tailored approaches for 
codon optimization based on the tRNA pool of the specific cell line under the particular 




Chapter 6 Discussion and Future Work 
CHO cell lines are the most widely used mammalian expression system for the production of 
complex recombinant biopharmaceuticals, due to their ability to grow in suspension and 
produce correctly folded proteins at a large scale with human compatible post-translational 
modifications and secrete the final product (Butler & Spearman, 2014; Dumont et al., 2016; 
Mauro, 2018). Although the CHO cell is generally an effective mammalian cell factory system 
for the production of secreted biotherapeutic proteins, the final yield of product is influenced 
by the interplay of environmental factors including the cellular machinery of a given clone 
and the site of integration of the exogenous recombinant genes, feeding of the cells during 
culture and culture temperature, the complexity of the recombinant protein and the 
regulation of biological pathways in the cell; cell growth, effective translation and secretion. 
mRNA translation in particular is a central regulator of cell proliferation, cellular processes 
and recombinant protein productivity determined in part by translation factors and 
ribosomes interacting with the mRNA to translate a given transcript, the availability of 
transfer RNAs and the regulation of non-coding RNAs, as summarized in Chapter 1. ncRNAs 
are indeed emerging as key regulators of many biological processes in the cell, where they 
can act in the nucleus at an epigenetic level to silence or to enhance single genes or even 
entire genomic regions, and in the cytoplasm, where they compete with miRNAs targets or 
selectively enhance/repress translation of specific mRNAs (Geisler & Coller, 2013). Hence, 
the work described in this thesis focused on providing the first landscapes of expression of 
in particular long non-coding RNAs under different culture conditions in CHO cells and relate 
the expression of these to functional pathways in the cell and identify new targets for cell 
manipulation (Chapters 3 and 4). At the same time, I wanted to investigate the tRNA pool 
response to the environment and how this affects elongation, the central phase of 
translation and whether a knowledge of tRNA abundance could be used to aid design of 
specific recombinant mRNA transcripts with decoding speeds (Chapter 5). The findings of 
each of these previous chapters have been discussed at the end of each chapter, here these 
are reviewed and collectively considered alongside suggestions for future work and 
directions.  
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6.1 Mapping and Investigation of Long non-coding RNA Expression in CHO Cells 
6.1.1 CHO-S dataset 
In Chapter 3 I presented the first published lncRNA expression profile in CHO cells under 
batch and fed-batch conditions together with the coding transcriptome using a 
comprehensive commercially available Mouse microarray, detecting 24603 lncRNAs (68.5% 
of the total probes) and 19617 mRNAs (78.8% of the total probes). Several hundred lncRNAs 
showed differential expression on different days of culture and in particular between Batch 
and Fed-batch culture (Section 3.3.2). While the profile of differential expression was similar 
between coding and non-coding genes, only 16-28% of the lncRNA probes had a matching 
transcript in CH, as opposed to 58-80% of the mRNAs. A combined approach was then taken 
to identify lncRNAs, whereby the Chinese hamster genome, literature search and database 
mining were jointly considered to find and relate lncRNAs differentially expressed in the CHO 
cell system with an established biological function. The main findings from this work are 
discussed in Chapter 3, however it is important to note that the results showed it is possible 
to successfully use mouse sequences as probes for microarray detection of CHO lncRNAs 
and, subsequently, identify unannotated non-coding transcripts through secondary structure 
conservation, homology with model organisms and RT-qPCR experimental validation.  
Following the global analysis and RT-qPCR validation of a number of lncRNAs of interest, the 
study focused on the lncRNAs MALAT1, NEAT1 and PVT1 among the group of differentially 
expressed lncRNAs.  These three non-coding genes are among the most well characterized 
in mouse and human, with an association of their expression with increased proliferation 
and regulation of alternative splicing and DNA repair reported, processes which we found to 
be strongly regulated in our pathway enrichment analysis. Further follow up work on the 
single non-coding genes is required to establish any impact the regulation of these has on 
the CHO cell phenotype, and if so, establish the exact biological mechanism(s) and the 
potential of these as targets for cell manipulation. Nevertheless, this work provided to the 
community the first comprehensive coding and non-coding dataset in CHO cells, particularly 
at the lncRNA level, allowing investigators to further probe the relationships between the 
expression and regulation of these two classes of RNA.  
Additional work would now be to look at over-expression or knockdown of the expression of 
these lncRNAs and determining if this impacted CHO cell growth or recombinant protein 
productivity phenotypes. Further, RNA-Seq data can also be analysed for the presence of the 
mapped lncRNAs we have confirmed using the mouse array to determine if these change in 
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different CHO host cell lines and recombinant clones and how their expression relates to the 
observed phenotype. Collectively these studies have the potential to identify new targets for 
cell engineering and facilitate development of new, engineered CHO host cell systems with 
enhanced bioprocessing characteristics. 
 
6.1.2 Symphogen datasets 
In Chapter 4 I further explored the coding and non-coding expression landscape of 5 IgG1 
producing CHO cell lines and 1 null pool (non-IgG expressing control) at different time points 
of culture cultivated under fed-batch conditions in an automated ambr15Ô system. Two 
main datasets (DAVI and JCE) differentiated by feeding, time point collection and cell lines 
used were collected for analysis in this project. As opposed to the microarray dataset 
described in Chapter 3, here I decided to use RNA sequencing and to sample cells at later 
stages of culture, namely day 4 and 12 for DAVI and day 4 and 9 for JCE. In addition, in the 
DAVI dataset two different commercially available feeding strategies were compared, Cell 
Boost 6 and Cell Boost 7, while the JCE dataset included an early time point collected from 
the seed train flasks used to inoculate the fed-batch cultures.  
Among the DAVI dataset, the cultured cell lines showed a range of cell specific productivities 
(Qp) which was clearly reflected in the PCA clustering of the transcript expression analysis 
and in the numbers of differentially expressed genes (Figure 4.2,  
Figure 4.3). As already noted for the CHO-S cell dataset described in Chapter 3, feeding 
proved to be a significant source of variability even at an early stage of culture. Indeed, the 
comparison of the seed train flask data used to inoculate the fed-batch process in JCE shows, 
for the first time, that there is a significant change in gene expression after only 4 days of 
culture among the same clone when the cells are in exponential growth phase and before 
the major phase of production of the protein of interest. Following KEGG functional 
enrichment analysis of the RNA-Seq datasets, the difference in the Replication and Repair 
domain pathways confirmed the tendency (already noted for the CHO-S cell line, Chapter 3) 
to be differentially regulated towards the later stages of culture, with the exception of the 
3080 cell line, the clone with the highest Qp.  
Based on these observations I suggest a higher productive capacity for those cells that are 
able to maintain genome integrity for longer periods of culture, considering most of the 
recombinant protein production happens in the later stages (once the maximum viable cell 
concentration is achieved) of the fed-batch process. Further comparisons of our dataset with 
the literature suggested Cd36, Hspa8, Serpinh1 and Vim as genes negatively correlated with 
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Qp, with heterogenous mechanisms of function but an overall detrimental effect on Qp. The 
impact of these could potentially be alleviate using Knock-Out (KO) or Knock-Down (KD) 
strategies with CRISPR or RNA interference. Along with coding genes, I identified, among 
many other lncRNAs, Adapt15, GAS5 and PVT1 as genes of particular interest, the latter being 
already identified and described in Chapter 3, as associated with higher Qp. Although these 
lncRNAs are well described in model organisms and human diseases (Colombo et al., 2015b; 
Hollander et al., 1996; Ma et al., 2016), they lack any form of annotation in CH of CHO cell 
genomes, or indeed, in any mammalian cell factory related to recombinant protein 
production. Therefore, the work presented in both Chapter 3 and Chapter 4 provides a base 
of knowledge for the mammalian recombinant protein production community to evaluate 
the impact of the long non-coding transcriptome on different systems and start working on 
single or groups of lncRNAs for cell engineering purposes.  
 
6.1.3 Future work on lncRNAs 
The biological significance and mechanisms of each single lncRNA in CHO cells remains to be 
experimentally investigated as most of our present knowledge comes from studies related 
to diseases where the setting and the environment are profoundly different. One of the 
challenges when investigating lncRNAs compared to coding genes is the lack of an open 
reading frame, which requires dedicated KO and KD approaches where the full-length gene 
is targeted by RNA interference or CRISPR. The study described here is likely to be of 
particular interest to the community as it has been made completely publicly available from 
controlled fed-batch ambr15Ô datasets using industrial cell lines and feedings; such reports 
are rare in the literature, even less so with complete transcriptomics data. The work 
described here provides a comprehensive detailing of cell culture parameters and 
transcriptomic analysis and will be fully released and made available to the community for 
further studies. These studies should involve comparison of the analysis reported here with 
the expression of lncRNAs in other CHO hosts and recombinant cell lines and then the 
validation of manipulation of key, differentially regulated lncRNAs on CHO cell phenotypes. 
 
6.2 tRNA abundance and mRNA translation 
In Chapter 5 is described the exploration of one of the main parameters influencing 
translation, specifically elongation of the polypeptide, and the application of an elongation 
phase model to predict the decoding speed of any coding sequence of choice. Most codon 
optimization tools commonly use tRNA gene copy numbers and codon usage to select the 
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‘best’ sequence for optimal translation elongation and hence the ‘best’ or highest levels of 
recombinant protein expression. While this approach can lead to development of a coding 
sequence with codon usage that results in an effective increase in yield of protein for many 
protein molecules over that from the ‘native’ coding sequence, the magnitude and the 
effects on quantity and product quality are often unpredictable. One of the reasons for this 
was hypothesised to be the heterogeneity of the tRNA pool among different CHO cell lines 
used in industry and across culture, a parameter often overlooked due to the lack of 
information on tRNA abundancies and limitations of standard RNA-Seq protocols to detect 
and tRNAs.  
 
6.2.1 Quantification of tRNA species through an optimized RNA-Seq protocol 
During the studies described here, an adapted ARM-Seq protocol was designed for CHO and 
HEK293 cell lines to measure tRNA abundance and is described in Section 5.1. These 
measurements were then related to codon usage tRNA gene copy numbers in CHO cells 
(Section 5.2.8), showing a statistically significant correlation between tRNA abundance as 
determined by RNA-Seq and tRNA gene copy number for the CHO-S cell samples but not for 
the Symphogen dataset. The reasons for the discrepancy between the two datasets could be 
due to an actual biological difference in the tRNAs pools between the cell lines used in the 
experiments. Indeed, CHO cells are known to have a high genetic variability, which is likely 
to reflect at the tRNA level, as well as on the rest of the genome, causing CHO cell host and 
recombinant cell line specific tRNA expression profiles. A further reason could be the much 
higher percentage of reads aligned to tRNAs in the Symphogen datasets, ranging between 
74.3-88.5% compared to 28.9-48.9% for the data from the CHO-S cells (Table 5.2). While the 
expression of the IgG1 in the Symphogen dataset could also have been considered a source 
that impacted on the variation of the tRNAs pool, the null-producer 3478 gave results similar 
to the rest of the cell clones, suggesting that the presence of large amounts of heavy and 
light chain transcript, and the translation of these, did not impact upon the tRNA 
abundancies observed.  
The differences in the tRNA abundancies between the CHO-S and Symphogen cell lines with 
respect to the degree of correlation with the tRNA gene copy number has potential 
implications of design of sequences and codon selection between different host cells. Simply 
designing a recombinant sequence based on gene copy number alone for any given CHO cell 
host is unlikely to deliver the ‘optimal’ sequence and the data presented here, and discussed 
in the following section, suggests that the knowledge of an individual host cell lines tRNA 
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abundancies is likely to facilitate design of recombinant sequences tailored such individual 
cell lines for ‘optimal’ elongation and recombinant protein production.  
In addition to investigating the CHO cell tRNA abundancies and how this changed throughout 
culture and with feeding, the HEK293 cell tRNA abundancies were also investigated (Section 
5.2.12). The HEK293 cell dataset showed correlations similar to the CHO-S cell line for 
comparison of RNA-Seq determined tRNA abundancy with tRNA gene copy numbers, while 
a comparison with codon usage was not significant. Comparing the HEK293, CHO-S and 
Symphogen datasets showed a solid correlation between sequenced tRNAs, with the 
exception of the MetCAT and PheGAA tRNAs, which were sensibly higher in the HEK293 
samples. While the quantification of MetCAT is likely to be influenced by the alignment of 
both the initiator and the elongator Met, due to a lack of a clear distinction in the annotation, 
biases in PheGAA quantification could be due to the presence of specific chemical 
modifications which impair or particularly enhance the de-methylation reaction efficiency. 
Further experimental validation on single tRNAs species will be required to elucidate the 
biological significance of the described results. Nonetheless, this represent the first attempt 
to quantitatively measure tRNAs in CHO cells in a variety of cell lines and conditions. 
 
6.2.2 mRNA translation decoding speed simulation using an elongation model 
Section 1.5.1 introduced the computational elongation model used in Section 5.2.11 to 
calculate the decoding speed of an IgG1 (both heavy and light chains) and Etanercept based 
on the CHO-S cell sequenced tRNA pool abundancies. In addition to calculating the predicted 
elongation decoding speed of a coding sequence for each codon, the model generates a 
prediction of the fastest and the slowest possible combination of codons that yield the same 
amino acid sequence. A graphical output of the simulated decoding speeds can be created 
fitting a Loess regression line along the length of the original sequence and the codon 
combinations generated by the model (Figure 5.7, Figure 5.8, Figure 5.9). I observed the 
alternation of regions with a slower decoding speed followed by faster regions in the original 
and the slowest predicted coding sequences, particularly towards the first half of the 
transcript for the heavy chains. On-the-other-hand, the predicted slowest possible 
combination of codons showed a smooth regression fit line along the entire transcript length. 
While a faster decoding speed should intuitively increase the translation rate of the mRNA 
and hence the synthesis of the protein of interest, the presence of naturally occurring regions 
with a slower decoding speed could be important for the correct co-translational folding of 
the nascent polypeptide. This speculation or hypothesis is strengthened by the prevalent 
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location of these variable speed regions at the beginning of the heavy chain, where ribosome 
pausing at particular domains could promote correct folding and avoid ribosome collisions 
further along the transcript. Experimental validation of the predicted sequences generated 
by the model will be essential to evaluate what translation rate is optimal for specific IgGs 
and other recombinant biotherapeutics, fine tuning the presence of regions with different 
decoding speed rates to increase final yield without impacting quality. This strategy would 
integrate current codon optimization approaches based on tRNA gene copy numbers and 
codon usage of the host organism only, allowing the generation of tailored approaches for 
the cell line specific tRNA pool. 
 
6.2.3 Future work on tRNAs and translation 
The work described in this thesis was aimed at integrating current codon optimization 
approaches with experimental measurement of the tRNA pool under various conditions. 
While this method allows a tailored optimization strategy for each different cell line, culture 
condition and molecule of interest, additional work is required to improve our capacity to 
predict translation elongation speed and the impact on the translation of specific transcripts. 
Along with tRNA abundance, the charge state of each tRNA is a key parameter to consider. 
Previous studies have showed most cytosolic tRNAs in HEK293T cells are charged at >80% 
levels, except for the tRNAs for tRNASer and tRNAThr that are charged at lower levels (Evans 
et al., 2017). Investigating the charge state of tRNAs in CHO cells would identify which tRNAs 
show a lower charge level and if this is constant through time and changes with different 
feed protocols.  
Chemical modifications to nucleotides have also been shown to influence tRNA behavior 
during translation, depending on their position in the tRNA molecule (Section 1.3.5). The use 
of dedicated mass-spectroscopy techniques, already applied in other organisms to 
investigate and determine tRNA modifications (Leidel et al., 2009), would improve our 
understanding of how translation can be modulated without changing the relative 
abundances of each tRNA in a pool. tRNAs are particularly abundant in the cell, constituting 
up to 88.5% of the whole small RNA population (Section 5.2.3). Therefore, limited variations 
in terms of fold-change among a particular tRNA, in the order of FC of around 1.4, can 
massively alter the balance among the pool and have noticeable effects on cell metabolism 
(Pavon-Eternod, Gomes, Rosner, & Pan, 2013). This could explain the absence of particularly 
high FC values in our differential tRNA expression analysis when comparing cell lines with 
different productivities and feeding strategies (Sections 5.2.9 and 5.2.10). Overexpression of 
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single tRNAs will be fundamental to understand what level of upregulation is required to 
have an effect on cell growth or productivity in CHO cells, and if this level is constant for each 
tRNA species. In addition, the interplay of other factors involved in translation will have to 
be evaluated. mRNA stability and secondary structures can deeply influence the speed of 
elongation of particular transcripts (Gorochowski et al., 2015). This parameter becomes 
particularly important when we modify the codon combination of a given sequence to favour 
particular codons, potentially creating repetitions and secondary structures which could 
have a detrimental impact on translation. Changing of a transcript codon sequence, whilst 
not impacting the amino acid sequence coded for, could also impact on the turnover or half-
life of specific transcripts that could subsequently impact on the yield of protein observed.  
 
6.3 Overall Conclusions 
Cell engineering in CHO cells, had until recently almost exclusively concentrated on coding 
genes, with the exception of miRNAs that have been manipulated by a number of groups to 
show that these can impact the growth and productivity characteristics of CHO cells. Some 
of the reasons for the lack of studies reporting manipulation of other non-coding RNAs and 
genes are the lack of sufficient annotation in CH and CHO cell genomes for lncRNAs 
compared to model organisms and the technical challenges posed by tRNA sequencing. 
Nonetheless, focusing on ncRNAs for cell engineering in CHO would bring several benefits 
due to the variety of their mechanisms of action, the absence of a translational burden 
applied on the cell when manipulating the expression of these molecules as opposed to 
manipulating coding genes, and the huge number of potential targets unexplored. During 
this PhD I have generated the first landscape of lncRNA expression in various CHO cell lines 
under different conditions, identified transcripts with a potential for cell engineering and 
improved their annotation. In parallel, I have adapted a tRNA sequencing protocol in CHO 
and HEK293 cells to quantify tRNAs and evaluated their impact on translation using a model 
of the elongation phase. All of this work has been, or will be, made publicly available to 
benefit the community and allow/facilitate further studies. I believe this effort will pave the 
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Appendix 
Supplementary figures - Chapter 3 
 
Supplementary Figure 3.1 - (A) The figures show principal component analysis (PCA) for lncRNAs (above) and  
RNAs (below) based on expression levels of each measured replicate among the four groups, enclosed in   
corresponding calculated correlation circles. (B) Summary of the first 10 dimensions with corresponding 
percentage of explained variances for lncRNAs and mRNAs. 
 
 
Supplementary Figure 3.2 - (A) NEAT1 and MALAT1 loci in Chinese hamster based on Ensembl database, with 











Supplementary Figure 3.3 - A) Schematic representation of the conserved domains based on Rfam and literature 
found in the putative MALAT1 locus in Chinese hamster. The probe used in the array is indicated as 
ASMM10P018835 B) Schematic representation of the conserved domains based on Rfam and literature found in 




Supplementary Figure 3.4: - (A) Mouse annotation for the NEAT1 locus. (B) Chinese Hamster annotation for the 
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RNA-seq intron features, aggregate (filtered), NCBI Mus musculus Annotation Release 106
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Supplementary figures - Chapter 4 
 
Supplementary Figure 4.1 - Ammonia, glutamine and glutamate concentrations over time for the DAVI dataset 






Supplementary Figure 4.2 - Enriched KEGG pathways based on differentially expressed genes for each 
comparison between different cell lines at the same time point  in the DAVI dataset. Each dot represents a 
pathway, with color shade representing the p-value, size proportional  to the overlap size (differentially expressed 





Supplementary Figure 4.3 - Enriched KEGG pathways based on differentially expressed genes for each 
comparison among different cell lines at day 4 and day 7 in the JCE dataset. Each dot represents a pathway, with 
color shade representing the p-value, size proportional  to the overlap size (differentially expressed genes in the 




Supplementary Figure 4.4 - Enriched KEGG pathways based on differentially expressed genes for each 
comparison among the same cell line at day 4 against seed train culture in the JCE dataset. Each dot represents a 
pathway, with color shade representing the p-value, size proportional  to the overlap size (differentially expressed 
genes in the pathway) and x-coordinate recall (overlap size divided by the total number of genes in the pathway). 
 
 
Supplementary Figure 4.5 - Top 30 differentially expressed genes among the replication and repair domain in the 
DAVI dataset (A) and JCE dataset (B). 
 
 







Supplementary figures - Chapter 5 
 
 





Supplementary Figure 5.2 – RNA Screentape performed at the RNA-Seq facilities to check integrity of the de-






Transcript\Gene Forward Reverse 
B2M ACGGAGTTTACACCCACTGC CAGACCTCCATGATGCTTGA 
B-Actin AGCTGAGAGGGAAATTGTGCG GCAACGGAACCGCTCATT 
GAPDH GCCAAGAGGGTCATCATCTC CCTTCCACAATGCCAAAGTT 
XR_001721626.1 CCTCGTCTTGGGTTTCTTGA GATTGCATTGTGTTGCGTATG 
XR_001722284.1 AAGGCACCTTGGGACTTTTT ACAGCTACATGTTCTTTCTTGACCT 
XR_001723852.1 CTGACAGCACCCATTTACTTCA TTTCTTTGCCCAAATGGCTA 
XR_001725088.1 GCACCTTTGTACCCAACCAT CAGTATCTTCGTGCCAGCAA 
XR_001725445.1 AGACTACGGCAGGAGGATCA AATGGTTTGGGGCTATAGGAA 
XR_001725951.1 CCGAATAACTGGGAGCTGAA AGCAGGTAGAGGTGCTGCTG 
XR_001726746.1 GCACTAACTCACACCCCAGAA TCTTGGCCATTCTCTTGTCC 
XR_480869.2 AGCATCTCCCAGTGATGAGC AGAACCTGATGAGTCTGTTTCTGTT 
XR_481007.2 GCTCGCTCACAGAGAACACA CCCTAGTGGGAGATGCTGAG 
XR_482085.2 CAAGAACTCCCTGGAACTGG GGTGCCTTGGTTGGTCTAAA 
XR_482984.2 CTCCAATAGGTTGGACCACAG GCAGCTTTTCACACATCCAG 
XR_483663.2  TCATCTTTATGTCCACCCACAC AGGGTGACTCTGGCTTCCTT 
Gadd45a GTGACGAACCCACATTCATC ACTGGAACCCACTGATCCAT 
Por GAGACAGAGAGCACCTGTGGA AGGTGTTCTGCACGTCTTTGG 
Bcl6 GCCGCGGTGTTTGTATTTTGG TGCACCAAGGGGGAAAAATGA 
Ccna2 ACCTACCTCAGAGCAGCACA GTGTCTCTGGTGGGTTGAGA 
Top2a CTGAGGGAATTGGTACCGGG GGCAGAGGCTCTTCTCCATC 
Aurkb AGCCACAGTGAGACATACCG AGCCGATCTGAGGGTTTATG 
Rad51 ACACCGAGGGTACGTTTAGG GTGTTGAACCCTCGAGCATA 
Rad51 ACCAACCAGGTAGTAGCCCA GCCTGGTTGTTGATGCATGG 
PVT1 TTGTAGCATCCCAAGGCCAG CCTCACGTGGGGATTCTCTG 
Gas5 TGCTATGTGTTTTGGCCTGC AAAACCTAACCAAGCCCGGA 
Gas5 TGGAATCCAACACCGGCTAT ACGAGACAACACACGCAGAT 
Adapt15 GAATTCAGTGTAGGCCGGGA TGAACAGAGCTGGCAATGACT 
Trmt61a AGTTCCAGGAGCATCGTGTG AGAAGACAGCATCAGCCACG 
List of primers used in Chapter 3 (upper panel) and Chapter 4 (lower panel) for validation of 







































The Long Non-Coding RNA Transcriptome Landscape in
CHO Cells Under Batch and Fed-Batch Conditions
Davide Vito and Christopher Mark Smales*
The role of non-coding RNAs in determining growth, productivity, and
recombinant product quality attributes in Chinese hamster ovary (CHO) cells
has received much attention in recent years, exemplified by studies into
microRNAs in particular. However, other classes of non-coding RNAs have
received less attention. One such class are the non-coding RNAs known
collectively as long non-coding RNAs (lncRNAs). The authors have undertaken
the first landscape analysis of the lncRNA transcriptome in CHO using a mouse
based microarray that also provided for the surveillance of the coding
transcriptome. The authors report on those lncRNAs present in a model host
CHO cell line under batch and fed-batch conditions on two different days and
relate the expression of different lncRNAs to each other. The authors
demonstrate that the mouse microarray is suitable for the detection and
analysis of thousands of CHO lncRNAs and validated a number of these by
qRT-PCR. The authors then further analyzed the data to identify those lncRNAs
whose expression changed the most between growth and stationary phases of
culture or between batch and fed-batch culture to identify potential lncRNA
targets for further functional studies with regard to their role in controlling
growth of CHO cells. The authors discuss the implications for the publication
of this rich dataset and how this may be used by the community.
1. Introduction
Mammalian expression systems are widely used for the
production of recombinant protein biopharmaceuticals, largely
due to their ability to correctly fold, assemble, post-translation-
ally modify, and secrete complex human like proteins.[1] Among
these, the Chinese hamster ovary (CHO) cell is the most widely
utilized expression platform used in industry, especially for the
production of monoclonal antibodies (mAbs), and are used for
the expression of more than 60% of biotherapeutic proteins
made in mammalian cells.[1–5] The most widely used bioprocess
for the production of biopharmaceuticals from CHO cells
involves fed-batch culture, this offering an advantage over batch
culture in terms of cell growth, viability, and product yields due
to the supplementation of nutrients result-
ing in higher biomass accumulation, less
build-up of toxic metabolic by-products,
and enhanced productivity.[6–8]
The prominence of CHO cell expression
systems has driven innovation in the
industry such that CHO expression systems
and associated bioprocesses have been
developed that can deliver yields of mAb
in excess of 5–10 g L!1 in stably expressing,
fed-batch systems.[9,10] Despite this, some
biotherapeutic recombinant proteins, and
particularly some of the non-mAb novel
biotherapeutics in development, remain
difﬁcult to express in CHO cell or other
mammalian cell expression systems.[11,12]
Using a prior knowledge about cellular
systems, various approaches have been
taken to engineer cells to deliver enhanced
product yields and quality including the
engineering of chaperones,[13,14] glycosyla-
tion machinery,[15–17] and proliferation con-
trol strategies, including manipulation of
the cell cycle,[18,19] apoptosis,[20,21] and
autophagy.[22,23] A long side this approach,
there have been studies to further our
understanding of the potential cellular
constraints on the production of mAbs,[24,25] other recombinant
biotherapeutics[26] anddifﬁcult toexpress recombinantproteins[27]
inorder to identifybottlenecks in the recombinantgeneexpression
pathway and to develop new bioprocesses or adapt/engineer novel
hosts for enhanced production and/or quality of such mole-
cules.[28,29] The majority of these studies to date have focussed
upon manipulation of coding genes, however with the discovery
and improved understanding of non-coding RNA in the control of
cellular processes, there has beenmuch interest in the last decade
or so in these non-coding RNAs in CHO cells. In particular, the
manipulation ofmicroRNAs to enhance the ability ofCHOcells to
produce biotherapeutic proteins has attracted much attention.[30–
33] An advantage of manipulating such non-coding RNAs for
modulating CHO cell phenotypes is that such engineering does
not place an addition protein synthetic burden upon the host
cell,[34] unlike engineering of coding genes, and often such non-
codingRNAs canmodulatewhole pathways rather than individual
steps or processes as when manipulating many coding genes.
It has been estimated that at least 75% of transcripts originate
from non-coding sequences.[35] Investigations into these tran-
scripts has resulted in the identiﬁcation of a class of transcript
collectively known as Long non-coding RNAs (lncRNAs).[36]
LncRNAs are deﬁned as transcripts longer than 200 nucleotides
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that lack a signiﬁcant open reading frame (ORF), are usually
transcribed by RNA polymerase II and spliced, with or without 30
polyadenylation.[37–39] A number of lncRNAmolecules have been
shown to play key regulatory roles in various biological processes
including epigenetic regulation,[40] transcriptional control,[41]
splicing events,[42] and mRNA translation.[43] Indeed, lncRNAs
are capable of modulating a wide range of cellular processes and
mechanisms both in the nucleus and the cytoplasm.[44] The
majority of our understanding into lncRNAs and themechanism-
(s) by which they elicit their responses has come from studies
relating to disease[45] and developmental studies.[46] LncRNAs
elicit their effects by acting as competing endogenous RNAs
(ceRNAs) by binding to and sequesteringmicroRNAs,[47] by acting
as architectural RNAs (arcRNAs) whereby they form functional
structures,[48] act as cismolecules to enhance (eRNAs) coding gene
expression[49] or as trans protein binding RNAmolecules that can
recruit chromatin modifying,[50,51] as microRNA precursors,[52]
modulators of mRNA stability[53] and to impact upon post-
translational modiﬁcations.[54,55]
Despite the importance of lncRNAs in controlling cellular
processes, and unlike small non-coding RNAs (e.g., siRNAs,
microRNAs), the impact(s) of lncRNA expression on CHO cell
bioprocessing with regard to growth/proliferation and recombi-
nantproteinyieldsandqualityhasbarelybeenexplored,withonlya
smallnumberof studies reported.[56,57]However, these twostudies
showthatmanipulationof lncRNAscan impactuponrecombinant
protein production from CHO cells. One of the reasons for the
small number of studies on lncRNAs in CHO cells is the lack of a
comprehensive annotation of non-coding transcripts in CHO,
hampering their identiﬁcation, genome wide assessment of their
expressionandmodulationduring culture, functional studies, and
hence identiﬁcation of target lncRNAs for cell engineering. One
way to address this problem is to take advantage of the reported
similarities between the Chinese hamster, CHO, and mouse
genome,[58] where the number of well annotated non-coding
transcripts ismuch higher. The similarity between CHO cells and
mouse has already been utilized for the identiﬁcation of 416
ncRNAs based on sequenced transcripts from a pooled CHO
sample compared to the fRNAdb database of non-coding RNAs
using BLAST, with most hits coming from mouse.[59] Here, we
report the ﬁrst analysis in CHO cells of both the coding and the
non-coding transcriptome (speciﬁcally the lncRNAs) during batch
and fed-batch culture at twodifferent timepoints.We report on the
identiﬁcation of differentially expressed lncRNAs and mRNA,
their interconnections and their potential impact on cellular
pathways. This has allowed themapping of the lncRNA landscape
in CHO cells and identiﬁcation of lncRNAs targets in CHO for
further manipulation with a view to increase proliferation and to
sustain viability throughout batch and fed-batch culture.
2. Experimental Section
2.1. Model Cell Line and Cell Culture Conditions
The CHO─S Freestyle host cell line (ThermoFisher Scientiﬁc,
MA, USA) was used as amodel CHO cell line for this study. Cells
were routinely cultured in a Lab-Therm LT-X (Ku ̈hner AG, Basel,
Switzerland) shaking incubator at 37 "C, 5% CO2, 125 rpm, and
70% humidity in chemically deﬁned serum-free growthmedium
(CD CHO, ThermoFisher Scientiﬁc). Fed-batch cultures were
supplemented with CHO CD Efﬁcient Feed B Liquid Nutrient
Supplement (ThermoFisher Scientiﬁc). Initial supplementation
testing was conducted in duplicate following Conditions 3 and 9
as described in the CHO CD Efﬁcient Feed manual. Cultures
with a viability>98%were used to seed initial fed experiments at
3 # 105 viable cellsmL!1 in a 50mL working volume in 250mL
polycarbonate Erlenmeyer ﬂasks with vented caps (Corning,
Wiesbaden, Germany). From the initial feeding experiments,
Condition 3 was used for all future fed-batch cultures and for
generating samples analyzed during this study. This adopted
feeding strategy consisted of a 15% (v/v) supplementation of
CHO CD Efﬁcient Feed B to the CD CHO starting volume
immediately on Day 0, followed by 10% (v/v) supplementation
on Day 3 and Day 6. Four biological replicates of each culture
process (batch and fed-batch) were seeded at 3 # 105 viable
cellsmL!1 from 20mL cultures with a culture viability $ 98.5%
in 120mL CD CHO starting working volume in 500mL
polycarbonate Erlenmeyer ﬂasks with vented caps (Corning).
Viable cell concentrations and culture viability were determined
daily using a Vi-CELL XR Cell Viability Analyzer (Beckman
Coulter, Inc., Brea, CA, USA) on 1mL culture samples.
2.2. Sampling from Cell Cultures and Subsequent RNA
Extraction
Samples of 1 # 107 viable cells were taken from each ﬂask after
96 h (Day 4) and 144 h (Day 7) of culture and total RNA
immediately extracted using the commercially availablemirVana
miRNA Isolation Kit (ThermoFisher Scientiﬁc) and treated with
RapidOut DNA Removal Kit (ThermoFisher Scientiﬁc). The
RNA quantity and quality were determined using a NanoDrop
ND-1000 (ThermoFisher Scientiﬁc) instrument and the integrity
of RNA assessed by standard denaturing agarose gel
electrophoresis.
2.3. lncRNA and Coding RNA Microarray and Data Analysis
2.3.1. Microarray Details
Three of the four cultures were selected for analysis. Analysis of
extracted RNA for coding and lncRNAs was undertaken using the
commercially available ArrayStarMouse lncRNAMicroarray V3.0
(Rockville,MD, USA). RNA labeling and array hybridization were
performed according to the Agilent One-Color Microarray-Based
Gene Expression Analysis protocol (Agilent Technologies, Santa
Clara,CA,USA)withminormodiﬁcations.RibosomalRNAswere
removed from total RNA using the mRNA-ONLY Eukaryotic
mRNAIsolationKit, (Epicentre,Madison,WI,USA). Each sample
was then ampliﬁed and transcribed into ﬂuorescent cRNA along
the entire length of the transcripts without 30 bias utilizing a
mixture of oligo(dT) and random primers using the Arraystar
Flash RNA Labeling Kit (Arraystar). The labeled cRNAs were
puriﬁed by RNeasy Mini Kit (Qiagen, Hilden, Germany). The
concentration and speciﬁc activity of the labeled cRNAs were
determined by NanoDrop ND-1000 (ThermoFisher Scientiﬁc). A
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total of 1mg of each labeled cRNAwas then fragmented by adding
5mL of 10 # Blocking Agent and 1mL of 25 # Fragmentation
Buffer before heating at 60 "C for 30min. Finally, 25mL of 2 # GE
Hybridization buffer was added to dilute the labeled cRNA. A
sample of 50mL of the hybridization solution was then dispensed
into the gasket slide and assembled to the LncRNA expression
microarray slide. The slides were incubated for 17h at 65 "C in a
Microarray Hybridization Oven (Agilent Technologies). The
hybridized arrays were then washed, ﬁxed and scanned using
the G2505C DNA Microarray Scanner (Agilent Technologies).
2.3.2. Microarray Data Analysis
Agilent Feature Extraction software (version 11.0.1.1) was used
to analyze acquired array images. Quantile normalization and
subsequent data processing were performed using the Gene-
Spring GX v12.1 software package (Agilent Technologies). After
quantile normalization of the raw data, lncRNAs and mRNAs
that were present in $ 3 of 12 samples were selected for further
data analysis. Raw p-values were calculated by unpaired t-test,
then the differentially expressed lncRNAs and mRNAs with
statistical signiﬁcance between compared groups were ﬁltered
for a FC $ 2 and a false discovery rate (FDR) % 0.10 calculated by
the Benjamini–Hochberg procedure. GO analysis was per-
formed using the Bioconductor package topGO[60] and with a
raw p-value cut-off of 0.05 calculated by Fisher’s exact test,
subsequently ﬁltered for an FDR % 0.10. Pathway analysis for
differentially expressed mRNAs was performed based on the
KEGG database (http://www.genome.jp/kegg) with a raw
p-value cut-off of 0.05 calculated by Fisher’s exact test,
subsequently ﬁltered for an FDR % 0.10.
2.4. RT-qPCR Validation of lncRNAs Identified as
Differentially Expressed by Microarray
Primers for RT-qPCR were designed using OligoPerfect
Designer (ThermoFisher Scientiﬁc) and synthetized by Euroﬁns
Scientiﬁc (Luxembourg) (described in Table S1, Supporting
Information). RT-qPCR reactions were conducted using a
Mastercycler EP Realplex instrument (Eppendorf) following
the QuantiFast SYBR Green RT-PCR Kit protocol (Qiagen).
Speciﬁcity of ampliﬁcation was checked by the generation of Tm
curves and by analysis of the reaction products by 2% agarose gel
electrophoresis to conﬁrm the presence of a single amplicon of
the expected size. The results were analyzed applying the
standard ΔCt method and normalized to GAPDH, β-actin, and
B2M housekeeping gene expression.
3. Results
3.1. Growth Characteristics and Sampling of CHO─Cells
Throughout Batch and Fed-Batch Culture for (Non)-Coding
RNA Analysis
The steps followed to generate the results presented in this work
are summarized in Figure 1. Initially, growth comparisons and
supplementation testing were undertaken using CD CHO and
Figure 1. Summary of the experimental workflow. Growth and culture viability of a CHO─S cell line in Batch and Fed-batch cultures were measured for
10 days and samples for RNA extraction taken at Day 4 and at Day 7. The samples were analyzed on a mouse array containing all the coding and non-
coding transcripts stored in the main public databases. The measured intensities were log-normalized and differentially expressed transcripts/genes
were filtered for a fold change (FC) $ 2 and an FDR % 0.10. A selected group of genes was validated through RT-qPCR (Supplementary Material). Due to
the poor annotation of lncRNAs in CHO, the identification of potential targets with a described biological role required the comparison of human and
mouse literature and databases, followed by alignment against the Chinese hamster genome, leading to predicted lncRNAs transcripts and previously
un-annotated genomic regions (Table 1). At the same time, GO and pathway enrichment was implemented on mRNAs.
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the associated commercially available feds (Efﬁcient Feds A and
B). From these preliminary experiments, we selected Efﬁcient
Feed B Liquid Nutrient Supplement for experimental Fed-batch
cultures as this gave the highest viable cell concentrations across
a 10-day process from the feed strategies investigated (data not
shown). Cells under Fed or Batch culture grew almost identically
up until Day 4 of culture whereupon their growth characteristics
differed (Figure 2A). Whilst growth of the Batch cultures slowed
dramatically after Day 4, with a mean peak viable cell
concentration on Day 6 of approximately 1 # 107 cellsmL!1,
in the Fed-batch cultures growth and proliferation continued
until Day 6 where a mean peak viable cell concentration of
almost 2 # 107 cellsmL!1 was obtained (Figure 2A). After Day 6
the viable cell number and viability of both cultures decreased
with time, however while culture viability rapidly declined in the
Batch culture such that by Day 9 culture viability was close to 0%,
in the Fed-batch mode cultures had a mean viability of 83.6% at
Day 10 (Figure 2A). The ﬁrst-time point at which samples were
harvested was Day 4, when both types of culture had grown in a
similar way and were still in the exponential growth phase (late
Figure 2. A) Growth profiles for the model CHO─S host cell line throughout Batch and Fed-batch culture. Viable cell concentration (VCC) and culture
viability are shown (red for Batch and blue for Fed-batch). The percentage of CHO CD Efficient Feed B Liquid Nutrient Supplement added to the existing
working volume are shown for each feeding Day (Days 0, 3, and 6). The arrows indicate when samples for microarray analysis were harvested (Day 4 and
Day 7). B) Hierarchical clustering heatmaps arranging samples into groups based on their averaged log-normalized expression levels. Only transcripts/
genes with an expression variance between each group above the 80th percentile are shown. The dendrogram shows the relationships for lncRNAs (left
panel) andmRNAs (right panel). C) Down-regulated (green bars) and up-regulated (red bars) mRNAs (full bars) and lncRNAs (textured bars) in CHO─S
cells during batch and fed-batch culture for each of the compared pairs showing a fold change $ 2 and an FDR % 0.10. D) Venn diagrams showing the
number of lncRNAs and mRNAs differentially expressed (DE) in Fed-batch vs Batch (FC $ 2, FDR % 0.10). Genes DE at both Day 4 and Day 7 are
represented in the overlaps while genes DE only at one time point are represented inside their corresponding circle.
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exponential for batch), whilst the second time point at which
cells were harvested for RNA analysis was on Day 7,
corresponding to the end of the stationary phase/ﬁrst day of
decline for both cultures. In the case of the Fed-batch cultures,
these two sampling points were also 24 h after addition of the
Efﬁcient Feed B.
3.2. Microarray Analysis of mRNA and lncRNA Transcripts
in Batch and Fed-Batch Culture
3.2.1. Differential Expression of lncRNAs and mRNAs in
Fed-Batch v Batch Comparisons
The Arraystar Mouse LncRNA Microarray V3.0 used in this
study is based on publicly available databases and publications,
allowing for the potential simultaneous surveillance of 35923
lncRNAs and 24881 coding transcripts. The lncRNAs collection
is based on the NCBI Refseq, UCSC Known Gene 6.0, Ensembl
38.71, Fantom3, RNAdb 2.0, NRED databases, a number of
literature publications, T-UCRs, and evolutionary constrained
lncRNAs.[61–68] Positive probes for housekeeping genes and
negative probes are printed onto the array for hybridization
quality control. After quantile normalization of the raw data,
24603 unique lncRNAs and 19617 mRNAs were selected for
analysis. Firstly, we implemented Principal Component Analysis
(PCA) on the log2 transformed intensities and plotted the ﬁrst
three components against each other, where lncRNAs and
mRNAs showed very comparable results, especially where for
the ﬁrst two components samples from Batch cultures at both
days grouped closely compared to Fed-batch samples, which
showed a wider separation even between the same condition
(Figure S1, Supporting Information). Then we applied hierar-
chical clustering, arranging samples into groups based on their
averaged log-normalized expression levels to show the relation-
ships among gene expression patterns of samples for both
lncRNAs and mRNAs (Figure 2B). We continued performing
differential expression analysis (DE) where we compared Fed-
batch against Batch at Day 4, Fed-batch against Batch at Day 7,
Fed-batch at Day 7 against Fed-batch at Day 4, and Batch at Day 7
against Batch at Day 4. At this point, the expression of a selected
number of the identiﬁed DE transcripts was conﬁrmed by RT-
qPCR, that showed these transcripts were present but that lower
fold-changes were observed between samples than from the
array analysis (Table S1, Supporting Information). The genes
identiﬁed as DE were then ﬁltered based on a threshold fold
change (FC) $ 2 and a false discovery rate (FDR) % 0.10 (Table S2
and S3, Supporting Information). When we compared Batch
Day 7 to Batch Day 4 samples, we found surprisingly low
numbers of mRNAs or lncRNAs where the expression changed
beyond the set thresholds, with 0 mRNAs being up and 19 down
regulated between the 2 days whilst for the lncRNAs there were
no transcripts that changed above the thresholds set (Figure 2C).
To check whether this lack of identiﬁed transcripts changing was
due to the FC $ 2 threshold, we repeated the analysis for
FC $ 1.5 and FC $ 1.25, FDR % 0.10 (Table S4–S11, Supporting
Information). For a FC $ 1.25, 99 mRNAs were down and 30
were up-regulated while none met the threshold for the
lncRNAs. We then carried on with the FC $ 2, FDR % 0.10
thresholds for the remaining comparisons. Fed-batch Day 7 vs.
Day 4 revealed 693 mRNAs up-regulated and 421 down-
regulated whilst for the lncRNAs we found 545 up-regulated and
200 down-regulated genes (Figure 2C). When we compared Fed-
batch against Batch at Day 4 and Day 7, 1048 and 1875 lncRNAs
were up-regulated respectively in addition to 856 down-regulated
at Day 4 and 1018 down-regulated at Day 7. For the same
comparisons we saw more down-regulated mRNAs at Day 4
(1538) and Day 7 (1397) while there were 716 up-regulated
mRNAs at Day 4 and 1121 at Day 7 (Figure 2C).
3.3. Identification of lncRNAs Differentially Expressed as
Potential Engineering Targets for Modulation of Cell
Growth
As one of the aims of this work was to identify new transcripts for
manipulation in CHO, we reduced the list of potential targets to
a manageable group for further experimental validation. Firstly,
we aligned all the 60 nucleotide mouse probes corresponding to
the differentially expressed genes identiﬁed for each comparison
against the Chinese hamster (CH) genome using the discontig-
uous megablast algorithm to check howmany transcripts had an
annotation in CHO. Only 16–28% of the probes corresponding
to differentially expressed lncRNAs had a matching transcript in
CH, as opposed to 58–80% of themRNAs (Table S12, Supporting
Information). This is likely due to the poor annotation of the CH
transcriptome compared to mouse, where the number of
described lncRNAs is signiﬁcantly higher. If we consider the
ENSEMBL 91 database release alone, 2563 lncRNAs and 446
pseudogenes are listed for Chinese hamster as opposed to 9308
lncRNAs and 12363 pseudogenes in mouse. To address this
issue we complemented this approach with literature and
databases mining (NCBI, ENSEMBL, lncRNAdb, LNCipedia) to
identify differentially expressed lncRNAs already described in
mouse but not in Chinese hamster, revealing genomic positions
that align with potential lncRNAs (Figure S2–S4, Supporting
Information). The identiﬁed sequences were then examined
using the Rfam database[69] to assess their resemblance to
existing non-coding RNA families. A list of potential lncRNAs
found using the described approaches is reported in Table 1,
along with literature references describing their biological
function.
The role of lncRNAs in diseases is well established, especially
linked to cell proliferation in cancer[70] and several of those
identiﬁed here have been investigated in such systems. NEAT1
(nuclear-enriched abundant transcript 1) and MALAT1 (also
known as NEAT2), found to be up-regulated at both days in our
Fed-batch cultures (Table 1), are among the most well
characterized lncRNAs and have been reported to promote cell
proliferation through regulation of gene expression at the
nuclear level. MALAT1 is a mostly un-spliced transcript around
6.7 kb in mouse, with a long half-life due to the tRNA-like
structure adopted at the 30 end.[37] This structure is cleaved to
generate a 61 nt mascRNA (MALAT1-associated small cyto-
plasmic RNA) exported to the cytoplasm where it is subjected to
canonical CCA nucleotides addition and accumulates in the
cytoplasm.[71,72] We were able to identify the JH002628.1
genomic region in Chinese hamster using the above mentioned
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complementary approaches and we could recognize all of its
main conserved domains (Figure S2, Supporting Information).
The structure of this genomic region is conserved in the most
recent CHOK1GS_HDv1 genome and resembles the pattern
found in human and mouse, where close to MALAT1 is the
NEAT1 locus. The NEAT1 locus is regulated by alternative 30 end
processing, where the primary transcript can be cleaved and
polyadenylated to generate a 3.2 kb long MENe isoform or
cleaved and non-polyadenylated to generate the 20.8 kb long
MENβ isoform.[37] We were able to identify a predicted 3.2 kb
long non-coding transcript (NCBI Ref XR_478750.2) arising
from a locus (LOC103159497, C_griseus_v1.0) with similar
primary structure to both the 3.2 kb and the 20.8 kb isoforms
(E-value 0.0, Identity 80%, algorithm megablast). MALAT1 and
NEAT1 both localize to the paraspeckles stress-responsive
nuclear bodies in the cell,[73] where they are reported to
inﬂuence the splicing machinery[70,74] and the DNA repair
machinery.[75] The Plasmacytoma Variant Translocation 1
(PVT1) lncRNA is considered a biomarker for various cancers
due to its ability to promote cell proliferation with a range of
proposed mechanisms.[76–79] We identiﬁed a predicted non-
coding RNA in Chinese hamster (NCBI Ref XR_478426.2) which
contained the PVT1_3 RFAM domain and was up-regulated at
both Day 4 (FDR ¼ 1.2E-01) and Day 7 in the Fed-batch
compared to Batch (Table 1).
3.4. Comparison of mRNAs with Existing Datasets
We compared our Fed-batch against Batch dataset with previous
work to identify coding genes related to growth in CHO.
Although all these works used different approaches and cell
lines, we saw the opportunity to ﬁnd common patterns of
expression in CHO across various conditions. The ﬁrst dataset
compared was Clarke 2011,[80] where we observed 10 of their
reported down-regulated genes at Day 4 and 7 at Day 7 of our
dataset (Table S13, Supporting Information). On comparing our
data to Clarke 2012,[81] only the kinesin family member C1
(KIFC1) gene, up-regulated at both Day 4 and Day 7, was
observed to behave in the same way. Lastly, when we considered
the translatome analysis in Courtes 2013 we identiﬁed 3 genes at
Day 4 and 8 genes at Day 7 among our down-regulated
transcripts, together with 1 gene at Day 4 and 2 genes at Day 7
among the up-regulated transcripts.[82] Interestingly, a group of
the common genes between the selected works and our dataset
(CDC20, MAD2L1, MCM7, MCM4, GTF2H4) are involved in
cell cycle and DNA replication, supporting the ﬁndings in the
pathway enrichment analysis (described in section 3.5).[83–85] In
addition, we found single genes in consistently enriched
pathways in our pathway analysis such as HNRNPC, involved
in RNA molecule binding or LGMN, participating in protein
degradation in the lysosome.[86] Interestingly, HNRNPs proteins
are well known to bind and mediate the functions of lncRNAs,
and HNRNPC in particular has been reported to interact with
MALAT1 in a tightly regulated N6-methyladenosine-dependent
manner.[87,88]
3.5. GO Analysis and Pathway Enrichment
We performed GO term analysis on the differentially expressed
mRNAs with an FDR cut-off of 0.10 calculated by the BH
method, followed by pathway enrichment analysis based on the
KEGG database (Table S14–S29, Supporting Information),
allowing the determination of the signiﬁcantly enriched
biological pathways ﬁltered for an FDR % 0.10 and grouped
based on KEGG class annotation (Table 2). The pathway
enrichment identiﬁed 22 pathways containing down-regulated
Table 1. Summary of the lncRNAs identified using the described approaches, consisting in a direct alignment of the differentially expressed gene
probe against the Chinese hamster genome to literature search and RNA families conservation in RFAM.
Gene symbol NCBI ref FC Day 4 FC Day 7 FDR Day 4 FDR Day 7 Rfam family Rfam ID E-value References
MALAT1 JH002628.1 3.5 4.5 2.4E-02 1.0E-02 MALAT1 RF01871 7.5E-13 Sun et al.[70]; Wilusz[37]
mascRNA-menRNA RF01684 7.0E-16
MEG3 JH001208.1 2.9 2.8 5.9E-02 4.7E-02 MEG3_2 RF01872 3.5E-14 He et al.[106]
MIAT XM_007625231.2 2.6 0.0 2.6Eþ 00 1.0E-02 MIAT_exon1 RF01874 7.0E-12 Liao et al.[107]
NEAT1 XR_478750.2 6.1 3.3 3.9E-02 6.3E-02 NEAT1_1 RF01955 5.4E-18 Adriaens et al.[75]; Hirose et al.[108]
NEAT1_2 RF01956 1.2E-17
NEAT1_3 RF01957 2.2E!19
PVT1 XR_478426.2 2.5 3.5 1.2E-01 2.7E-02 PVT1_3 RF02166 1.7E-16 Colombo et al.[79]; Zhu et al.[76]
TERC AF221928.1 – 6.3 – 4.0E-02 Telomerase-vert RF00024 5.7E-58 Engreitz et al.[109]




From left to right, the columns show the gene symbol, the NCBI accession reference, the fold-change measured at Day 4 and Day 7 with the corresponding FDRs, the ID of
the non-coding RNA family found for the sequence in Rfam database with the corresponding ID and E-value and the references describing the biological function of the
gene.
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Table 2. Summary of the enriched pathways based on the list of up-regulated (lysosome) and down-regulated (lower tables) transcripts in
Fed-batch vs Batch comparison at Day 4 (left panel) and Day 7 (right panel).
KEGG ID Pathway FDR Diff. expressed (DE) genes Total genes (TG) DE:TG ratio
UP fed D4 v batch D4
04142 Lysosome 6.3E-02 14 124 0.11
UP fed D7 v batch D7
04142 Lysosome 7.1E-04 21 124 0.17
DOWN fed D4 v batch D4
05034 Alcoholism 8.5E-11 48 203 0.24
04110 Cell cycle 2.3E-09 34 125 0.27
05322 Systemic lupus erythematosus 6.8E-07 33 147 0.22
03030 DNA replication 3.5E-04 12 35 0.34
03460 Fanconi anemia pathway 8.5E-04 14 51 0.27
05203 Viral carcinogenesis 1.1E-03 37 243 0.15
03410 Base excision repair 1.3E-03 11 35 0.31
03430 Mismatch repair 4.4E-03 8 22 0.36
01200 Carbon metabolism 4.5E-03 21 117 0.18
00480 Glutathione metabolism 5.7E-03 13 56 0.23
00900 Terpenoid backbone biosynthesis 6.4E-03 8 24 0.33
04114 Oocyte meiosis 8.5E-03 20 116 0.17
05200 Pathways in cancer 1.3E-02 48 397 0.12
03440 Homologous recombination 1.6E-02 8 28 0.29
04914 Progesterone-mediated oocyte maturation 1.8E-02 16 90 0.18
01212 Fatty acid metabolism 2.1E-02 11 51 0.22
04540 Gap junction 2.8E-02 15 86 0.17
00280 Valine, leucine and isoleucine degradation 4.2E-02 11 56 0.20
04115 p53 signaling pathway 6.4E-02 12 68 0.18
00240 Pyrimidine metabolism 6.4E-02 16 104 0.15
03420 Nucleotide excision repair 6.5E-02 9 44 0.20
00630 Glyoxylate and dicarboxylate metabolism 7.6E-02 7 30 0.23
DOWN fed D7 v batch D7
04110 Cell cycle 7.9E-14 38 125 0.30
03030 DNA replication 1.2E-09 17 35 0.49
03013 RNA transport 1.2E-09 38 170 0.22
03040 Spliceosome 1.3E-07 30 134 0.22
05203 Viral carcinogenesis 2.8E-06 40 243 0.16
03430 Mismatch repair 2.2E-05 10 22 0.45
03460 Fanconi anemia pathway 2.3E-05 15 51 0.29
03410 Base excision repair 3.3E-04 11 35 0.31
05322 Systemic lupus erythematosus 9.3E-04 24 147 0.16
03440 Homologous recombination 1.4E-03 9 28 0.32
03420 Nucleotide excision repair 2.5E-03 11 44 0.25
05034 Alcoholism 3.5E-03 28 203 0.14
04114 Oocyte meiosis 4.2E-03 19 116 0.16
03008 Ribosome biogenesis in eukaryotes 2.0E-02 14 83 0.17
00240 Pyrimidine metabolism 2.3E-02 16 104 0.15
03015 mRNA surveillance pathway 2.6E-02 15 96 0.16
(Continued)
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genes at Fed-batch vs. Batch Day 4 and 24 at Fed-batch vs. Batch
Day 7 while only one contained up-regulated genes (Lysosome,
ID: 04142) at either day. This is most likely a reﬂection of the
lower number of up-regulated genes compared to down-
regulated (Figure 3). The Metabolism domain includes seven
enriched pathways at Day 4 while only one of these was still
enriched at Day 7, suggesting a central role of metabolism
together with p53 signalling predominantly during the expo-
nential growth phase. On the contrary, toward Day 7 we see the
prevalent enrichment of pathways related to translation
regulation and RNA interaction at different levels, from
transport to splicing. The most evident pattern of enrichment
between Day 4 and Day 7 is represented by the Replication and
Repair class, where the majority of the pathways involved in
genome maintenance and diverse repair mechanisms are
consistently enriched, indicating an early and sustained
regulation of these genes throughout culture. DNA damage is
reported to stimulate the expression of NEAT1 and, together with
MALAT1, to promote the formation of paraspeckles, which
regulate alternative splicing and promote proliferation.[73,75,89]
We then compared our results with relevant KEGG pathway
enrichment datasets available for CHO[90] and found four
common pathways, which were enriched exclusively at Day 7 in
our dataset: RNATransport (ID: 03013), mRNA surveillance (ID:
03015), RNA degradation (ID: 03018), Spliceosome (ID: 03040).
Taken together, these results suggest the importance of cell cycle
Table 2. (Continued)
KEGG ID Pathway FDR Diff. expressed (DE) genes Total genes (TG) DE:TG ratio
00310 Lysine degradation 3.1E-02 10 52 0.19
04914 Progesterone-mediated oocyte maturation 3.4E-02 14 90 0.16
03018 RNA degradation 4.4E-02 13 83 0.16
05166 HTLV-I infection 4.8E-02 32 294 0.11
05222 Small cell lung cancer 4.9E-02 13 85 0.15
00020 Citrate cycle (TCA cycle) 5.5E-02 7 32 0.22
05215 Prostate cancer 6.7E-02 13 89 0.15
01210 2-Oxocarboxylic acid metabolism 1.0E-01 5 20 0.25
The columns show from left to right the ID from KEGG, the pathway name, the FDR associated with the enrichment (FDR % 0.10 threshold), the number of differentially
expressed genes in the pathway, the number of total genes listed in the pathway, the differentially expressed genes over total genes ratio.
Figure 3. Graphical representation of the enriched KEGG pathways listed in Table 2, hierarchically grouped based on KEGG Pathway Maps. Each filled
rectangle (in red for Day 4, in blue for Day 7) contains the corresponding enriched pathways, with pathways enriched at bothDay 4 andDay 7 enclosed in the
overlapsbetween the filled rectangles.Theenrichment isbasedongenesdifferentially expressed inFed-batchvs.BatchatDay4andDay7withanFDR % 0.10.
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and genome repair mechanism control likely due to the high
proliferation of the fed-batch system. In addition, the active
regulation of RNA transport, RNA maintenance and splicing
seems to be particularly important toward the later stages of our
Fed-batch cultures.
4. Discussion
By taking advantage of a comprehensive commercially available
mouse microarray containing 35923 lncRNAs and 24881
mRNAs, we have provided the ﬁrst mapping of the CHO
lncRNA landscape, together with the coding transcriptome.
Previous reports have shown that more than 70% of the
assembled CHO transcriptome is similar to mouse (Mus
musculus) and closely related to rat (Rattus norvegicus) tran-
scriptomes[58] suggesting that this approach was likely to be valid
for lncRNAs as well. Due to the species and tissue-speciﬁcity of
lncRNAs compared to mRNAs, the number of detectable
lncRNAs in CHO is likely to be lower than the 35923 probes
included in the array. Nevertheless, using this approach we were
able to detect 24603 lncRNAs (68.5% of the total probes) and
19617 mRNAs (78.8% of the total probes), and found that the
several hundreds of lncRNAs exhibit changing expression
proﬁles on different days of culture and between Batch and
Fed-batch culture in a model CHO─S system. This was
especially true for the Fed system, where comparing Day 4
and Day 7 we observed 1114 differentially expressedmRNAs and
745 lncRNAs, as opposed to the Batch, were we saw only 19
differentially expressed mRNAs and no lncRNA for the same
comparison, suggesting a prevalent variability induced by the
Fed supplement as compared to time only.
Among the differentially expressed genes, between 16–28% of
the lncRNAs probes had a matching transcript in CH, as
opposed to 58–80% of the mRNAs. This required a speciﬁc
approach where the Chinese hamster genome, literature search,
and databases mining were combined to detect lncRNAs
differentially expressed in our system with an established
biological function. Within these lncRNAs, we focused on
MALAT1, NEAT1, and PVT1 to provide a comparison between
the mouse gene and the Chinese hamster putative homologues.
The number of lncRNAs with a fully understood role in the cell
remains small, however these three non-coding genes are
among the most well characterized.[91] MALAT1 and NEAT1 in
particular are associated with increased proliferation and
participate in the regulation of alternative splicing and DNA
repair, which we found to be strongly regulated in our pathway
enrichment analysis. This suggests a potential role for these
lncRNAs in CHO, although further experimental studies on the
single genes are now required to assess the actual effects on the
cell under different conditions.
Several approaches to investigate and conﬁrm the functional
annotation of lncRNAs in other organisms have been described,
including the perturbation of lncRNA expression by over-
expression, knockout or knockdown,[92,93] in addition to
complementary strategies.[39] Future developments in CHO will
have to proceed with a mix of functional prediction tools to
assess the properties of the transcriptome and evaluate the
degree of conservation with other species[94–96] and of targeted
approaches to ameliorate the annotation and propose mecha-
nisms of action for the single transcripts.[97–100] Further, the data
reported here is for both lncRNAs and mRNAs and hence will
allow investigators to further probe the relationships between
the expression and regulation of these two classes of RNA. As the
majority of the lncRNAs reported in the literature are discussed
and related to human or model organism systems, our work
aimed at unveiling the role of lncRNAs in CHO under
industrially relevant conditions to identify new targets for
manipulation to sustain proliferation. Examples of successful
cell engineering of lncRNAs to selectively enhance transla-
tion[101] and product yield[57] have already been reported in CHO,
demonstrating the potential of manipulation of lncRNAs for
enhancing industrial processes. Moreover, since it was reported
up to 15% of the total ribosome occupancy can be occupied by a
single recombinant mRNA, the intrinsic characteristics of
lncRNAs place them as ideal candidates for cell line engineering
of protein production cell factories, as they do not add any
translational burden on top of the coding gene of interest.[102]
Our work has identiﬁed potential lncRNA targets differen-
tially expressed in Fed-batch compared to Batch culture from
which we selected a group of molecules to be experimentally
studied (Table 1). In addition to the expression of lncRNAs we
also looked at expression of mRNAs (coding transcripts) and
found a consistent change in differentially expressed mRNAs
when comparing batch and fed-batch cultures. Pathway
enrichment analysis (Figure 3) underlined the importance of
genes involved in cell cycle and genome maintenance pathways
along with the regulation of lysosome formation as potential
targets for cell engineering to enhance proliferation. Our
approach allowed the identiﬁcation of previously undescribed
lncRNAs in CHO along with mRNAs to identify the connections
between them and compared these with existent literature. This
network of reciprocal interactions is beginning to be unveiled in
other organisms[103–105] and our work will help pave the way for
the deﬁnition of new layers of regulation involving single
transcripts or even entire pathways in CHO.
5. Conclusions
He we report on the lncRNA landscape and how this changes in
CHO cells, presenting a full dataset of those lncRNAs present
as determined from an array study and how these change
through a Batch and Fed-batch culture and between the two
culture systems. From analysis of the data, we have determined
those lncRNAs whose expression changes the most between
2 days in culture and between fed and batch culture that are
attractive targets for cell engineering. This resource will now
provide the community with the opportunity to undertake
functional validation studies by undertaking single or multiple
knock downs/outs, or by the up-regulation of target lncRNAs,
and determine the impact on growth, and productivity,
characteristics of CHO cells. Ultimately, we anticipate such a
resource will be incorporated into wider genome analysis
datasets including coding mRNAs and other non-coding RNAs
to develop a wider appreciation of the role of RNAs in
controlling recombinant CHO cell line growth and productivity
characteristics.
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Engineering of the cellular translational machinery and
non-coding RNAs to enhance CHO cell growth,
recombinant product yields and quality
Davide Vito and C Mark Smales
Chinese hamster ovary cells are the main mammalian cell
expression system currently used for the production of
recombinant protein biopharmaceuticals. One of the key
processes determining the achievable biomass of cells in the
bioreactor and the yield and quality of recombinant protein
from such systems is mRNA translation. Translation is the
process by which ribosomes and associated cellular machinery
decode an mRNA to produce a polypeptide. In recent years the
roles of different classes of non-coding RNAs in controlling
global and transcript specific mRNA translation has also come
to light. Here we review approaches to engineer the
translational machinery and non-coding RNAs, particularly long
non-coding RNAs and tRNAs in CHO cells and then outline the
challenges and potential of such approaches to revolutionize
the yields and quality of recombinant protein from CHO and
other mammalian cell expression systems.
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Introduction
For the production of biopharmaceuticals, Chinese ham-
ster ovary (CHO) cells are the most widely used mam-
malian cell expression system, able to produce secretory
yields of monoclonal antibody in fed-batch culture in
excess of 5 g/L [1]. The secretory yield from such an
expression system is governed by the number of cells in
the bioreactor across the culture (the integral of viable cell
concentration or IVC) and the average amount of material
expressed by each cell, usually referred to as the cell
specific productivity (qP) and expressed as pg of protein/
per cell/per day [2]. mRNA translation is a key cellular
process that is involve in determining global and protein
specific synthesis, and hence control of the abundance of
proteins that constitute the cellular machinery, cell
growth, division and the IVC of culture. Likewise, mRNA
translation plays a key role in determining the qP of a
given cell line and hence is a key regulatory process
impacting on the yields and quality of recombinant pro-
tein from CHO cells [3].
mRNA translation is the process by which the ribosome
and associated cellular machinery decodes a target
mRNA to yield a polypeptide. Translation is a key step
in the gene expression pathway and is the predominant
process by which protein cellular abundance is controlled
[4]. Over the last few decades it has been established that
the control in mammalian cells of mRNA translation, and
hence protein synthesis, is not only determined by the
translational machinery, modulation of the activity of
various translation factors by phosphorylation, and the
abundance, availability and makeup of a given mRNA,
but also by availability, abundance and activity of non-
coding RNAs [5]. Non-coding RNAs are generally
described as either long non-coding RNAs of >200
nucleotides in length or small non-coding RNAs <200
nucleotides and includes microRNAs (also referred to as
miRs) and tRNAs. The discovery of the mechanism(s) by
which non-coding RNAs exert an influence on gene
expression has opened up new opportunities for the
engineering of cells to manipulate cell processes that
underpin cell growth and recombinant protein production
and quality. Further, manipulation of such non-coding
RNAs offers the advantage of not placing an additional
translational burden on the cell that over expression of
coding mRNAs does. Here we briefly review our under-
standing of the control of mRNA translation in CHO cells,
describe approaches and outcomes to engineer the trans-
lational machinery and non-coding RNAs in CHO cells,
and discuss current and future cell engineering opportu-
nities and challenges such approaches present (Summa-
rized in Table 1).
The translational machinery, mRNA analysis and
manipulation
As mRNA translation is a key process in defining cell
growth, biomass accumulation and recombinant protein
yields and quality from cultured CHO cells [3,6], the
translational machinery and the abundance and availabil-
ity of global and recombinant mRNAs between cell lines
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and process conditions has been investigated using a
variety of approaches. For example, the phosphorylation
of the translation initiation factor eIF2a and attenuation
of global protein synthesis during recombinant protein
production in CHO cells is known to occur [7]. Culture
temperature has been shown to impact mRNA translation
and the quality of recombinant product produced [8] and
the PERK-eIF2a pathway was reported to impact upon
the aggregation of a recombinant TNFR-Fc fusion pro-
tein [9]. Indeed the activity and availability of translation
factors has been shown to change during culture and
under different culture conditions, where for example
under reduced temperature translation elongation factor 2
(eEF2) becomes phosphorylated and a reprogramming of
translation occurs that means transcripts with particular
codon usage can escape the general global attenuation of
translation under such conditions and the translation of
these transcripts is actually enhanced [10].
High producing antibody cell lines have been shown to
maintain translation initiation factors at levels that allow
such cells to maintain enhanced recombinant protein
synthesis above that of lower producing cells [3]. With
regard to monoclonal antibody synthesis in CHO and
other cells, investigations have shown that recombinant
antibody production is limited by translational efficiency
[3,11–13]. Manipulation of the cellular translational
machinery is however, not straightforward. One global
regulator of ribosome biogenesis and translation is
mTORC1, which coordinates cellular responses to sig-
naling pathways involved in sensing growth factors, nutri-
ent availability, intracellular energy status and other
perceived cell stresses and modulates translation and
ribosome biogenesis in response [14]. In particular,
mTORC1 can influence translation initiation via phos-
phorylation of eukaryotic initiation factor 4E binding
protein (4E-BP1), which when phosphorylated at multi-
ple sites promotes dissociation of 4E-BP1 from the initi-
ation factor eIF4E. Increased phosphorylation of 4E-BP1
has been correlated with increased interferon-g produc-
tion [15] whilst the stoichiometry of 4E-BP1 to eIF4E is
reported to relate to recombinant antibody productivity
[16]. Exogenous mTOR expression has also been shown
to enhance recombinant protein expression in CHO cells
by improving cell viability, growth, proliferation and cell
specific productivity [17].
One approach applied to investigate mRNA amounts, and
hence determine gene expression profiles of high produc-
ing or fast growing recombinant cell lines is
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Table 1
Summary of non-coding RNA cell engineering studies discussed in this review grouped by type of approach, with the reported
experimental effect and the appropriate reference
Method Effect Reference
siRNA LDH-A activities were decreased by 75–89%, while the specific glucose consumption rates reduced by 54–
87% and the specific lactate production rates reduced to 45–79% of the control cell line level.
[32]
siRNA mediated inhibition of PDHKs and LDH-A in CHO cells expressing a therapeutic monoclonal antibody
reduced lactate production, increased specific productivity and volumetric antibody production by 90%, 75%
and 68%, respectively.
[33]
Ribosome profiling identified NeoR as a highly transcribed and translated gene in an IgG-producing CHO cell
line. Viable cell concnetration was increased by 35% upon siRNA knock-down of NeoR, which was
accompanied by an 18% increase in product titer.
[34]
Combined transient siRNA-mediated knockdown of the expression of the endoplasmic reticulum localized
proteins CerS2 and Tbc1D20 resulted in a 50–66% increase in specific productivity of CHO-IgG cells.
[35]
miRNA Co-expression of miR-557 and a difficult-to-express antibody resulted in a two-fold increase in product titer. [27]
miR-143 overexpression resulted in a 20% final increase in mAb productivity. [28]
Addition of a synthetic 3’UTR to destabilize DHFR expression allowed the generation of stable DG44-derived
cell pools expressing a model monoclonal antibody (mAb) with low MTX concentrations.
[29]
Inhibition of miR-124-3p and miR-19b-3p in CHO increased X-linked inhibitor of apoptosis protein levels,
enhancing CHO cell growth and prolonged culture longevity while additionally boosting productivity.
[31!]
lncRNA Engineering of CHO cells with SINEUP long non-coding RNAs resulted in a 150% increase in periostin levels in
cell supernatant at 72 h post-transfection.
[50!!]
The development of a ’universal’ protein expression enhancer tool based upon long non-coding RNAs gave
expression enhancement in various mammalian cells of recombinant proteinsin the order of 50-1000%, with
more than 200% enhancement in most cases.
[51!]
Codon optimization Modification of human interleukin-2 (IL-2) through codons with high gene copy number and high codon usage
bias significantly increased protein productivity in CHO-K1 cells.
[52]
Codon de-optimization of a bispecific antibody sequence through the introduction of less frequently occurring
codons in CHO gave a 2-fold final yield increase.
[55]
In vivo expression of various codon context (CC) optimized IFN-g in CHO cells exhibited at least 13-fold
increase in expression compared to the wild-type IFN-g while a maximum of 10-fold increase was observed
for the individual codon usage (ICU) optimized genes.
[60]
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transcriptomics. A general assumption of most such stud-
ies is that the amount of mRNA present at a given
timepoint reflects the ‘state’ or ‘need’ of a cell with regard
to the proteins that these mRNAs encode for. As such,
transcriptomic profiling has been applied to identify
mRNAs whose abundance correlates with cell growth
and recombinant protein productivity and quality with
a view to using the identification of such targets to
engineer the cell for improved performance. Many of
these initial studies were hampered by the lack of the
CHO genome and appropriate arrays, however the eluci-
dation of the genome [18,19] and advent of RNA-Seq has
made it possible to undertake such studies with a higher
degree of precision. Despite this, there has been little
consensus across transcriptomic studies to date with
regard to those mRNAs that correlate with cell growth
and recombinant protein productivity [20]. Further, pre-
vious correlation analysis has shown that transcript
amounts and translation efficiency are uncoupled for
around 95% of investigated genes [21], providing strong
evidence that global and mRNA specific translational
control needs to be understood and determined to evalu-
ate the impact of mRNAs on phenotype rather than
simple mRNA abundance itself.
In order to address this issue, investigators have begun to
apply ribosome footprint profiling or RiboSeq analysis to
unravel the fine detail of translational control in CHO
cells [22]. This powerful approach allows genome wide,
but also transcript specific, detail on initiation and elon-
gation stages of mRNA translation to be studied and
identification of those mRNAs that are being translated
at any given time (as opposed to just their abundance), the
efficiency of mRNA translation and how this changes
during a process or between cell lines to identify targets
for cell line engineering [22]. Indeed, any given mRNA in
the cell may be translated by one or multiple ribosomes
(so call polysomes) at any one time [23]. In some cases the
number of ribosomes per transcript has been used to
estimate translational efficiency of a transcript assuming
that more ribosomes on a transcript indicates greater
translational efficiency [24], but this does not account
for elongation speed that RiboSeq analysis can. RNA-Seq
approaches can also potentially be used to investigate
translational activity at the single cell level. The applica-
tion of such approaches is certain to provide a more
detailed understanding of mRNA translation and its
control in recombinant protein producing CHO cells, at
the population and single cell level and at a global and
transcript specific level, revealing new engineering
approaches by which translation can be modulated to
enhance protein production.
MicroRNAs and siRNAs
mRNA translation can also be tuned by non-coding
RNAs. One such class of non-coding RNA that has been
applied to reprogramming translation in CHO cells is that
of microRNAs (also known as miRs or miRNAs). The
potential application of microRNAs to CHO cell engi-
neering has recently been reviewed elsewhere [25].
These RNAs are transcribed as long primary transcripts
but then processed to yield small (20–23 nucleotide) non-
coding RNAs and were first described in Caenorhabditis
elegans. MicroRNAs tend to act as repressors of translation
of target mRNAs by interacting with the 30untranslated
regions (30UTRs) of such mRNAs. A given microRNA
can in theory target multiple mRNAs via base pairing and
hence modulate multiple mRNAs and pathways without
placing an additional translational burden on the cell [25].
Early microRNA studies were limited by the lack of
available Chinese hamster sequence annotation of micro-
RNA primary transcripts, and hence chimeric microRNAs
that contained the mature miR sequence but flanking
sequences in the primary transcript from other species
were used. Subsequent studies showed that endogenous
CHO microRNA flanking sequences gave rise to higher
expression when over expressing microRNAs [26].
Recent engineering approaches harnessing microRNAs
include studies that look to enhance the ability of CHO
cells to produce so called ‘difficult to express proteins’.
For example, one such study showed that a CHO cell line
constitutively over expressing miR-557 and a difficult to
express antibody produced twice the antibody yield of
cells engineered to express a negative control microRNA
[27]. A further study reported that both transient and
stable miR-143 over expression resulted in enhanced
difficult to express protein production and targeted
MAPK7 in CHO [28]. The natural repertoire of micro-
RNAs has also been harnessed to repress expression of
the DHFR selection marker during cell line construction
and allow the generation of higher producing cell pools
[29]. Others have shown that microRNA fingerprints or
signatures can be correlated with growth rate across a
number of different CHO cell lines [30].
However, although microRNA engineering appears an
attractive approach by which to tune translation of multi-
ple mRNAs and translation of specific targets, the poten-
tial large number of predicted targets of any given micro-
RNA means that the outcome of such engineering
approaches can be difficult to predict as is identifying
which targets a given microRNA interacts with. Barron
and colleagues have described a system termed ‘miR-
CATCH’ that allows the investigator to identify those
microRNAs that interact with a given target and thus
validate these for potential cell engineering approaches
[31!]. The authors had identified that the overexpression
of the X-linked inhibitor of apoptosis (XIAP) enhanced
CHO cell productivity, growth and culture longevity. To
avoid overexpressing this gene and placing an additional
translational burden on the cell, microRNA regulators of
XIAP were identified using a biotin-labelled antisense
DNA for XIAP resulting in the capture of interacting
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microRNAs. Inhibition of two of these microRNAs
resulted in increased XIAP protein expression, validating
the microRNA catch approach and the utility of this for
identifying cell engineering targets.
The use of small interfering RNAs (siRNAs) has also
proved to be an effective strategy for CHO cell line
engineering to selectively knockdown expression of tar-
get genes detrimental to cell growth or productivity. The
advantage of knockdown, as opposed to knockout strate-
gies, is that essential genes can be reduced in their
expression and the impact on cell phenotype assessed
when knockout proves fatal. One successful application
of siRNA engineering has been the inhibition of lactate
dehydrogenase-A (LDH-A) on its own [32], or in combi-
nation with pyruvate dehydrogenase kinases (PDHKs)
[33] to significantly reduce lactate accumulation in cul-
tured CHO cells without negatively impacting cell
growth and enhancing cell specific productivity. A further
group undertook ribosomal profiling in CHO cells and
identified the resistance marker NeoR as being highly
transcribed and translated, and as expression of this
exogenous gene in CHO cells is not required, used siRNA
knockdown to reduce its expression with a resultant
improvement in production and growth of the host
observed [34]. Finally, an siRNA approach was used to
knockdown the expression of the endoplasmic reticulum
localized proteins ceramide synthase 2 (CerS2) and Rab1
GAP Tbc domain family member 20 (Tbc1D20) in CHO
IgG producing cells with a subsequent observed increase
in recombinant protein specific productivity and
enhanced cell growth [35].
Long non"coding RNAs (lncRNAs) and their
manipulation
Recent genome wide analysis in mammalian cells esti-
mates that 75% of the transcriptome is composed of non-
coding sequences [36] and led to the identification of a
heterogeneous class of transcripts known as Long non-
coding RNAs (lncRNAs) [37]. LncRNAs are defined as
transcripts longer than 200 nucleotides that lack a signifi-
cant open reading frame (ORF) and are usually tran-
scribed by RNA polymerase II and spliced, with or
without, 30 polyadenylation [38]. These molecules are
emerging as key regulators in various biological processes
both in the nucleus and the cytoplasm [39], including
epigenetic regulation, transcriptional control, splicing
events, and mRNA translation. While most of our current
understanding into lncRNAs and the underlying mecha-
nism(s) by which they elicit their responses has come
from studies relating to disease and developmental stud-
ies, their potential as targets for cell engineering in
mammalian cell factories remains largely unexplored.
The first analysis of the non-coding transcriptome in
CHO cells under batch and fed-batch conditions has
recently been published, unveiling a number of
differentially regulated lncRNAs depending on feed
and culture time which could be targets for cell engineer-
ing [40!]. One of the main challenges in identifying
lncRNAs is the low sequence conservation between
species. This, coupled with incomplete genome
sequences and partial annotations of coding and non-
coding genes of most vertebrates including Chinese ham-
ster, have impaired an effective lncRNAs annotation
outside from model organisms (Figure 1).
A recent study compared lncRNAs among 16 vertebrates
and the echinoid sea urchin finding thousands of human
lincRNAs homologs with conserved genomic position
sharing 50-biased patches of sequence nested in rewired
exonic architectures [41]. The FANTOM consortium
applied a cap analysis of gene expression (CAGE) to data
obtaining more than 27,919 human lncRNA genes with
high-confidence 50 ends and expression profiles across
1829 samples from the major human primary cell types
and tissues [42]. Through the incorporation of conserva-
tion and expression data, the consortium was able to
identify 19,175 potentially functional lncRNAs in the
human genome. Because of the tissue-specificity of
lncRNAs, comparing the expression among several cell
types has led to a more robust identification of functional
targets. By modelling their effects on the activity of
transcription factors, RNA-binding proteins, and micro-
RNAs in 5185 TCGA tumors and 1019 ENCODE assays,
it was possible to identify potential lncRNAs involved in
dysregulated cancer pathways. This approach indicated
OIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, as syner-
gic lncRNAs leading to dysregulated cancer pathways in
multiple tumor contexts [43]. A similar effort using
nascent RNA capture sequencing identified 1145 tempo-
rally expressed S-phase-enriched lncRNAs across TCGA
data sets in several cancer models showing effects on
pathways including FGF/FGFR and its downstream
PI3K/AKT and MAPK pathways [44].
The NEAT1 lncRNA is a central component of para-
speckles, nuclear bodies that regulate multiple aspects of
gene expression, promoting their formation through ATR
signaling in response to replication stress and p53 activa-
tion [45]. The RNA-binding NONO–PSF heterodimer
binds a large number of expressed pri-miRNAs in the
paraspeckles to promote processing by the Drosha–
DGCR8 Microprocessor. NEAT1 thus regulates efficient
processing of potentially an entire class of small non-
coding RNAs in the nucleus by interaction with the
NONO–PSF heterodimer as well as other ribosome
binding proteins (RBPs) [46].
The relationship between lncRNAs and the translational
machinery was further elucidated with the discovery of a
long nucleolus-specific lncRNA (LoNA) [47!]. LoNA is
expressed at high levels at resting state suppressing
rRNAs transcription in the nucleoli through the
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combined effects of its 50 portion, which binds and
sequesters nucleolin, and its snoRNA like 30 end, which
recruits and diminishes fibrillarin activity to reduce rRNA
methylation. When the cell needs to sustain an elevated
translational load, LoNA expression decreases leading to
elevated rRNA and ribosome levels, an increased propor-
tion of polysomes, mRNA polysome loading, and even-
tually protein synthesis.
The first successful engineering of lncRNAs for enhanced
recombinant protein production involved manipulation of
SINEUPs, natural and synthetic antisense lncRNAs that
can activate translation in a gene-specific manner using an
inverted SINEB2 sequence [48]. A Binding Domain (BD)
located towards the 50 region of the SINEUP overlaps a
target mRNA of choice conferring specificity, while an
inverted SINEB2 element defined as the Effector
Domain (ED) provides the translation activation function
[49]. Synthetic SINEUPs have been used to increase
translation and secretion of recombinant proteins in a
range of mammalian cell lines, including CHO [50!!] and
HEK293 [51!]. As further studies define those lncRNAs
present in CHO cells and how these influence cell
growth, fate and recombinant protein production, engi-
neering of these non-coding RNAs is sure to offer poten-
tial to further tune and enhance mRNA specific and
global mRNA translational efficiency.
tRNAs and translation
The use of specific codons with high gene copy number
and high codon bias coupled with the modulation of
intracellular tRNA concentration has been shown to
improve protein production in CHO cells [52]. However,
despite translational efficiency often being considered
the mere result of codon optimization based on the
correlation between codon bias and tRNA gene copy
numbers (Figure 2), recent evidence suggests a consider-
ably more intricate picture where ribosome collisions, co-
translational folding, mRNA stability, composition,
charge status and post-transcriptional modifications of
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The figure shows the number of genes for each annotated class in the ENSEMBL database for Chinese hamster (CriGri_1.0, GCA_000223135.1
and CHOK1GS_HDv1, GCA_900186095.1), mouse (GRCm38.p6, GCA_000001635.8) and human (GRCh38.p12, GCA_000001405.27). While the
number of coding genes is comparable between the four organisms, human contains 14,720 and mouse 9443 annotated long non-coding genes
as compared to 2563 for CriGri.
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the tRNA pool all contribute to finely tune protein
production in response to the environment [53]. Control-
ling the translational capacity of an expression system
through the use of alternative codon combinations mod-
ulates ribosome decoding speed, impacting protein qual-
ity as well as final yield [54]. The use of suboptimal
codons has been reported to slow translation at key
structural motifs in order to facilitate correct co-transla-
tional polypeptide folding and signal recognition particle
(SRP) recognition, which assists in protein translocation
across membranes [55]. Thus, although recombinant
genes are often ‘codon optimized’, we do not currently
have all the information required around codon usage,
context, tRNA abundance, modifications and charging to
fully harness codon usage in recombinant sequences or to
engineer tRNA abundance.
Codon bias has been referred to as a secondary genetic
code that impacts on the fidelity of translation, efficiency
of translation, polypeptide/protein folding and mRNA
stability/half-life [56]. The cell utilizes such codon effects
to tailor the proteome and allow reprogramming, such as
under cold stress whereby reprogramming and synthesis
of specific proteins is enhanced through codon bias [10].
Codon bias or optimization is also linked to tuning mRNA
stability and stable mRNAs are found to be enriched in
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The gene copy numbers for each codon were retrieved from the genomic tRNA database (GtRNAdb) while the codon usage was sourced from
either the Codon Usage Database (kazusa.or.jp/codon/), indicated as ‘Kazusa’, or the Codon Usage Table Database (hive.biochemistry.gwu.edu/
review/codon), indicated as ‘Hive’. For each aminoacid, the summary of every single codon coding for the same aminoacid is shown as a % of
the total. Cricetulus griseus (CriGri) is shown in blue, Human in grey, and Mouse in orange. The figure shows in panel (a) the correlation between
the Hive and gene copy number, panel (b) shows the correlation between the Kazusa and gene copy number and panel (c) shows the correlation
between Kazusa and Hive. The two databases perform similarly, giving a significantly higher correlation (R = 0.68–0.70) with a lower p-value
(0.0007 and 0.0004) for Human, while Mouse and CriGri have lower correlations and higher p-values.
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codons that are considered optimal whilst also impacting
on ribosome translocation [57]. Specific combinations of
adjacent codons in yeast and mammalian cells can have an
effect on translation efficiency resulting in reduced
expression, proving how the focus must be on global
translation efficiency and codon context as opposed to
single codons optimality [58!,59,60]. On top of this,
mRNA secondary structure combined with tRNA abun-
dance modulate translational elongation speed among
different regions of the same transcript to avoid exces-
sively slow or fast ribosome movement [61]. As such,
there remains enormous potential to enhance recombi-
nant protein yields from further manipulation of codon
usage.
In order to further enhance recombinant protein yields by
manipulation of codon usage it is necessary to further
understand the abundance and modifications of tRNAs
and the role these play in their activity. Determination of
tRNA copy numbers can now be undertaken using RNA-
Seq approaches. tRNA secondary structure and nucleo-
tide modifications, mainly methylations, impair the effi-
ciency of standard sequencing. Dedicated protocols based
on an initial de-methylation step were recently developed
to overcome this limitation, allowing for direct measure-
ment of each tRNA abundance and detailed mapping of
modifications [62,63]. While some methods focus exclu-
sively on mature tRNAs [64], partial alkaline RNA hydro-
lysis complemented with tRNA precursors enrichment
identified tRNA leaders, trailers, and introns and showed
that around half of all predicted tRNA genes are tran-
scribed in human cells [65]. While tRNA abundance is a
major modulator of translational elongation, the aminoa-
cylation state has to also be considered. The addition of
chemical steps that specifically remove the 30A residue in
uncharged tRNA coupled with the aforementioned de-
methylation RNA-Seq protocols showed most cytosolic
tRNAs in HEK293T cells are charged at >80% levels,
whereas tRNASer and tRNAThr are charged at lower
levels [66].
An additional layer of regulation during elongation is
chemical modification of nucleotides among tRNAs
[67]. One of the key enzymes to regulate the methylation
state of tRNAs is the demethylase ALKBH1, which acts
dynamically in response to specific conditions such as
variations in glucose availability to impact translation at
both the initiation and the elongation phases [68]. These
modifications can have different effects depending on the
target tRNA and the position in the transcript, as it was
shown ALKBH1 is required for the formation of essential
methylations at position 34 of anticodon in cytoplasmic
tRNALeu and mitochondrial tRNAMet [69]. Advances in
high-throughput sequencing and data analysis have also
allowed the identification of new classes of small non-
coding RNAs derived from tRNAs: stress-induced tRNA
halves (tiRs) and tRNA-related fragments (tRFs). These
RNAs act on cell proliferation, priming of viral reverse
transcriptase, regulation of gene expression, RNA proces-
sing, modulation of the DNA damage response, tumor
suppression, and stress response [70]. The application of
such approaches to study tRNAs in CHO cells will further
elucidate the mechanism(s) by which tRNAs and their
modifications modulate translation.
Future directions and challenges
Our understanding and ability to manipulate the transla-
tional machinery and harness non-coding RNAs to
enhance global and recombinant protein synthesis in
CHO cells has advanced rapidly in the last decade.
Further, the advent of the Chinese hamster and CHO
cell line genomes has helped in the identification of non-
coding RNAs such that these can be studied and manip-
ulated. The ability of non-coding RNAs, in particular
microRNAs, siRNAs, lncRNAs and tRNAs to tune both
global and transcript specific translation, and hence pro-
tein synthesis, offers enormous opportunities to use these
to enhance cell growth and proliferation, extend culture
lifetimes, and increase recombinant protein yields and
quality. However, our ability to harness these non-coding
RNAs by engineering of CHO cells is currently limited by
our knowledge of the mechanisms and targets by which
many of these non-coding RNAs elicit their responses.
The manipulation of microRNAs that can, in theory, tune
multiple target transcripts appears an appealing approach,
however in our view this approach alone is unlikely to
deliver new commercially viable host cells with dramati-
cally enhanced phenotypes due to the fact these are
‘tuning’ molecules and tend to be negative regulators
and off target approaches can be difficult to control.
Where these might be more applicable is for the tuning
of transcript targets with a specific role, such as enzymes
involved in glycosylation or to harness modulation of the
cells own endogenous microRNA pool as inducible con-
trollers of exogenous gene circuits. The potential of
lncRNA engineering is very much in its infancy and
would appear to offer the potential to act as negative
and positive regulators of gene expression. The limitation
here is that many of these are, as the name suggests, long
RNAs and thus the manipulation is more challenging and
we do not yet understand what, if any, role many of these
play in the cell. The control of gene expression via the
elongation step of mRNA translation and tRNA availabil-
ity, charging and modification, linked with improved
predictive models for how such changes in abundance
or modification change elongation rates of target mRNAs
is likely to offer advances that can be directly applied
industrially to engineering of the target recombinant gene
(s) and of pathways in the cell to deliver new engineered
host cell lines with improved growth, productivity and
post-translational modification abilities. However, the
major challenge will be to unravel the mechanisms by
which the control on gene expression that these different
non-coding RNAs provide are coordinated together, in
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order to reprogram the translational efficiency of current
CHO cell chassis, under appropriate bioprocessing con-
ditions (including continuous processes) to generate new
chassis with enhance bioprocessing properties.
Conflict of interest statement
Nothing declared.
Acknowledgement
The authors acknowledge the European Commission for funding this work
(EC - Horizon 2020 MSCA ITN 2014 - 642663).
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
! of special interest
!! of outstanding interest
1. Povey JF, O’Malley CJ, Root T, Martin EB, Montague GA, Feary M,
Trim C, Lang DA, Alldread R, Racher AJ, Smales CM: Rapid high-
throughput characterisation, classification and selection of
recombinant mammalian cell line phenotypes using intact cell
MALDI-ToF mass spectrometry fingerprinting and PLS-DA
modelling. J Biotechnol 2014, 184:84-93 http://dx.doi.org/
10.1016/j.jbiotec.2014.04.028.
2. Kunert R, Reinhart D: Advances in recombinant antibody
manufacturing. Appl Microbiol Biotechnol 2016, 100:3451-3461
http://dx.doi.org/10.1007/s00253-016-7388-9.
3. Mead EJ, Masterton RJ, Feary M, Obrezanova O, Zhang L,
Young R, Smales CM: Biological insights into the expression of
translation initiation factors from recombinant CHOK1SV cell
lines and their relationship to enhanced productivity. Biochem
J 2015, 472:261-273 http://dx.doi.org/10.1042/BJ20150928.
4. Schwanha¨usser B, Busse D, Li N, Dittmar G, Schuchhardt J,
Wolf J, Chen W, Selbach M: Global quantification of mammalian
gene expression control. Nature 2011, 473:337-342 http://dx.
doi.org/10.1038/nature10098.
5. Janakiraman H, House RP, Gangaraju VK, Diehl JA, Howe PH,
Palanisamy V: The long (lncRNA) and short (miRNA) of it: TGFb-
mediated control of RNA-binding proteins and noncoding
RNAs. Mol Cancer Res 2018, 16:567-579 http://dx.doi.org/
10.1158/1541-7786.MCR-17-0547.
6. McLeod J, O’Callaghan PM, Pybus LP, Wilkinson SJ, Root T,
Racher AJ, James DC: An empirical modeling platform to
evaluate the relative control discrete CHO cell synthetic
processes exert over recombinant monoclonal antibody
production process titer. Biotechnol Bioeng 2011, 108:2193-
2204 http://dx.doi.org/10.1002/bit.23146.
7. Underhill MF, Birch JR, Smales CM, Naylor LH: eIF2a
phosphorylation, stress perception, and the shutdown of
global protein synthesis in cultured CHO cells. Biotechnol
Bioeng 2005, 89:805-814 http://dx.doi.org/10.1002/bit.20403.
8. Masterton RJ, Roobol A, Al-Fageeh MB, Carden MJ, Smales CM:
Post-translational events of a model reporter protein proceed
with higher fidelity and accuracy upon mild hypothermic
culturing of Chinese hamster ovary cells. Biotechnol Bioeng
2010, 105:215-220 http://dx.doi.org/10.1002/bit.22533.
9. Wang K, Zhang T, Chen J, Liu C, Tang J, Xie Q: The effect of
culture temperature on the aggregation of recombinant TNFR-
Fc is regulated by the PERK-eIF2a pathway in CHO cells.
Protein Pept Lett 2018, 25:570-579 http://dx.doi.org/10.2174/
0929866525666180530121317.
10. Bastide A, Peretti D, Knight JRP, Grosso S, Spriggs RV, Pichon X,
Sbarrato T, Roobol A, Roobol J, Vito D et al.: RTN3 is a novel cold-
induced protein and mediates neuroprotective effects of
RBM3. Curr Biol 2017, 27:638-650 http://dx.doi.org/10.1016/j.
cub.2017.01.047.
11. Mead EJ, Chiverton LM, Spurgeon SK, Martin EB, Montague GA,
Smales CM, von der Haar T: Experimental and in silico
modelling analyses of the gene expression pathway for
recombinant antibody and by-product production in NS0 cell
lines. PLoS One 2012, 7 http://dx.doi.org/10.1371/journal.
pone.0047422 e47422.
12. Roobol A, Roobol J, Bastide A, Knight JRP, Willis AE, Smales CM:
p58IPK is an inhibitor of the eIF2a kinase GCN2 and its
localization and expression underpin protein synthesis and ER
processing capacity. Biochem J 2015, 465:213-225 http://dx.
doi.org/10.1042/BJ20140852.
13. O’Callaghan PM, McLeod J, Pybus LP, Lovelady CS, Wilkinson SJ,
Racher AJ, Porter A, James DC: Cell line-specific control of
recombinant monoclonal antibody production by CHO cells.
Biotechnol Bioeng 2010, 106:938-951 http://dx.doi.org/10.1002/
bit.22769.
14. Foster KG, Fingar DC: Mammalian target of rapamycin (mTOR):
conducting the cellular signaling symphony. J Biol Chem 2010,
285:14071-14077 http://dx.doi.org/10.1074/jbc.R109.094003.
15. Chong WPK, Sim LC, Wong KTK, Yap MGS: Enhanced
IFNgamma production in adenosine-treated CHO cells: a
mechanistic study. Biotechnol Prog 2009, 25:866-873 http://dx.
doi.org/10.1002/btpr.118.
16. Josse´ L, Xie J, Proud CG, Smales CM: mTORC1 signalling and
eIF4E/4E-BP1 translation initiation factor stoichiometry
influence recombinant protein productivity from GS-CHOK1
cells. Biochem J 2016, 473:4651-4664 http://dx.doi.org/10.1042/
BCJ20160845.
17. Dreesen IAJ, Fussenegger M: Ectopic expression of human
mTOR increases viability, robustness, cell size, proliferation,
and antibody production of chinese hamster ovary cells.
Biotechnol Bioeng 2011, 108:853-866 http://dx.doi.org/10.1002/
bit.22990.
18. Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M,
Wang W, Hammond S et al.: The genomic sequence of the
Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol 2011
http://dx.doi.org/10.1038/nbt.1932.
19. Lewis NE, Liu X, Li Y, Nagarajan H, Yerganian G, O’Brien E,
Bordbar A, Roth AM, Rosenbloom J, Bian C et al.: Genomic
landscapes of Chinese hamster ovary cell lines as revealed by
the Cricetulus griseus draft genome. Nat Biotechnol 2013 http://
dx.doi.org/10.1038/nbt.2624.
20. Tamoaitis L, Smales CM: Meta-analysis of publicly available
Chinese Hamster Ovary (CHO) cell transcriptomic datasets for
identifying engineering targets to enhance recombinant
protein yields. Biotechnol J 2018 http://dx.doi.org/10.1002/
biot.201800066. e1800066.
21. Courtes FC, Lin J, Lim HL, Ng SW, Wong NSC, Koh G, Vardy L,
Yap MGS, Loo B, Lee D-Y: Translatome analysis of CHO cells to
identify key growth genes. J Biotechnol 2013, 167:215-224
http://dx.doi.org/10.1016/j.jbiotec.2013.07.010.
22. Tzani I, Monger C, Kelly P, Barron N, Kelly RM, Clarke C:
Understanding biopharmaceutical production at single
nucleotide resolution using ribosome footprint profiling. Curr
Opin Biotechnol 2018, 53:182-190 http://dx.doi.org/10.1016/j.
copbio.2018.01.030.
23. Godfrey CL, Mead EJ, Daramola O, Dunn S, Hatton D, Field R,
Pettman G, Smales CM: Polysome profiling of mAb producing
CHO cell lines links translational control of cell proliferation
and recombinant mRNA loading onto ribosomes with global
and recombinant protein synthesis. Biotechnol J 2017, 12 http://
dx.doi.org/10.1002/biot.201700177 1700177.
24. Liu B, Qian S-B: Characterizing inactive ribosomes in
translational profiling. Transl (Austin, Tex) 2016, 4 http://dx.doi.
org/10.1080/21690731.2015.1138018 e1138018.
25. Valde´s-Bango Curell R, Barron N: Exploring the potential
application of short non-coding RNA-based genetic circuits in
Chinese hamster ovary cells. Biotechnol J 2018 http://dx.doi.
org/10.1002/biot.201700220. 1700220.
26. Klanert G, Jadhav V, Chanoumidou K, Grillari J, Borth N, Hackl M:
Endogenous microRNA clusters outperform chimeric
206 Biotechnology and bioprocess engineering: biomanufacturing
Current Opinion in Chemical Engineering 2018, 22:199–208 www.sciencedirect.com
sequence clusters in Chinese hamster ovary cells. Biotechnol J
2014, 9:538-544 http://dx.doi.org/10.1002/biot.201300216.
27. Fischer S, Marquart KF, Pieper LA, Fieder J, Gamer M, Gorr I,
Schulz P, Bradl H: miRNA engineering of CHO cells facilitates
production of difficult-to-express proteins and increases
success in cell line development. Biotechnol Bioeng 2017,
114:1495-1510 http://dx.doi.org/10.1002/bit.26280.
28. Schoellhorn M, Fischer S, Wagner A, Handrick R, Otte K: miR-143
targets MAPK7 in CHO cells and induces a hyperproductive
phenotype to enhance production of difficult-to-express
proteins. Biotechnol Prog 2017, 33:1046-1058 http://dx.doi.org/
10.1002/btpr.2475.
29. Josse´ L, Zhang L, Smales CM: Application of microRNA
targeted 3’UTRs to repress DHFR selection marker
expression for development of recombinant antibody
expressing CHO cell pools. Biotechnol J 2018 http://dx.doi.org/
10.1002/biot.201800129.
30. Klanert G, Jadhav V, Shanmukam V, Diendorfer A, Karbiener M,
Scheideler M, Bort JH, Grillari J, Hackl M, Borth N: A signature of
12 microRNAs is robustly associated with growth rate in a




Griffith A, Kelly PS, Vencken S, Lao NT, Greene CM, Clynes M,
Barron N: miR-CATCH identifies biologically active miRNA
regulators of the pro-survival gene XIAP, in Chinese hamster
ovary cells. Biotechnol J 2018, 13 http://dx.doi.org/10.1002/
biot.201700299 1700299.
The authors developed a system to identify and validate microRNAs that
target a specific mRNA and used this to identify microRNAs that nega-
tively regulate the pro-survival gene XIAP. They subseqeuntly show that
reducing or inhibiting two of the microRNAs that target this transcript
resulted in enhanced XIAP expression and prolonged culture duration.
32. Kim SH, Lee GM: Down-regulation of lactate dehydrogenase-A
by siRNAs for reduced lactic acid formation of Chinese
hamster ovary cells producing thrombopoietin. Appl Microbiol
Biotechnol 2007, 74:152-159 http://dx.doi.org/10.1007/s00253-
006-0654-5.
33. Zhou M, Crawford Y, Ng D, Tung J, Pynn AFJ, Meier A, Yuk IH,
Vijayasankaran N, Leach K, Joly J, Snedecor B, Shen A:
Decreasing lactate level and increasing antibody production
in Chinese Hamster ovary cells (CHO) by reducing the
expression of lactate dehydrogenase and pyruvate
dehydrogenase kinases. J Biotechnol 2011, 153:27-34 http://dx.
doi.org/10.1016/j.jbiotec.2011.03.003.
34. Kallehauge TB, Li S, Pedersen LE, Ha TK, Ley D, Andersen MR,
Kildegaard HF, Lee GM, Lewis NE: Ribosome profiling-guided
depletion of an mRNA increases cell growth rate and protein
secretion. Sci Rep 2017, 7:40388 http://dx.doi.org/10.1038/
srep40388.
35. Pieper LA, Strotbek M, Wenger T, Gamer M, Olayioye MA,
Hausser A: Secretory pathway optimization of CHO producer
cells by co-engineering of the mitosRNA-1978 target genes
CerS2 and Tbc1D20. Metab Eng 2017, 40:69-79 http://dx.doi.org/
10.1016/j.ymben.2017.01.003.
36. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A,
Tanzer A, Lagarde J, Lin W, Schlesinger F et al.: Landscape of
transcription in human cells. Nature 2012, 489:101-108 http://
dx.doi.org/10.1038/nature11233.
37. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R,
Willingham AT, Stadler PF, Hertel J, Hackermuller J, Hofacker IL
et al.: RNA maps reveal new RNA classes and a possible
function for pervasive transcription. Science 2007, 316:1484-
1488 http://dx.doi.org/10.1126/science.1138341.
38. Wilusz JE: Long noncoding RNAs: re-writing dogmas of RNA
processing and stability. Biochim Biophys Acta 2016, 1859:128-
138 http://dx.doi.org/10.1016/j.bbagrm.2015.06.003.
39. Geisler S, Coller J: RNA in unexpected places: long non-coding




Vito D, Smales CM: The long non-coding RNA transcriptome
landscape in CHO cells under batch and fed-batch conditions.
Biotechnol J 2018 http://dx.doi.org/10.1002/biot.201800122.
e1800122.
This is the first report of the global lncRNA transcritpome landscape in
CHO cells, using an array approach to identify the presence of lncRNAs,
qPCR to confirm the array results on selected transcripts and demon-
strates how these change during batch and fed-batch culture.
41. Hezroni H, Koppstein D, Bartel DP, Ulitsky I: Principles of long
noncoding RNA evolution derived from direct comparison of
transcriptomes in 17 species. Cell Rep 2015, 11:1110-1122
http://dx.doi.org/10.1016/j.celrep.2015.04.023 Correspondence,
M.G. Schwartz, A. Avrutin, I. Ulitsky.
42. Hon CC, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJL,
Gough J, Denisenko E, Schmeier S, Poulsen TM, Severin J et al.:
An atlas of human long non-coding RNAs with accurate 50
ends. Nature 2017, 543:199-204 http://dx.doi.org/10.1038/
nature21374.
43. Chiu H-S, Somvanshi S, Patel E, Sood AK, Gunaratne PH,
Correspondence PS, Chen T-W, Singh VP, Zorman B, Patil SL
et al.: Pan-Cancer analysis of lncRNA regulation supports their
targeting of cancer genes in each tumor context. Cell Rep
2018, 23:297-312 http://dx.doi.org/10.1016/j.celrep.2018.03.064.
44. Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-
Figuiere M, Abrahamsson J, Mondal T, Kanduri C: PAN-cancer
analysis of S-phase enriched lncRNAs identifies oncogenic
drivers and biomarkers. Nat Commun 2018, 9 http://dx.doi.org/
10.1038/s41467-018-03265-1.
45. Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P,
Boeckx B, Wijnhoven PWG, Radaelli E, Vermi W et al.: p53
induces formation of NEAT1 lncRNA-containing paraspeckles
that modulate replication stress response and
chemosensitivity. Nat Med 2016, 22:861-868 http://dx.doi.org/
10.1038/nm.4135.
46. Jiang L, Shao C, Wu QJ, Chen G, Zhou J, Yang B, Li H, Gou LT,
Zhang Y, Wang Y et al.: NEAT1 scaffolds RNA-binding proteins
and the microprocessor to globally enhance pri-miRNA




Li D, Zhang J, Wang M, Li X, Gong H, Tang H, Chen L, Wan L, Liu Q:
Activity dependent LoNA regulates translation by
coordinating rRNA transcription and methylation. Nat Commun
2018, 9 http://dx.doi.org/10.1038/s41467-018-04072-4.
The authors demonstrate how a specific long non-coding RNA plays a
pivitol role in regulating translation by coordinating rRNA transcription
and methylation making this a target for cell engineering.
48. Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S,
Pesce E, Ferrer I, Collavin L, Santoro C: Long non-coding
antisense RNA controls Uchl1 translation through an
embedded SINEB2 repeat. Nature 2012 http://dx.doi.org/
10.1038/nature11508.
49. Podbevek P, Fasolo F, Bon C, Cimatti L, Reißer S, Carninci P,
Bussi G, Zucchelli S, Plavec J, Gustincich S: Structural
determinants of the SINE B2 element embedded in the long




Patrucco L, Chiesa A, Soluri MF, Fasolo F, Takahashi H,
Carninci P, Zucchelli S, Santoro C, Gustincich S, Sblattero D,
Cotella D: Engineering mammalian cell factories with SINEUP
noncoding RNAs to improve translation of secreted proteins.
Gene 2015, 569:287-293 http://dx.doi.org/10.1016/j.
gene.2015.05.070.
The authors report the first engineering of CHO cells with SINEUP long
non-coding RNAs. They subsequently show that this resulted in
enhanced translation of recombinant proteins and increased secretory




Yao Y, Jin S, Long H, Yu Y, Zhang Z, Cheng G, Xu C, Ding Y,
Guan Q, Li N et al.: RNAe: An effective method for targeted
protein translation enhancement by artificial non-coding RNA
with SINEB2 repeat. Nucleic Acids Res 2015, 43 http://dx.doi.
org/10.1093/nar/gkv125.
The authors develop a ’universal’ protein expression enhancer tool based
upon long non-coding RNA elements. The authors identifed a minimal
RNAe element which consists of a pairing sequence for specificity, a short
non-pairing interspersed nuclear element that enhnaces ribosome
Engineering non-coding RNAs in CHO cells Vito and Smales 207
www.sciencedirect.com Current Opinion in Chemical Engineering 2018, 22:199–208
recruitment and a polyA tail. The authors claim expression enhancement
in various mammalian cells of recombinant proteins in the order of 50–
1000%.
52. Ou K-C, Wang C-Y, Liu K-T, Chen Y-L, Chen Y-C, Lai M-D, Yen M-
C: Optimization protein productivity of human interleukin-2
through codon usage, gene copy number and intracellular
tRNA concentration in CHO cells. Biochem Biophys Res
Commun 2014, 454:347-352 http://dx.doi.org/10.1016/j.
bbrc.2014.10.097.
53. Hanson G, Coller J: Translation and protein quality control:
codon optimality, bias and usage in translation and mRNA
decay. Nat Rev Mol Cell Biol 2018, 19:20-30 http://dx.doi.org/
10.1038/nrm.2017.91.
54. Zhao F, Yu C-H, Liu Y: Codon usage regulates protein structure
and function by affecting translation elongation speed in
Drosophila cells. Nucleic Acids Res 2017, 45:8484-8492 http://
dx.doi.org/10.1093/nar/gkx501.
55. Magistrelli G, Poitevin Y, Schlosser F, Pontini G, Malinge P,
Josserand S, Corbier M, Fischer N: Optimizing assembly and
production of native bispecific antibodies by codon de-
optimization. MAbs 2017, 9:231-239 http://dx.doi.org/10.1080/
19420862.2016.1267088.
56. Hanson G, Coller J: Codon optimality, bias and usage in
translation and mRNA decay. Nat Rev Mol Cell Biol 2017, 19:20-
30 http://dx.doi.org/10.1038/nrm.2017.91.
57. Presnyak V, Alhusaini N, Chen Y-H, Martin S, Morris N, Kline N,
Olson S, Weinberg D, Baker KE, Graveley BR, Coller J: Codon




Gamble CE, Brule CE, Dean KM, Fields S, Grayhack
Correspondence EJ, Grayhack EJ: Adjacent codons act in
concert to modulate translation efficiency in yeast. Cell 2016,
166:679-690 http://dx.doi.org/10.1016/j.cell.2016.05.070.
The authors demonstrate in yeast how codon context is important in
modulating translational efficiency and the imporatnce of considering
codon usage in the context of the local environment and not as single
codons alone.
59. Ang KS, Kyriakopoulos S, Li W, Lee D-Y: Multi-omics data driven
analysis establishes reference codon biases for synthetic
gene design in microbial and mammalian cells. Methods 2016,
102:26-35 http://dx.doi.org/10.1016/j.ymeth.2016.01.016.
60. Chung BKS, Yusufi FNK, Mariati YYang, Lee DY: Enhanced
expression of codon optimized interferon gamma in CHO
cells. J Biotechnol 2013, 167:326-333 http://dx.doi.org/10.1016/j.
jbiotec.2013.07.011.
61. Gorochowski TE, Ignatova Z, Bovenberg RAL, Roubos JA: Trade-
offs between tRNA abundance and mRNA secondary
structure support smoothing of translation elongation rate.
Nucleic Acids Res 2015, 43:3022-3032 http://dx.doi.org/10.1093/
nar/gkv199.
62. Cozen AE, Quartley E, Holmes AD, Hrabeta-Robinson E,
Phizicky EM, Lowe TM: ARM-seq: AlkB-facilitated RNA
methylation sequencing reveals a complex landscape of
modified tRNA fragments. Nat Methods 2015, 12:879-884 http://
dx.doi.org/10.1038/nmeth.3508.
63. Zheng G, Qin Y, Clark WC, Dai Q, Yi C, He C, Lambowitz AM,
Pan T: Efficient and quantitative high-throughput tRNA
sequencing. Nat Methods 2015, 12:835-837 http://dx.doi.org/
10.1038/nmeth.3478.
64. Shigematsu M, Honda S, Loher P, Telonis AG, Rigoutsos I,
Kirino Y: YAMAT-seq: an efficient method for high-throughput
sequencing of mature transfer RNAs. Nucleic Acids Res 2017,
45:e70 http://dx.doi.org/10.1093/nar/gkx005.
65. Gogakos T, Brown M, Garzia A, Meyer C, Hafner M, Tuschl T:
Characterizing expression and processing of precursor and
mature human tRNAs by hydro-tRNAseq and PAR-CLIP. Cell
Rep 2017, 20:1463-1475 http://dx.doi.org/10.1016/j.
celrep.2017.07.029.
66. Evans ME, Clark WC, Zheng G, Pan T: Determination of tRNA
aminoacylation levels by high-throughput sequencing. Nucleic
Acids Res 2017, 45 http://dx.doi.org/10.1093/nar/gkx514.
67. Pan T: Modifications and functional genomics of human
transfer RNA. Cell Res 2018, 28:395-404 http://dx.doi.org/
10.1038/s41422-018-0013-y.
68. Liu F, Clark W, Luo G, Klungland A, Wang X, Fu Y, Wei J, Wang X,
Hao Z, Dai Q et al.: ALKBH1-mediated tRNA demethylation
regulates translation. Cell 2016, 167:816-828 http://dx.doi.org/
10.1016/j.cell.2016.09.038.
69. Kawarada L, Suzuki T, Ohira T, Hirata S, Miyauchi K, Suzuki T:
ALKBH1 is an RNA dioxygenase responsible for cytoplasmic
and mitochondrial tRNA modifications. Nucleic Acids Res 2017,
45:7401-7415 http://dx.doi.org/10.1093/nar/gkx354.
70. Kumar P, Kuscu C, Dutta A: Biogenesis and function of transfer
RNA-related fragments (tRFs). Trends Biochem Sci 2016,
41:679-689 http://dx.doi.org/10.1016/j.tibs.2016.05.004.
208 Biotechnology and bioprocess engineering: biomanufacturing
Current Opinion in Chemical Engineering 2018, 22:199–208 www.sciencedirect.com
Article
RTN3 Is a Novel Cold-Induced Protein and Mediates
Neuroprotective Effects of RBM3
Graphical Abstract
Highlights
d Cooling-induced reprogramming of the translatome
increases synthesis of RTN3
d The neuroprotective protein RBM3 binds RTN3 mRNA and
drives its expression
d RTN3 overexpression prevents synaptic loss in mice with
prion disease
d RTN3 expression is a mediator of RBM3-induced
neuroprotection
Authors
Amandine Bastide, Diego Peretti,
John R.P. Knight, ..., C. Mark Smales,







neuroprotective, and the cold shock
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mediating synaptic repair processes that
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SUMMARY
Cooling and hypothermia are profoundly neuropro-
tective, mediated, at least in part, by the cold
shock protein, RBM3. However, the neuroprotective
effector proteins induced by RBM3 and the mecha-
nisms by which mRNAs encoding cold shock pro-
teins escape cooling-induced translational repres-
sion are unknown. Here, we show that cooling
induces reprogramming of the translatome, includ-
ing the upregulation of a new cold shock protein,
RTN3, a reticulon protein implicated in synapse for-
mation. We report that this has two mechanistic
components. Thus, RTN3 both evades cooling-
induced translational elongation repression and is
also bound by RBM3, which drives the increased
expression of RTN3. In mice, knockdown of
RTN3 expression eliminated cooling-induced neuro-
protection. However, lentivirally mediated RTN3
overexpression prevented synaptic loss and cogni-
tive deficits in a mouse model of neurodegenera-
tion, downstream and independently of RBM3. We
conclude that RTN3 expression is a mediator of
RBM3-induced neuroprotection, controlled by novel
mechanisms of escape from translational inhibition
on cooling.
INTRODUCTION
Therapeutic hypothermia is a powerful neuroprotectant, acting
through multiple mechanisms, although the underlying path-
ways are not fully understood [1, 2]. We recently showed that
the cold shock RNA-binding protein, RBM3, plays a critical
role in mediating synaptic repair processes essential for neuro-
protection in mouse models of neurodegenerative disease [3].
Thus, the inability to induce RBM3 expression in early disease
results in defective structural synaptic plasticity and hence
reduced regenerative capacity, leading to synapse loss and
eventually neuronal loss. Inducing endogenous RBM3 expres-
sion in vivo through cooling, or by lentiviral-mediated overex-
pression, prevented synapse loss in prion and Alzheimer-type
mice, rescued memory deficits, protected against neurodegen-
eration, and significantly prolonged survival [3]. How RBM3
mediates these effects is unknown, although it is likely to be
related to its RNA chaperone function, as it facilitates selective
mRNA translation following a number of cellular stresses,
including cooling [4–6]. RBM3 is also implicated in protection
against cell death [7, 8] and increases local protein synthesis
at dendrites [9].
Upon cooling, the changes to the protein synthesis machin-
ery are similar to those observed with other stress inducers
(e.g., UVB exposure) [10, 11] and include phosphorylation of
eukaryotic initiation factor 2 (eIF2) on the alpha subunit
[12, 13]. However, cold shock differs because relieving eIF2a-
mediated inhibition of translation is insufficient to restore pro-
tein synthesis rates [12]. Instead, the rapid reduction in protein
synthesis that accompanies cooling [12–15] is a result of a
decrease in translational elongation mediated by the phosphor-
ylation of elongation factor 2 (eEF2) by elongation factor 2 ki-
nase (eEF2K; a negative regulator of eEF2) [12]. Importantly,
suppression of eEF2K and subsequent reactivation of eEF2
significantly increases the rate of protein synthesis rates in
cooled cells [12], consistent with the concept that elongation
is a major regulatory node under specific pathophysiological
conditions [16, 17].
To examine the relationship between cold stress, RBM3 in-
duction, and the modulation of mRNA translation for the synthe-
sis of putative neuroprotective proteins, we investigated the
post-transcriptional response to hypothermia in vitro and vali-
dated the data in vivo in a mouse model of neurodegeneration,
in which we know cooling is protective, mediated by RBM3.
We show that, following cold shock/cooling, the global decrease
in protein synthesis rates is associated with selective reprogram-
ming of the translatome. We find enhanced synthesis of specific
proteins: not only the cold shock protein RBM3 (as predicted) but
also of a number of proteins with a role in development and func-
tion of the nervous system, including reticulon 3 (RTN3). RTN3
has a role in synaptic plasticity and synapse formation [18, 19]
and is thus a compelling candidate for the neuroprotective
effects mediated by increased RBM3 expression. We find that
both RBM3 and RTN3 evade translational repression and that
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Figure 1. Mild Cooling Results in Translation Regulation of a Defined Set of Transcripts
(A) Protein synthesis rates determined by [35S]-methionine label incorporation after 24 hr incubation of HEK293 cells at 32!C. Values were normalized to cells
incubated at 37!C. Error bars represent SE within three independent experiments.
(B) HEK293 cells were incubated at 37!C or at 32!C for 24 hr and immunoblotted for RBM3 and CIRP, eIF2 alpha eEF2, and b-actin.
(legend continued on next page)
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RBM3 binds RTN3mRNA and plays a major role in driving cool-
ing-induced upregulation of RTN3 expression. Finally, we show
that RTN3 expression, downstream of RBM3 induction, medi-
ates cooling-induced neuroprotection in mice with neurodegen-
erative disease and importantly is neuroprotective even in the
absence of cooling.
RESULTS
Cooling Induces Reprogramming of the Translatome
Both transcriptional and post-transcriptional control mecha-
nisms are required for the overall response to cell stress [20].
In order to examine the genome-wide changes accompanying
cooling, we incubated HEK293 cells at 32!C for 24 hr. This re-
sulted in reduction in protein synthesis (Figure 1A) and phos-
phorylation of the translation initiation and elongation factors
eIF2a and eEF2 (Figure 1B; in agreement with previous studies
[12]). We chose HEK293 cells because the response to cooling
is well documented [12, 15, 21] and, in addition, they express
many markers associated with neuronal lineage [22]; thus, using
this cell line increases the potential for the identification of cold-
induced putative neuroprotective proteins. Transcriptional ana-
lyses of the cooled HEK293 cells showed that 119 genes were
downregulated at the transcriptional level, with no significant in-
creases in transcription of any mRNAs (Figure S1; Table S1). In
addition, no differences greater than 2-fold were identified in
the expression of microRNAs (miRNAs) (Table S2). These data
support regulation of protein synthesis as an important mecha-
nism for control of gene expression following cooling. We have
shown previously that cooling reduces global rates of protein
synthesis and importantly that elongation repression is the driver
of this process (Figures 1A and 1B [12]). We hypothesize that,
during cooling, specificmRNAs are able to evade a global reduc-
tion in translation elongation so that the expression of the corre-
sponding proteins is maintained or even increased. However,
identifying such mRNAs represents a technical challenge. Under
conditions in which the initiation of translation is inhibited, the
number of actively translating ribosomes decreases [10, 23]
and polysome profiling can be used to identify those mRNAs
that remain polysomally associated; this generally correlates
with increased synthesis of the corresponding proteins [20].
However, under conditions in which elongation is inhibited, the
number of polysomally associated ribosomes will stay the
same or increase, and therefore it is difficult to identify mRNAs
that either escape or are relatively insensitive to elongation
slow down. Therefore, to identify proteins whose synthesis
was increased during cooling, computational modeling was
used in conjunction with polysome profiling.
Sucrose density gradient analysis was carried out on cooled
samples to separate polysomes and the associated transcripts
(Figure 1C), which were subsequently purified and analyzed by
cDNA microarray. By microarray 71, mRNAs were identified
that were associated with a decreased number of polysomes
at 32!C (Figures 1D and S2; Tables S3 and S4). Importantly, in-
genuity pathway analysis showed that there was significant
enrichment for mRNAs that encode proteins that function in
the nervous system and its development (15/71; marked by an
arrow, Figure 1E). To predict which of these neuronal-related
mRNAswere translated in cooled cells, we used a computational
model of elongation control [24] generated by defining the intra-
cellular concentration of ribosomes, translation factors, and
tRNAs (Table S5). The model allows the speed of decoding to
be estimated for any given open reading frame [25], assuming
that decoding speed is not significantly limited by tRNA-inde-
pendent parameters, such as mRNA secondary structure or
modifications. We have previously shown that, despite this
assumption, the model can be used to rank expression levels
from multiple elongation-controlled mRNAs reliably [25]. The
model predicts that, under eEF2 ablation, fast codons (which
are decoded by abundant tRNAs) change their elongation rate
by an order of magnitude, whereas slow codons are relatively
unaffected (see Figures S3A–S3C).
We applied the model to the transcripts that encoded mRNAs
with roles in neuronal processes identified by polysome profiling
(Figure 1D) to analyze elongation over the initial 20 codons (Fig-
ure 1F; Table S6). Our analysis showed that a subset of mRNAs,
including RTN3 and Noggin, contained codons that require less
abundant tRNAs in the 50 end of the transcripts (Figure 1F), and
our model predicted that these could escape the repression of
elongation.
mRNAs Encoding a Subset of Neuronal Proteins
Overcome Elongation Inhibition on Cooling
Western analysis showed that expression of Noggin and RTN3,
and as expected RBM3, increased at 32!C, whereas GBBR1
and LDHA levels, which are encoded by mRNAs that contain co-
dons requiring abundant tRNAs, were unchanged in both cell
lines (Figure 2A). To confirm a post-transcriptional response,
we examined mRNA expression changes of RTN3 and Noggin
using qPCR (Figure 2B); there was a small reduction in the levels
of Noggin, consistent with the transcriptional profiling data
(Table S1; Figure S1) and no change for RTN3. There was an
increase in the expression of RBM3 mRNA, in agreement with
previous studies [4].
To confirm escape of translation elongation repression and
identifya strongcandidateproteinwithaneuroprotective function,
(C) Sucrose density gradient ultracentrifugations were performed fromHEK293 cells incubated at 37!Cor 32!C for 24 hr. Plots show the distribution of RNAwithin
subpolysomes (40S, 60S, and 80S) and polysomes. Northern analysis was carried out on individual fractions, which were probed for b-actin or PABP.
(D) mRNAs from gradient fractions were pooled and subjected to cDNA microarray. The color scale represents the ratio of mRNA in subpolysome and polysome
fractions, normalized log2 (polysome/subpolysome) value; yellow is polysome- and blue subpolysome-associated mRNAs.
(E) mRNAs that showed significant change in polysome/subpolysome (P/S) ratio on cooling were clustered into functional groups. Biological functions associated
with decreased polysomal-associated transcripts, obtained from the ingenuity pathways analysis. Fisher’s exact test was used to calculate a p value (threshold
p < 0.05) for each biological function represented in the red bar chart. The blue line represents number of proteins per category.
(F) Predictive modeling of transcript-decoding speed was performed on the initial 20 codons of human transcript sequences from those that showed decreased
polysomal association. The boxplot showsmRNAs that have a decrease in polysomal association and contain an initial 20 ‘‘slow’’ codons (e.g., RTN3 and Noggin
[NOG]) compared to those that contain ‘‘fast’’ codons, such as LDHA.
See also Figures S1–S3 and Tables S1–S6.
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we focused on RTN3, a protein that has known function in
synaptogenesis in the adult nervous system [26–28] and a role
in neuroprotection. To reduce elongation by an alternative
method,we treatedcells grownat37!Cwithcycloheximide,which
stalls the translocation step in the elongation cycle [29]. As ex-
pected, incubation with cycloheximide decreased global protein
synthesis rates (Figure 2C) and reduced expression of c-Myc,
which is known to have a short half-life of 20 min. However, there
was increased RTN3 expression, consistent with our model’s
prediction that slowed elongation enhances synthesis of this pro-
tein (Figures 2D and S4).
To mimic the cooling-induced elongation block, we reduced
eEF2 expression by RNAi (Figure 2E). This resulted in an increase
in RTN3 levels, suggesting that the rate of elongation alongRTN3
mRNA is relatively unaffected by reduced availability of eEF2, in
agreement with our model (Figure S3).
Whereas we have shown previously there is a small effect
of cooling on the stability of specific proteins [21], RTN3 is
Figure 2. RTN3 Is Subject to Elongation Control
(A) Extracts from control or cooled HEK293 or SHSY5Y cells were immunoblotted for RTN3 and Noggin, GBBR1, and LDHA. b-actin is used as a loading control.
(B) qRT-PCR was performed on corresponding transcripts. Error bars represent 1 SD from themean within three independent experiments.GAPDHwas used as
a control.
(C) Protein synthesis rates determined by [35S]-methionine label incorporation after 24 hr incubation of HEK293 cells at 37!C with cycloheximide. Values were
normalized to untreated cells. A two-tailed paired Student’s t test was used to calculate statistical significance. Error bars represent SE within three independent
experiments. **p < 0.001, all three conditions.
(D) Extracts from cells exposed to 10 mg/mL cycloheximide at 37!C were immunoblotted for RTN3, c-Myc, and b-actin. Error bars represent 1 SD from the mean
within three independent experiments. *p < 0.01.
(E) eEF2 expression was reduced by siRNA, proteins extracted and immunoblotted with the antibodies shown.GAPDHwas used as a loading control. Error bars
represent 1 SD from the mean within three independent experiments. *p < 0.01.
See also Figures S4 and S5A.
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a relatively stable protein with a half-life of at least 24 hr, and
therefore, any effects of turnover in the time frame of the exper-
iment will be minimal (Figures S5A and S5B).
RBM3 Binds to RTN3 mRNA and Increases Its
Translation through trans-Acting Effects on Initiation
Cooling also reduces the rate of translation initiation, via inhibi-
tory phosphorylation of eIF2a (Figure 1A) [12], which compen-
sates for the reduction in translation elongation, as fewer
ribosomes will be available for initiation while they are limited
by globally reduced elongation speeds. A similar phenomenon
has been suggested to occur previously in yeast [25, 30]. Thus,
we predict that, in order to increase their translation, transcripts
also overcome the cooling-induced initiation block. This is likely
to be driven by trans-acting factors acting upon cis elements
within the transcripts. Because RBM3 is an RNA chaperone
whose expression is increased in cooled cells [31, 32] and is
known to mediate the neuroprotective effects of cooling [3],
we hypothesized that cooling-induced RBM3 may act as a
trans-acting factor promoting RTN3 translation and that some
of the neuroprotective effects of RBM3 may be mediated
through RTN3.
To address whether RBM3 interacted with RTN3 mRNA, we
carried out immunoprecipitation reactions, and data showed
that RBM3 binds toRTN3mRNA in both HEK293 cells and in hip-
pocampus of wild-typemice (Figures 3A and 3B). We then asked
whether RBM3 expression affects RTN3 levels in HEK293 cells
and mouse brain by transfecting with RBM3-expressing con-
structs or lentiviruses, respectively. In each case (Figures 3C
and 3D), the data show that overexpression of RBM3 resulted
in a dramatic increase in RTN3 protein expression, with no cor-
responding increase in RTN3 transcript levels in vitro (Figure 3C)
or in vivo (Figure 3D).
cis-Acting Elements in RTN3 Contribute to Evasion of
the Initiation Block
To examine the role of cis-acting elements in 50 UTR of RTN3 in
its post-transcriptional regulation by RBM3, we used a luciferase
reporter construct containing the RTN3 50 UTR (Figure 3E). At
25!C, therewas a 5-fold increase in translation ofmessages con-
taining the 50 UTR of RTN3, compared to the control (Figure 3F).
Further, overexpression of RBM3 resulted in a 5-fold induction of
luciferase expression at 37!C (Figure 3Gi). In contrast, RNAi of
RBM3 produced a small but significant reduction in luciferase
activity (Figure 3Gii). Taken together, the data support a role
for RBM3 in controlling RTN3 expression through the RTN3 50
UTR cis-regulatory sequence.
Cooling Induces RTN3 Expression In Vivo through
Post-transcriptional Mechanisms
Given the role of RBM3 in regulating RTN3 (Figures 2 and 3), we
focused on RTN3 as a potential mediator of the neuroprotective
effects of RBM3 induction. RTN3 is a strong candidate for this
role. It is a member of the reticulon family of proteins, with mul-
tiple functions in the nervous system, including axon and neurite
outgrowth [18, 19] and synapse formation [26–28]. It also has an
indirect role in synaptic plasticity through its inhibition of BACE1,
a secretase involved in cleavage of APP and a negative modu-
lator of pCREB levels [28, 33, 34].
We testedwhether RTN3 expression was increased in brain on
cooling in vivo by inducing hypothermia in wild-type FVB mice
using 50 AMP, as described [3, 35]. We found the levels of both
RBM3 and RTN3 increased on cooling (Figure 4Ai) without corre-
sponding changes in respective mRNA levels (Figure 4Aii),
consistent with post-transcriptional upregulation. Further, cool-
ing induced a reduction in global protein synthesis rates to
"40% of control levels (Figure 4B), as observed in vitro (Fig-
ure 1A) (although the abundance of polysomes was not reduced
to an equivalent extent [Figure 4C], again consistent with in vitro
findings [Figure 1C] [12]). Knockdown of RBM3 in mice via lenti-
virallymediated RNAi significantly reduced the RTN3 increase on
cooling (Figure 4D), confirming physiological relevance of this
functional interaction and suggesting that RTN3 expression is
downstream of RBM3 in cooling in vivo.
RTN3 Mediates Cooling-Induced Neuroprotective
Effects of RBM3
We next asked to what extent RTN3 is neuroprotective in mice
with neurodegenerative disease, using mice with prion disease,
specifically tg37 mice [36] inoculated with Rocky Mountain Lab-
oratory (RML) strain as in our previous studies [3, 37–41]. These
mice overexpress prion protein (PrP) and have a rapid disease
course, succumbing to disease in 12 weeks [36]. In these
mice, synaptic loss is associated with the failure to induce
RBM3 on cooling early in the disease course at 6 weeks post-
inoculation (w.p.i.) [3], developing behavioral deficits at
9w.p.i., with neuronal loss from 10w.p.i. In general, terminal clin-
ical signs appear at around 12 w.p.i.
We first confirmed that increased RTN3 expression is down-
stream of RBM3 in prion-diseased mice. Lentivirally mediated
RNAi of RTN3 reduced RTN3 levels in hippocampi (Figure 5A),
but not RBM3 levels (Figure 5A). Further, RNAi of RTN3 did not
affect high RBM3 levels induced by cooling while preventing,
as predicted, the cold-induced rise in RTN3 (Figure 5B). This
allowed us to address whether and to what extent RTN3
mediates the neuroprotective effects of RBM3. We found that
lentivirally mediated RNAi of RTN3 in prion-infected mice abol-
ished the protective effects of cooling on behavioral impairments
(Figure 5C), accelerated neuronal loss (Figure 5D), and abolished
the cooling-associated increase in survival in prion-infected
mice (Figure 5E). Thus, reducing levels of RTN3 largely abolished
the protective effects of high levels of cold-induced RBM3,
supporting the conclusion that RTN3 is a major mediator of the
effects of RBM3. Even in the absence of cooling, RNAi of
RTN3 accelerated synapse loss in disease (Figures S5C and
S5D), supporting a role for RTN3 in synapse maintenance and
formation/plasticity. However, the exact mechanism remains
unknown.
RTN3 Is Neuroprotective in Neurodegenerative Disease
RBM3 induction is profoundly neuroprotective in both prion and
5XFAD mice, effects that are abrogated if animals undergo
knockdown of RBM3 [3] or of RTN3 (Figures 5C–5E). To address
whether RTN3 is neuroprotective in the absence of cooling, we
injected prion-infected tg37 mice with lentiviruses overexpress-
ing RTN3 (LV-RTN3). This increased expression of RTN3 as
expected (Figure 6A), importantly without increasing RBM3
expression, consistent with RTN3 being downstream of RBM3
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Figure 3. RTN3 Expression Is Downstream of RBM3
(A) Schematic representation of an RNA immunoprecipitation (RNA-IP) assay. Immunoblots of input lysate from HEK293 cells or hippocampus, immunopre-
cipitated with either rabbit IgG or RBM3 antibody, are shown.
(B) qRT-PCR was performed on RNA-IP samples using primers specific for human (HEK293) or mouse (hippocampus) samples. All values are normalized with
respect to the initial RNA input material, and the enrichment is plotted relative to GAPDH. A two-tailed paired Student’s t test was used to calculate statistical
significance. Error bars represent 1 SD from the mean within three independent experiments. **p < 0.01; ***p < 0.001.
(C) HEK293 cells were transfected with an expression plasmid construct encoding RBM3 or a control plasmid, and extracts were immunoblotted for RTN3.
b-actin was used as a loading control. RNA expression of RTN3 was assessed by qRT-PCR.
(D) Mouse hippocampi stereotaxically injected with lentivirus containing a construct to overexpress RBM3 and extracts were immunoblotted for RTN3 and
GAPDH. qRT-PCR was used to assess the expression of RTN3.
(E) Schematic representation of the RTN3 containing plasmid constructs encoding firefly luciferase.
(F) HEK293 cells were transfected with construct containing the 50 UTR of RTN3 and a Renilla luciferase control and incubated at either 37!C or 25!C for 24 hr.
Firefly luciferase activity was calculated relative to Renilla luciferase for each condition and expressed as the fold induction from 37!C to 25!C.
(Gi) HEK293 cells were transfected with either control (pcDNA3.1) or RBM3 expression plasmid (pcDNA-RBM3) and then transfected with either RTN3 50 UTR
pGL3 or pGL3 and Renilla luciferase constructs and luciferase activity determined. A two-tailed paired Student’s t test was used to calculate error. Error bars
represent 1 SD from the mean within three independent experiments. ***p < 0.001.
(Gii) HEK293 cells were transfected with either control siRNA (siCONT) or RBM3 siRNA (siRBM3) and then transfected with pGL3 and Renilla luciferase con-
structs. The fold repression from RTN3 50 UTR pGL3 compared to the control pGL3 was calculated and normalized to siCONT transfection. A two-tailed paired
Student’s t test was used to calculate statistical significance. Error bars represent 1 SD from themeanwithin three independent experiments. *p < 0.05; **p < 0.01;
***p < 0.001.
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(Figure 6A). To assess neuroprotective effects of RTN3 overex-
pression, we measured synapse number (Figure 6B), burrowing
activity (Figure 6C), and neuron number in CA1 of hippocampus
from diseased animals treated with LV-RTN3 compared to con-
trols (Figure 6D) over the time course of disease. All of these pa-
rameters decline in the course of prion disease in the absence of
intervention. Importantly, RTN3 overexpression restored syn-
apse number to wild-type levels, markedly above levels seen in
untreated mice at the same and later time points (Figure 6B),
and prevented the decline in burrowing behavior (Figure 6C).
RTN3 overexpression also conferred marked neuroprotection
at the histological level, with very notable conservation of
the CA1 pyramidal neuron layer (Figure 6D). Importantly, LV-
RTN3 significantly increased survival of prion-infected mice (Fig-
ure 6E), recapitulating the effects of LV-RBM3 we previously
described [3]. In our study of RBM3, we showed that onset of
synaptic failure correlates with failure of induction of RBM3 at
6 w.p.i. [3]. And interestingly, RTN3 induction at this time point
Figure 4. RBM3 Regulates RTN3 In Vivo
(Ai) Cooling increases RBM3 and RTN3 levels in hippocampi of wild-typemice. Representative western blots are shown. Bar graphs show quantification of RBM3
and RTN3 levels relative to b-actin and GAPDH, respectively. n = 5 control and 5 cooled mice for RBM3. n = 9 control mice and 9 cooled mice for RTN3. *p < 0.05;
***p < 0.001
(Aii) qRT-PCR of RNA isolated from hippocampi of cooled mice showed no significant change in the abundance of RBM3 or RTN3 mRNAs following cooling.
(B) Protein synthesis rates were determined by 35Smethionine incorporation into nascent protein using ex vivo hippocampus slices from cooled mice and control
mice. A two-tailed paired Student’s t test was used to calculate statistical significance. Error bars represent 1 SD from the mean within three independent
experiments. *p < 0.05.
(C) Sucrose density gradient ultracentrifugation performed of cytoplasmic extracts from hippocampi from control and cooled mice. Absorbance plots show the
distribution of RNA within subpolysomes (40S, 60S, and 80S) and polysomes.
(D) RTN3 induction on in vivo cooling is dependent on RBM3 protein expression. Knockdown of RBM3 resulted in a 38% decrease in RTN3 induction. n = 6
LV-control and 6 LV-shRNA-RBM3 mice. **p < 0.01.
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Figure 5. Lentiviral-Mediated Downregulation of Endogenous RTN3 Prevents Cooling-Induced RBM3-Mediated Neuroprotection
(A) LV-shRNA-RTN3 injected into hippocampi of prion-infected mice significantly reduces RTN3 protein levels compared to control shRNA (LV-shCONT). n = 6
prion+LV-control mice and 6 prion+LV-shRNA-RTN3 mice. Representative western blots and bar graphs quantification are shown.
(B) Western blot of RBM3 in LV-shRNA-RTN3-treated early-cooled prion mice shows no change in expression. n = 6 mice per experimental condition.
(C) The early-cooling-induced protection in burrowing behavior declines in LV-shRNA-RTN3 mice. Food pellet remaining in the tube measured after 2 hr
is expressed in percentage burrowed. Graph bar with prion (black bars; n = 12 mice), prion + early cooling (gray bars; n = 20 mice), and prion + early
cooling + LV-shRNA-RTN3 (light brown bars; n = 12 mice) is shown. One-way ANOVA with Tukey’s post-test was used for multiple comparisons. *p < 0.05;
***p < 0005.
(D) Representative images of H&E-stained hippocampal sections from uninfected control (top left-hand panel), prion-infected mice (top right-hand panel), prion-
infectedmice treated with early cooling and LV-control (bottom left-hand panel), and prion-infectedmice treated with early cooling and LV-shRNA-RTN3 (bottom
right-hand panel). Prion-infected mice show extensive neuronal loss, with associated spongiosis, whereas early cooling treatment prevents neurodegeneration.
This protection is abrogated with LV-shRNA-RTN3. The graph bar shows quantification of the average number of neurons for each condition in the CA1 area of
hippocampus. n = 3 mice (white bar), 7 mice (black bar), 7 prion mice (bar), and 9 mice (light brown bar). One-way ANOVA and Brown-Forsythe test with Tukey’s
post hoc analysis for multiple comparisons were used. ***p < 0.001. The scale bar represents 50 mm.
(legend continued on next page)
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is also lost (Figure 6F), supporting a functional relationship be-
tween these proteins in the context of disease and loss of synap-
tic structural plasticity.
Misfolded PrP levels were not affected by cooling or RTN3
expression, and levels were equivalent in all mice, precluding a
mechanism of action via prion protein aggregation, consistent
with our previous findings with RBM3 [3] (Figure S5D).
Thus, RTN3 overexpression results in neuroprotection at the
level of synapse number, behavior, neuronal numbers, and
increased survival, downstream and independently of cooling-
mediated RBM3 induction.
DISCUSSION
Themetabolic response to cooling is highly conserved [3, 35, 42].
The neuroprotective effects of hypothermia are essential for
healthy brain function after hibernation and are widely exploited
medically [43, 44]. However, relatively little is known about how
global gene expression changes bring about these protective
effects.
We have examined the genome-wide changes induced by
cold stress by carrying out transcriptional, miRNA, and transla-
tional profiling on cells that were subjected to cooling. Our
data show that specific induction of gene expression during
cold stress is regulated at the level of translation with no signifi-
cant transcriptional upregulation or changes in miRNA expres-
sion (Figures 1, S1, and S2; Tables S1 and S2).
Elongation rate control is the major determinant of global pro-
tein synthesis suppression upon cooling [12], but which tran-
scripts are controlled in this way was unknown. We therefore
generated a computational model to predict those messages
that were particularly sensitive to regulation at this stage (Fig-
ure S3). According to our model, expression from transcripts
that require abundant tRNAs would be dependent on eEF2 to
maintain efficient elongation and protein expression. In contrast,
mRNAs requiring rare tRNAs would be proportionally less
affected by reductions in eEF2 availability and would be pre-
dicted to display either a small decrease or exhibit no net change
in polysomal association upon cooling (Figure S3). In support of
this hypothesis, the RTN3mRNA is decoded by rare tRNAs and,
following cooling, exhibited reduced polysomal-associated yet
increased protein expression (Figure 2). We showed that cis-
and trans-acting factors were required for RTN3 to overcome
cooling-induced translation inhibition (Figure 3) and that the
RNA chaperone RBM3 [6, 31, 32] was required (Figures 3 and 4).
We were interested in the functional consequence of RTN3
upregulation in response to cold shock. We have previously re-
ported that RBM3 mediates the neuroprotective effects of cool-
ing in mouse models of neurodegeneration and is necessary for
maintenance of synaptic structural plasticity [3]. How it does this
was not understood. We considered RTN3 to be a candidate
neuroprotective protein specifically upregulated by RBM3 in-
duction on cooling. In support of this, knockdown of RTN3
reduced synapse number at an earlier stage and abolished the
neuroprotective effects of cooling in prion-diseased mice,
despite cooling-induced increase in RBM3 levels (Figures 5
and S5C). Conversely, lentivirally mediated overexpression of
RTN3 prevented synapse loss and neurodegeneration in prion-
diseased mice (Figure 6), recapitulating the neuroprotective
effects observed during RBM3 expression [3].
In conclusion, we propose that, following cooling, there is
translational reprogramming, leading to the overexpression of
specific cold-inducible proteins, including the known cold shock
protein, RBM3, but also of RTN3. Critically, we show that induc-
tion of RTN3 is downstream of RBM3 expression, and our data
suggest that RTN3 is a mediator of the RBM3-driven neuropro-
tective effects of cooling in prion-diseased mice, most likely
through its multiple roles in the regulation of neurite outgrowth
and regulation of synaptic plasticity. It is likely that RTN3 induc-
tion would mediate a similar neuroprotective role in other neuro-
degenerative conditions. Further, its inhibition of BACE1-medi-
ated cleavage of APP could also contribute to neuroprotection
in Alzheimer’s pathology. We propose that the control of RTN3
expression through escape from inhibition of translation on cool-
ing at the levels of initiation and elongation provides new targets
for neuroprotective therapies in neurodegenerative disease.
EXPERIMENTAL PROCEDURES
All animal work was conducted according to UK Home Office Regulations. For
details of antibodies, plasmids, and oligonucleotides, please see the Supple-
mental Experimental Procedures.
Cell Culture and Transfections
HEK293 cells were cultured under standard conditions in DMEM supple-
mented with 10% fetal bovine serum (FBS). For induction of cold stress, cells
were incubated at 32!C or at 25!C for 24 hr before harvesting. Small interfering
RNAs (siRNAs) were transfected using DharmaFECT 1 and plasmids with
Lipofectamine 2000 (Invitrogen).
SDS-PAGE and Western Blotting
Western blots were performed as described previously [45] with modifications
described in the Supplemental Experimental Procedures.
Determination of Protein Synthesis Rates
The rate of protein synthesis was measured by the incorporation of 35S-methi-
onine into trichloroacetic acid (TCA)-insoluble material as described previ-
ously [10]. Further details are provided in the Supplemental Experimental
Procedures.
Sucrose Gradient Density Centrifugation and RNA Detection
Sucrose density gradient analysis was carried out as described [10]. Full de-
tails are provided in the Supplemental Experimental Procedures.
RNA Extraction
Total RNA extraction was performed using Trizol reagent (Invitrogen) accord-
ing to the manufacturer’s instructions.
Microarray Hybridization
The human cDNA microarrays were manufactured in Nottingham University.
This custom cDNA microarray consists of 29,593 (32,448 total, including
2,855 control probes) oligonucleotide probes derived from MWG Human
30K slides A, B, and C. RNA from sucrose density gradient fractionation was
(E) Early cooling prolongs survival in prion-infected mice but is abolished by knockdown of RTN3. Kaplan-Meier plot; n = 25 cooled mice (gray line); n = 17 not
cooled (black line); n = 14 cooled + shRNA of RTN3 (light brown line). One-way ANOVA with Tukey’s post-test was used for multiple comparisons; not cooled
versus cooled mice ***p < 0.001; not cooled versus cooled + shRNA of RTN3 n.s.; cooled mice versus cooled + shRNA of RTN3 *p < 0.05.
See also Figures 5C and 5D.
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Figure 6. Enhanced RTN3 Expression Is Sufficient to Protect against Prion Disease in the Absence of Cooling
(A) LV-RTN3 delivery to hippocampi of prion-infected mice increases RTN3 in the absence of cooling compared to control lentiviral treatment (LV-control)
and endogenous RBM3 (remain constant). n = 6 mice LV-control and 6 mice LV-shRNA-RTN3. Representative western blots and bar graphs quantification are
shown.
(B) LV-RTN3 protected the deficit in synapse loss in prion-infected mice at 7 and 9 w.p.i. Representative electron micrographs are shown, pseudo-colored for
ease of synapse identification: presynaptic, dark pink; postsynaptic, light pink. Bar chart quantification is shown. n = 93 images from three animals per condition.
Data represent mean ± SEM; t test; ***p < 0.0001. The scale bar represents 1 mm.
(C) RTN3 overexpression prevented the decline in burrowing behavior of prion–infectedmice. Food pellets remaining in the tube weremeasured after 2 hr and are
expressed as percentage burrowed. Graph bar with prion (black bars; n = 14 mice) and prion + LV-RTN3 (orange bars; n = 20 mice) is shown. Kruskal-Wallis test
with Dunn’s multiple comparisons test; **p < 0.01.
(D) Representative images of H&E-stained hippocampal sections from uninfected control, prion-infected mice with LV-control, and prion-infected mice with LV-
RTN3. The graph bar shows quantification of the average number of neurons for each condition in the CA1 area of hippocampus. n = 3 mice (white bar), 5 mice
(black bar), and 15mice (orange bar). One-way ANOVA and Brown-Forsythe test with Tukey’s post hoc analysis for multiple comparisons were used. ***p < 0.001.
The scale bars represent 400 mm (top row) and 50 mm (bottom row).
(legend continued on next page)
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pooled into subpolysomal or polysomal fractions, labeled, and hybridized to
the arrays as described previously [10]. Microarray slides were scanned using
a GenePix 4200B microarray scanner and GenePix Pro 6.0 software (Axon
Instruments).
Analysis of Microarray Data
GenePix Pro 6.0 was used to quantify fluorescence intensities for individual
spots on the microarray. All statistical analysis was performed in the statistical
environment R, version 2.6.1, and the Limma package [46].
Northern Blot
Northern analysis was performed as described previously [10]. Visualization
and quantification of northern blot analysis was performed using a Molecular
Imager FX phosphoimager and ImageJ software.
RNA-Protein Complex Immunoprecipitation
Post-nuclear extracts were incubated with either anti-RBM3 antibody or
immunoglobulin G (IgG)-coated protein G magnetic beads and processed as
described in the Supplemental Information.
Reverse Transcription and qPCR
Reverse transcriptionwas carried out using randomprimers and Superscript III
Reverse Transcriptase (Invitrogen) according to manufacturer instructions.
qPCR was carried out using SensiFAST SYBR Lo-ROX Kit (Bioline) accord-
ing to manufacturer instructions. Primers used are in the Supplemental
Information.
Prion Infection of Mice
As described previously [37], hemizygous tg37 mice of both sexes were inoc-
ulated with 1% brain homogenate of Chandler/RML prions at 3–6 weeks of
age. Control mice received 1% normal brain homogenate.
Induction of Hypothermia in Mice
FVB wild-type (WT) or hemizygous Tg37 mice weighing more than 20 g were
cooled using 50 AMP as described [3]. Prion-infected mice were injected
with lentiviruses at 2 w.p.i. and subsequently cooled at 3 and 4 w.p.i.
Lentiviruses and Mice Stereotaxic Surgery
GenTarget generated lentiviral plasmids. Viruses were injected stereotaxically
into the CA1 region of the hippocampus as described [3]; additional informa-
tion is provided in the Supplemental Information.
Burrowing
Burrowing was performed as described [3]. Briefly, mice were placed in a cage
with a tube full of pellets, which they ‘‘burrowed.’’ The extent of burrowing was
assessed by the weight of pellets displaced in 2 hr.
Histology
Paraffin-embedded brains and pancreases were sectioned at 5 mm and
stained with H&E as described [38, 39]. Neuronal counts were determined
by quantifying NeuN-positive pyramidal CA1 neurons as described [39]. Syn-
apses were counted in electron microscopy (EM) images of the stratum
radiatum of the hippocampal CA1 region, blind. A synapse was defined as a
structure with synaptic vesicles, synaptic cleft, and post-synaptic density,
as described [3].
Computational Modeling
Translation elongation rates on human mRNAs were estimated using a pub-
lished computational model [24]. The model was re-parameterized for the
human decoding system using relative total tRNA abundances from [47] and
a total tRNA concentration in HEK293 cells of 5.6 pg per cell, which was deter-
mined by comparing the staining intensity of the tRNA band in total RNA preps
from HEK293 cells to the intensity of bands generated with known amounts of
commercial yeast tRNA. Individual tRNA selection and translocation reactions
were modeled in PRISM [48] using rate constants [49] and tRNA ratios for in-
dividual codons [24] as published.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is
ArrayExpress: E-MTAB-5437.
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five figures, and six tables and can be found with this article online at http://
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